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 Abstract 
Chinese hamster ovary (CHO) cells are the dominant cell factory for recombinant production             
of diverse biotherapeutics. The complexity of biotherapeutics and the increasing demand for            
their rapid, cost-effective and high-quality production have made the biomanufacturing in           
CHO cells a highly sophisticated process. To meet the demands for better and inexpensive              
biotherapeutics, further improvements of recombinant protein production in CHO cells seem           
necessary. In this thesis we present clone screening and gene engineering tools that aim to               
facilitate improved and more predictable recombinant protein production in the          
next-generation CHO cell factories. 
First, a reporter-based screening method for high production capacity was established, that            
is able to rank statically-grown clones according to either volumetric productivity (overall            
yield) or a proxy of specific productivity (per cell yield). By systematically comparing the two               
clone screening criteria, we demonstrated that they perform similarly in terms of isolating             
CHO clones with high volumetric productivity in suspension.  
Second, a toolbox combining the CRISPR/Cas9 system with a recombinase-based system           
was developed to generate cell lines with so-called landing pads integrated in defined             
genomic sites. The toolbox allows targeted gene integration, followed by streamlined           
recombination of the expression cassette into the landing pad of a genetically identical cell              
line. This approach is exploited for systematic evaluation of site-specific gene expression            
modulated by different expression cassette components. We demonstrated that distinct and           
robust recombinant gene expression can be achieved in defined integration sites in CHO             
cells.  
Third, ectopic expression of target genes for improving the secretory capacity of CHO cells              
was reviewed and studied. We identified three novel target genes increasing specific            
productivity of CHO cells, transiently expressing different monoclonal antibodies. We          
attempted to unveil the mechanism of novel target genes by examining the rate-limiting step              
in production of these monoclonal antibodies. 
Overall, the tools developed in this thesis can in the future enable more rational engineering               
of CHO cell factories for production of a variety of complex biotherapeutics.  
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 Dansk sammenfatning 
Kinesisk hamster ovarie (CHO) celler er den mest dominerende cellefabrik til produktion af             
forskelligartede rekombinante terapeutiske proteiner. Kompleksiteten af de terapeutiske        
proteiner, og den stigende efterspørgsel efter CHO cellers hurtige og omkostningseffektive           
produktion af produkter i høj kvalitet, har gjort fremstillingen til en yderst sofistikeret             
proces. For at imødekomme kravene til bedre og billigere terapeutiske proteiner er det             
nødvendigt at forbedre produktionen af rekombinante proteiner i CHO celler yderligere. I            
denne afhandling præsenterer vi klon screening og genmanipulationsværktøjer, der sigter          
mod at forbedre og lette forudsigeligheden af produktionen af rekombinante proteiner i            
næste generations CHO celle fabrikker. 
For det første blev der etableret en reporterbaseret screeningsmetode for høj           
produktionskapacitet, der er i stand til at rangere statisk dyrkede kloner i henhold til enten               
den volumetriske produktivitet (det samlede udbytte) eller en proxy for specifik produktivitet            
(udbytte per celle). Ved systematisk sammenligning af de to screeningskriterier viste vi, at de              
har tilsvarende effektivitet med hensyn til isolering af CHO kloner med høj volumetrisk             
produktivitet i suspension. 
For det andet blev en værktøjskasse, hvori CRISPR/Cas9-systemet blev kombineret med et            
rekombinase-baseret system, udviklet til at generere cellelinjer med såkaldte landingspuder          
integreret i definerede genomiske positioner. Værktøjskassen tillader målrettet        
genintegration, efterfulgt af rekombination af en udtrykkelseskassette i landingspuden i en           
genetisk identisk cellelinie. Denne fremgangsmåde udnyttes til systematisk evaluering af          
stedsspecifik genudtrykkelse moduleret af forskellige udtrykkelseskassettekomponenter. Vi       
demonstrerede, at robust rekombinant genudtrykkelse kan opnås i definerede         
integrationssteder i CHO celler. 
For det tredje undersøgte vi ektopisk udtrykkelse af specifikke gener med det formål at              
forbedre CHO cellernes sekretoriske kapacitet. Vi identificerede tre nye gener, der øger den             
specifikke produktivitet i CHO celler, der transient udtrykker forskellige monoklonale          
antistoffer. Vi forsøgte at afsløre mekanismen for de nye gener ved at undersøge det              
hastighedsbegrænsende trin i produktionen af disse monoklonale antistoffer. 
Samlet set kan værktøjerne der er blevet udviklet i denne afhandling fremover muliggøre             
mere rationel konstruktion af CHO cellefabrikker til produktion af en række komplekse            
terapeutiske proteiner.  
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 The aim of the thesis 
The aim of the thesis was to develop tools addressing different biomanufacturing            
developments towards improved and predictable recombinant protein production in Chinese          
hamster ovary (CHO) cells. In order to produce biotherapeutics faster and cheaper, the thesis              
had the following two overall objectives:  
1) To increase the titer of produced biotherapeutics via improvements in specific productivity             
(​q​
p​) ; and  
2) To increase the predictability and tunability of biotherapeutics production, enabling faster            
product development and speed-to-market.  
The first objective has been addressed by developing a method, capable of screening for CHO               
clones with high ​q ​
p
and by ectopically expressing target genes (throughout the thesis referred              
to as effector genes) improving the ​q ​
p
of CHO cells. The second objective has been addressed                
by developing a toolbox that allows systematic evaluation of site-specific recombinant gene            
expression levels in CHO cells in order to achieve predictable and desirable recombinant             
gene expression. 
The structure of the thesis 
The thesis is divided into the Introduction, Rationales and Chapters 1-4 and Concluding             
remarks and future perspectives. 
 
In the ​Introduction​, the topics addressed by different thesis chapters are presented in             
more detail. First, cell line development is discussed briefly, focusing on selection methods             
for isolating high-producing clones. And second, cell line engineering approaches by gene            
introduction are discussed due to engineering strategies used in the scope of this thesis.              
Specific focus is given to: a) CRISPR/Cas9-mediated and recombinase-based targeted gene           
integration into predefined integration sites, and b) host cell line engineering via effector             
gene overexpression.  
 
In ​Chapter 1 (​Research Article I​), a platform for selecting high-producing clones was             
established, able to assess two different early reporters under static cultivation of CHO cells:              
a proxy of ​q​
p
and titer. Further, the performance and predictability of the two early reporters                
for high ​q​
p​ and titer in suspension cultivation were systematically compared.  
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 Next, ​Chapter 2 (​Manuscript in submission II​) presents a CRISPR/Cas9-based          
toolbox, coupled with recombinase-based system that allows construction of CHO cell lines            
with a site-specifically integrated landing pad. By recombining different expression cassettes           
into the landing pad, a systematic evaluation of site-specific recombinant gene expression            
was performed. 
 
Chapter 3 (​Review Article III​) is a review, discussing the engineering potential of ectopic              
expression of beneficial effector genes to improve the secretory capacity of CHO cells. Several              
experimental and cellular factors are reviewed with the objective of guiding the future             
studies on overexpression of effector genes. 
  
Finally, ​Chapter 4 (​Manuscript in preparation IV​) is a study that identifies three novel              
effector genes that improve the ​q ​
p
of CHO cells when transiently producing different IgG1              
molecules. The work builds on guidelines from Chapter 3 to further examine the conditions              
enabling the effector genes to increase the secretory capacity of CHO cells. 
 
In the end, ​Concluding remarks and future perspectives provide a summary of the             
results achieved in this thesis, with the implications made in the field of recombinant protein               
production in CHO cells.  
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 Introduction 
1. Chinese hamster ovary (CHO) cells 
Production of recombinant proteins for biotherapeutic use in humans is commonly           
performed using mammalian cells, such as CHO cells or Human embryonic kidney            
(HEK293) ​(1, 2)​. CHO cells are a well-established and most popular host for biotherapeutics              
production due to their ability to make human-like post-translational modifications and           
having a long history of regulatory approval and established bioindustrial pipelines ​(3)​.            
Further, CHO cells are non-permissive for most human viruses and are easily adapted to              
grow at high density in serum-free suspension conditions and chemically defined media ​(4)​.             
Despite being the mammalian host of choice with sufficient recombinant protein yields, CHO             
cells still exhibit significant bottlenecks in comparison to bacteria and yeast regarding            
growth capacity, cultivation time and product yield ​(5, 6)​. Even though some biotherapeutics             
are produced in bacteria due to above-mentioned advantages, the majority of top-selling            
biotherapeutics requires post-translational modifications (including monoclonal antibodies       
(IgGs) and erythropoietin), such as glycosylation. The post-translational modification         
profiles of biotherapeutics significantly influence solubility, bioactivity, stability and         
immunogenicity ​(4)​. Therefore, most biotherapeutics are produced in mammalian cells,          
accounting for over 70% of biotherapeutics sales revenue ​(7)​, with 70% of those products              
produced in CHO cells.   
 
1.1. Biotherapeutics production  
Establishing an upstream (cell line development and bioreactor production) and          
downstream bioprocesses (product isolation and purification) for a new biotherapeutic          
requires considerable investment in time, labor and costs. To enable the development of             
manufacturing pipelines with cost-effective and high-yielding production of biotherapeutics,         
a steady improvement of CHO cell factories in regard to growth, product yield and quality is                
a key challenge ​(2)​. Further, there is a significant pressure to shorten the development              
timelines for new biotherapeutics, therefore, predictability and flexibility of production          
processes are of high importance. 
Due to the work conducted in this thesis, the focus of the introduction will be on the                 
upstream process development, as a way to achieve improved and predictable recombinant            
protein production in CHO cells.  
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 2. CHO cell line development 
For industrially relevant production of recombinant proteins, stably producing cell lines have            
to be established during a process of cell line development (CLD). The CLD process generally               
consists of: a) transfection of a gene of interest (GOI) and random integration into the               
genome; b) an enrichment of cells expressing the GOI via antibiotic selection typically             
combined with selection of cells with high expression levels by gene amplification; c)             
single-cell cloning; d) screening for desirable, high-producing clones; and finally e) scale-up            
of selected clones ​(8)​. Since these processes are time-consuming and labor-intensive, there is             
a great demand for optimizing the CLD. Traditionally, improvements were made by            
empirically optimizing a variety of the extrinsic factors such as: a) expression vectors ​(8)​, b)               
selection and gene amplification processes ​(9–11)​, c) production media ​(12) and d) methods             
for screening clones with high productivity ​(13)​.  
Optimization of the CLD and bioprocess has been the focus of the earlier studies, with               
innovative technologies developed, mostly improving the volumetric productivity (product         
titer) of recombinant proteins produced in CHO cells. Indeed, the CLD and bioprocess             
optimizations have greatly improved the recombinant protein titer in CHO cells by more             
than 100-fold over the past few decades ​(14)​, reaching yields well over 10 g/L ​(15)​. CHO CLD                 
is currently still predominantly focused on isolating high-producing clones and ensuring           
monoclonality. ​Selection of high-producing clones from a heterogenous pool of transfected           
cells remains one of the most crucial steps in CLD. That is because random integration of                
GOI generates clones with different integration sites and varying number of gene copies             
inserted ​(16)​, and therefore heterogenous recombinant protein expression levels. ​However,          
with the recent emergence and continuously improving Chinese hamster and CHO genomic            
resources ​(17–21) and efficient genome editing technologies, targeted genetic manipulation          
(22)​, -omics studies ​(23–26)​, and modeling efforts ​(27) have become increasingly important            
to further characterize and improve the CHO cell factory. To further increase the production              
characteristics of CHO cells, appropriate solutions beyond the natural biology of CHO cells             
seem necessary - that is, solutions from rational CHO cell engineering-based approaches. 
 
2.1 Development of selection methods for isolation of        
high-producing clones 
The traditional and straightforward selection methods for isolating high-producing clones          
include limiting dilution cloning ​(28)​, selection via antibiotic resistance ​(29) and gene            
amplification (​i.e. methotrexate/dihydrofolate reductase (MTX/DHFR) system and       
methionine sulphoximine/glutamine synthetase (MSX/GS) system) ​(11, 30)​. However, these         
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 fundamental methods are being replaced or combined with more advanced and           
high-throughput techniques in the industrial setting. To save time, labor and resources,            
fluorescence-activated cell sorting (FACS) has become increasingly more utilized for          
high-throughput isolation of high-producing clones ​(31)​. One of the most widely-used           
methods utilizing FACS is a technique that traps secreted recombinant protein on the surface              
of the cell at low temperature and detects it with a specific, fluorescently labelled antibody               
(32)​. This surface labeling method enables enrichment of cells with high ​q ​
p
and has been               
efficiently used in the industry. Increasingly more sophisticated automated selection systems           
have been developed to facilitate screening of hundreds to thousands of clones, reducing the              
required labor and significantly increasing the efficiency of selection. Fluorescence-based          
systems, such as ClonePix and LEAP ​(33–35)​, robotic systems, such as Cello and CellSpot              
(36, 37)​, and completely automated systems ​(38) have been developed, achieving remarkably            
high throughput. However, due to the high cost, the use of these automated systems is               
mostly limited to the industrial setting. Further, isolated high-producing clones have to be             
tested in large-volume bioreactors, relevant for the commercial ​production. It has been            
shown previously that high-producing clones at small growth scales are not necessarily the             
best clones for the industrial production ​(39, 40)​. Therefore, there is a high demand for clone                
selection methods that are predictive of clones’ commercial performance.  
 
3. CHO cell line engineering 
To meet the ever-growing demand for higher quantity, quality and affordability of produced             
biotherapeutics, further development of more efficient production cell lines is required.           
Expansion of the bioindustrial pipeline with a wide range of non-IgGs, more            
difficult-to-express biotherapeutics further challenges both, the manufacturability and        
timelines to achieve a commercially viable solution. Therefore, the empirical optimization of            
extrinsic factors during CLD would benefit from the rational engineering of the host cell. By               
rationally designing the desired phenotype, rather than screening for it, the predictability            
and further improvement of recombinant protein production in CHO cells can be achieved.  
Targeted engineering-based approaches for CHO cells have considerably improved         
biotherapeutic production and accelerated the manufacturing timelines, by optimizing a          
variety of cellular factors. Host cell engineering of cell growth, ​q​
p​, and protein quality have               
been performed using a variety of different molecular tools, such as gene overexpression,             
gene knockout and RNA interference-mediated knock-down ​(41)​.  
The availability of CHO genomic resources and generated -omics data, such as proteomics,             
transcriptomics, metabolomics and glycomics ​(42)​, have brought a vast potential to further            
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 improve the CHO host by identifying phenotypes of interest and effector genes to engineer.              
Highly efficient genome editing tools have recently become available to further realize the             
potential of engineering and facilitate validation and ​multiplexing of different engineering           
modifications ​(43)​. And finally, recently developed ​genome-scale models have the potential           
to be used for better understanding of the complex gene interactions and to predict the               
impact of the modifications and thereby further guide the engineering efforts  ​(27)​. 
   
3.1 Engineering of host cells with CRISPR/Cas9-mediated and        
recombinase-based targeted integration  
Targeted GOI integration might not be able to compete with recombinant protein yields             
achieved by random, multi-copy GOI integration. However, the main advantage of targeted            
integration seems to be the stability of gene expression and minimal clonal variation             
(44–47)​. Minimal differences in gene expression are observed due to diminished variability            
in gene copy numbers and the genomic integration site (so-called position effect) ​(48)​.             
Site-specific integration of GOI has traditionally been achieved using recombinase-based          
systems (such as Cre/loxP and Flp/FRT), that enabled integration of so-called landing pads,             
harboring recombination sites, into transcriptionally active sites of the genome ​(49, 50)​.            
Predictable and sustained gene expression can be achieved when GOIs are integrated into             
well-characterized integration sites, so-called ‘safe harbors’. Further, if these integration sites           
provide high-level gene expression, they are called transcriptional ‘hotspots’.         
Recombinase-based systems have been used to identify hotspots in the genome by random             
integration of a GOI vector and subsequent screening for a single-copy integration with high              
expression levels ​(51–53)​. As hotspots seem to be rare in the genome, extensive screening is               
needed to identify the desirable clone. Furthermore, since these newly discovered hotspots            
are uncharacterized, testing of expression stability has to be carried out. However, once             
identified, the master clone with an ideal hotspot can be reused for expression of any GOI                
using ​recombinase-mediated cassette exchange (RMCE)​.  
Recently, more advanced genome editing tools have been developed, such as zinc-finger            
nuclease (ZFNs), transcription activator-like effector nucleases (TALENs) ​and the latest          
RNA-guided engineered nucleases, such as CRISPR (clustered regularly interspaced short          
palindromic repeats)/Cas9 (CRISPR-associated protein 9) system ​(54)​. ​The cost and          
time-efcient manner together with the ease of use provided by the CRISPR/Cas9 systems             
offer major advantages over ZFNs and TALENs which require lengthier timeframes due to             
extensive protein engineering required ​(54)​. ​Originating as a component of prokaryotic           
adaptive immunity, CRISPR/Cas9 type II system has recently been repurposed into a            
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 versatile, highly efficient and remarkably powerful tool for genome engineering ​(55–60)​. The            
system is based on Cas9, an RNA-guided DNA endonuclease, that upon base pairing between              
the single guide RNA (sgRNA) and the target DNA site-specifically induces double strand             
breaks ​(61)​. Upon the double strand break, endogenous DNA damage repair pathways are             
activated, which can be harnessed for different genomic modifications, such as gene            
knockout, gene correction/knockin or chromosome rearrangements ​(62)​. ​The double strand          
break is repaired either by non-homologous end joining (NHEJ), that can result in insertions              
or deletions (indels), or homology-directed repair (HDR). Due to the work conducted in this              
thesis, only one application of CRISPR/Cas9-mediated genome editing will be discussed here            
in more detail,​ i.e. ​site-specific gene integration via HDR mechanism.  
When double strand breaks are desired to be repaired via HDR mechanism, an exogenous              
donor repair template harboring homologous DNA sequences (referred to as homology           
arms) can be co-delivered together with the CRISPR/Cas9 system. The donor repair template             
is then used to incorporate a GOI into a defined target site via HDR, specifically homologous                
recombination (HR) ​(63)​. This approach has been successfully used in mammalian cells to             
achieve site-specific integration of GOIs encoding reporter proteins and/or antibiotic          
selection markers ​(16, 55, 64)​. Nowadays, safe harbor integration sites conferring high and             
stable gene expression levels can be identified experimentally or predicted ​in silico and             
retargeted with CRISPR/Cas9-mediated genome editing via HDR. Previous work from our           
group has indeed demonstrated that stable and homogeneous gene expression with minimal            
clonal variation can be achieved using CRISPR/Cas9-mediated targeted integration ​(16, 65)​.           
Therefore, targeted integration into predefined, well-characterized integration sites using         
CRISPR/Cas9-mediated genome editing is an attractive approach for CLD. That is due to             
potentially no need for comprehensive clone screening and expression stability testing,           
which would significantly shorten the CLD timelines. CRISPR/Cas9-mediated targeted         
integration can be coupled with recombinase-based systems facilitating even more flexibility           
to express GOIs ​(65–67)​. Further, the combined approach can be undertaken to screen             
different GOI expression cassettes in a site-specific manner, as it will be demonstrated in              
Chapter 2​. 
In conclusion, the development of CRISPR/Cas9-mediated genome editing has transformed          
the way we approach CHO cell factory engineering ​(22)​. CRISPR/Cas9-mediated targeted           
gene integration into the host genome has enabled increased control over recombinant            
protein expression, thus accelerating the process of CLD for industrial CHO cell lines.             
Further, CRISPR/Cas9-mediated targeted engineering opens up opportunities for delivery of          
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 multigene systems and therefore further enhancement of CHO cells in regard to cell             
productivity, growth, metabolism and product quality.  
 
3.2 Engineering of host cells via ​effector gene​ overexpression 
Engineering of CHO cells via overexpression of ​effector genes for improvement of protein             
production has been frequently exploited in the last decades ​(41)​. Expression of beneficial             
effector genes can be achieved by ectopic overexpression, allowing for the establishment of a              
gain-of-function phenotype. Many different cellular pathways have been targeted by genetic           
engineering of CHO cells via effector gene overexpression to improve the recombinant            
protein production, such as apoptosis ​(68, 69)​, metabolism ​(70–72)​, cell cycle regulation            
(73) and glycosylation ​(74, 75)​. Another common strategy employed is overexpressing           
effector genes involved in protein biosynthesis ​(76–78) and secretory pathway ​(79–81)​, in            
order to increase the cellular productivity and secretion rates of recombinant proteins.            
Indeed, a recent CHO genome-scale metabolic model ​(27) predicts that traditionally used            
approaches to boost productivity in CHO cells, such as an addition of histone deacetylase              
inhibitors for general increase in mRNA and protein levels, are inefficiently utilizing the             
available metabolic resources. Instead, rational engineering of the host cells’ secretory           
pathways has a higher potential to improve the secretory capacity ​(27, 82)​. ​With the recent               
availability of the reference genome resources ​(17–21)​, a more complete gene expression and             
mutation landscape of CHO cell lines can be obtained, identifying novel effectors that could              
be overexpressed. This could facilitate cell engineering efforts and further improve           
recombinant protein production.  
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A Brute-Force Approach: Screening for 
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 Rationale 
In early stages of CLD, statically-grown monoclonal CHO cell lines are usually selected as              
high-producing either according to measurements of product titer or product titer           
normalized to cell number. Therefore, a relatively high-throughput clone screening method           
was developed as part of this thesis, assessing titer and confluence in 96-well microtiter              
plates. A proxy of ​q ​
p
​was established, so-called titer-to-confluence (TTC) ratio, mimicking the             
titer-to-integral viable cell density (IVCD) ratio (​i.e. ​q ​
p​). TTC was introduced as an early              
reporter in order to increase the selection of clones achieving high final titer through high ​q ​
p
                
characteristics. In this study, Etanercept-producing clones were generated and then ranked           
based on either titer or TTC with the objective to perform a first unbiased comparison of the                 
two early reporters for the clone performance in suspension culture. 
 
The project of developing a ​q​
p​-based clone screening method was primarily initiated to             
generate a panel of different recombinant protein-producing cell lines with high ​q ​
p​, needed             
in other studies within this thesis. Therefore, we also applied the presented ​q​
p​-based clone              
screening method for generation of IgG (Rituximab)-producing cell lines without the           
GS-based gene amplification in order to generate low-copy, high ​q​
p​-producing clones. First,            
stable high-producing clones were needed to discover new safe harbor integration sites for             
reverse engineering. A stable, relatively high-producing clone was identified with no           
detectable decrease in ​q​
p
or Rituximab gene copies throughout the long-term culturing            
(throughout the manuscripts referred to as the C6_2 producer). Using this clone, we were              
able to identify a novel integration site conferring high and stable gene expression. This              
newly discovered safe harbor integration site was used in ​Chapter 2​, where systematic             
evaluation of site-specific recombinant gene expression was carried out. And second,           
high-producing clones with possible secretion bottlenecks were needed as screening hosts to            
identify effector genes that would be beneficial for improving the secretory capacity of CHO              
cells. For that reason, two stable Rituximab high-producing clones (one of them being the              
C6_2 producer) were used in ​Chapter 4 during the process of characterization of novel,              
q​
p​-increasing effector genes. 
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171. Introduction
Chinese hamster ovary (CHO) cells con-
tinue to be the cell factory of choice for
large-scale biopharmaceutical produc-
tion.[1] To produce a therapeutic protein
with the required quality properties accord-
ing to FDA and EMA regulations, a stable
clonal cell line has to be generated,
enabling long-term and reproducible pro-
tein expression.[2] Therefore, the classical
cell line generation procedure consists of
random integration of the transgene into
the genome of host cells, followed by
selection of transgene containing cells
using antibiotics or other transgene selec-
tion strategies like methionine sulfoximine
(MSX). Subsequently, single-cell cloning
and ﬁnally, selection of high-producer
clones from the bulk of low- and non-
producers are performed.[3] Selection of
high-producer clones remains one of the
major bottlenecks in cell line development
(CLD), taking up 4 to 8 months and
consuming valuable ﬁnancial and human
resources.[4] Random transgene integra-
tion, different transgene copy numbers,and the selection pressure encountered during CLD all
contribute to genetically heterogeneous cell populations thatal Sciences
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- Chapter 1 -require efﬁcient screening processes. Several strategies have
been developed in recent years to improve the ease, throughput
and performance of the selection processes, carefully reviewed
by Priola et al.[5] These strategies are to a certain degree used in
academic labs, but even more so in industrial settings, where
highly automated pipelines are employed.[6–8]
One of the main interests during CLD is selecting clones
predictive of commercial performance. In order to increase the
chances of obtaining clones with desired high-producing
performances, the ﬁnal product yield (maximum titer) is a key
parameter to assess in early stages of CLD.High product yield can
be achieved via high speciﬁc productivity (qp) and/or high integral
of viable cell density (IVCD).[9] Both IVCD and qp depend on
extrinsic factors that differ substantially between small-scale and
large-scale cultures.[10] However, both parameters also depend on
the intrinsic features of the producer clone that must be selected
for during the screening process. When clones progress from
small-scale to large-scale cultures, they usually undergo several
assessment stages, which include different growth vessels. Early
assessment stages are known to not be very predictive of the
behavior in theﬁnalprocesses.[11,12]Nonetheless, earlypredictions
represent a critical decision-making step in theselectionprocessof
which clones to discard or conversely, which clones with the most
promising features to proceed with. Typically, the primary
screening and ranking of suspension-adapted clones cultured
statically (without shaking) in microtiter plates is based on either
theproductconcentration(titer)[7] oraproxyofqp.
[8,11]To thebestof
our knowledge, a side-by-side comparison of how these two early
reporters perform in terms of selecting CHO clones with high
volumetric productivity in suspension cultures has not yet been
reported.
In order to investigate the performance of titer and proxy of qp
as early reporters for volumetric productivity, we generated a
polyclonal cell line by transfecting CHO-S cells with a plasmid
co-expressing glutamine synthetase (GS) and etanercept and
then applied MSX-selection. Etanercept is a homodimeric Fc-
fusion therapeutic protein that is considered a potentially
difﬁcult-to-express protein due to its highly O-glycosylated
regions.[13–15] We then developed a screening platform that
combines enrichment of high qp by surface labeling-based
ﬂuorescence activated cell sorting (FACS) with high-throughput
(HT) and semi-automated conﬂuence analysis of cells cultured
statically as well as determination of titer in 96-well plates. A so-
called titer-to-conﬂuence (TTC) ratio is introduced as a proxy for
qp for statically cultured cells. Finally, we performed an unbiased
evaluation of titer- and TTC-based ranking as early reporters for
growth rate as well as for speciﬁc and volumetric productivity.
We conclude that using titer and TTC as early reporters results in
selection of etanercept clones with similar volumetric produc-
tivity in batch cultures.2. Experimental Section
2.1. Plasmid Design and Construction
A plasmid co-expressing GS and etanercept in a pcDNA3.1(þ)
backbone (PL_GS-etanercept; Figure S1, Supporting Informa-
tion) was constructed with uracil-speciﬁc excision reagentBiotechnol. J. 2018, 13, 1700216 1700216 (2
18cloning method using ﬂexible assembly sequence tags, uracil-
containing primers and Phusion
1
Hot-Start Flex polymerase
(New England Biolabs, Ipswich, MA), as previously described.[16]
The GS expression cassette (pSV40-GS-SV40pA) as well as the
vector backbone without the zeocin resistance gene expression
cassette were directly ampliﬁed from a pcDNA3.1/Zeo(þ)-GS
vector. The etanercept expression cassette was ampliﬁed
from a pDRIVE5-etanercept expression vector, which had been
made by subcloning a DNA fragment with the coding sequence
of etanercept (GeneArt, Regensburg, Germany) into the
commercial pDRIVE5 vector (InvivoGen, San Diego, CA). The
etanercept expression cassette (mCMV-hEF-1a-5’HTLV-etaner-
cept-SV40pA) comprises a promoter, consisting of an mCMV
enhancer element, a hEF-1a promoter element, and a 5’ HTLV
untranslated region (UTR). The etanercept coding sequence is
based on the amino acid sequence with accession number 7783
from the IMGT database.[17] The nucleotide sequences of the
etanercept and GS-expression cassettes are provided in Table S1
and S2, Supporting Information, respectively. Plasmids used as
PCR templates are listed in Table S3, Supporting Information.
Assembled PCR fragments were transformed into Escherichia
coliMach1 competent cells (Life Technologies, Carlsbad, CA). All
constructs were veriﬁed with sequencing and puriﬁed using
NucleoBond Xtra Midi EF (Macherey-Nagel, Du ̈ren, Germany)
according to manufacturer’s instructions.2.2. Cell Culture, Transfection, and Generation of an
Etanercept-Expressing Polyclonal Cell Line
CHO-S suspension cells (Life Technologies) were grown in CD
CHO medium (Life Technologies) supplemented with gluta-
mine synthetase expression medium supplement (GSEM;
Sigma–Aldrich, St. Louis, MO) and 2mL/mL anti-clumping
agent (Life Technologies). Cells were maintained in 125mL
Erlenmeyer shake ﬂasks (Corning Inc., Acton, MA), incubated at
37 C, 5% CO2 at 120 rpm (25mm shaking amplitude) and
passaged every 2–3 days. In order to establish a stable etanercept-
expressing polyclonal cell line, 4.5 106 cells were transfected
with 5.4 μg of plasmid DNA using Amaxa Cell Line Nucleofector
Kit V system (Lonza, Basel, Switzerland) and program U-024 on
a Nucleofector
1
2b device (Lonza), according to the manufac-
turer’s protocol. Cells were then seeded at 4.5 105 cells/mL in a
125mL shake ﬂask and 3 days after transfection, selection for GS
expression was initiated by adding 25 μMMSX (Sigma–Aldrich;
Cat. M5379). After 14 days of selection, cells were subjected to an
increased selection pressure (50 μM MSX).2.3. Surface Labeling of Etanercept and FACS
To enrich for cells with high qp, immunostaining of etanercept
on the plasma membrane (surface labeling) was performed on
the etanercept-expressing cell pool by staining with an anti-
human IgG Alexa Fluor 488 antibody (Thermo Fischer
Scientiﬁc; Cat. A-11013) and 0.4 μg/mL propidium iodide (PI,
Thermo Fischer Scientiﬁc) at 4 C, as previously described.[18]
Two gates were used for sorting cells on FACS (BD FACSJazzTM,
BD Biosciences, San Jose, CA): 1) a PI-positive/negative gate© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 10)
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high qp which was set at top 5% highest Alexa Fluor 488 intensity.
Only viable cells were sorted and cells were either gated for top
5% highest Alexa Fluor 488 intensity or not (surface labeled, top
5%-enriched and surface labeled, non-enriched, respectively).
Cells were bulk (1 105 cells/well) and single-cell sorted into
ﬂat-bottom Corning 96-well plate (VWR, Radnor, PA; Cat.
734-0954) and ﬂat-bottom Corning 384-well plates
(Sigma–Aldrich; Cat. CLS3542-50EA), respectively. Bulk-sorted
cells were expanded in suspension and transferred to a 6-well
plate, where cells were seeded at a density of 3 105 cells/mL
and cultivated under 50 μMMSX selection for 3 days to assess qp.
Single cells were sorted in 30 μL of CD CHO medium,
supplemented with GSEM, 1.5% HEPES (Gibco) and 1
Antibiotic-Antimycotic (Gibco). Fifteen days after single-cell
sorting, the entire volume of sub-conﬂuent clones incubated
statically in the absence of MSX was transferred to 200 μL of CD
CHO medium, supplemented with GSEM and 1 Antibiotic-
Antimycotic in ﬂat-bottom 96-well plates using an epMotion
1
5070 liquid handling workstation (Eppendorf, Hamburg,
Germany). Subsequently, the 384-well plates were visually
inspected in order to ensure that the majority of the cells had
been successfully transferred.2.4. Titer and Confluence-Based Screening of Clones
Following 2 days of static incubation in 96-well plates, the single-
cell sorted cells were re-suspended by pipetting to ensure an even
spread of cells on the bottom of the wells. The day after, all clones
were sub-conﬂuent and the conﬂuence (the percentage of the well
coveredbycells) andthenumberof cells ineachwellwasestimated
by image cytometry analysis using the Celígo Imaging Cell
Cytometer (Nexcelom Bioscience, Lawrence, MA) with the label-
free, bright ﬁeld conﬂuence or direct cell counting application,
respectively. A total of 100μL of the spent media from the 96-well
plateswere aspirated andanalyzed for etanercept titer as described
below. Titer valueswere divided by conﬂuence in order to compute
TTC ratios (TTC¼ titer[μg/mL]/conﬂuence[%]). Then either TTC
or titer alone were used to rank all clones. This initial titer- and
TTC-based ranking was used throughout the study in order to
evaluate the performance of titer and TTC as early reporters for
volumetric productivity.2.5. Batch Cultivation in 96-Well Plates in Suspension
Selected single-cell derived clones were expanded without MSX
selection into pre-sterilized polystyrene 96-square System Duetz
half-deepwell (HDW)-plates (CR1496c, Enzyscreen, Haarlem,
the Netherlands) capped with autoclaved low-evaporation
sandwich Duetz covers (CR1296a, Enzyscreen). Plates were
incubated in a humidiﬁed S41i shaking incubator (New
Brunswick, Eppendorf, Hamburg, Germany) at the following
conditions: 37 C, 5%CO2, 325 rpm (25mm shaking amplitude).
In order to assess productivity of clones, cells were seeded in a
range of 1 105–1.5 106 cells/mL. Clones below this seeding
range were excluded from the analysis. Viable cell density (VCD)
and viability were measured daily. In order to make exponentialBiotechnol. J. 2018, 13, 1700216 1700216 (3
19growth possible throughout the experiment, etanercept titers
were determined after 2 days. qp was calculated as described
elsewhere.[19] In parallel with the 2-day batch culture experiment,
a longer-term batch experiment was performed in 96-HDW
plates for the same set of clones. Seeding density was in the
range of 1 105–7.5 105 cells/mL. Clones outside of this
seeding range were excluded from the analysis. Final titers of the
entire set of clones were measured when 50% of the clones
reached a viability below 65%.2.6. Batch Cultivation in Shake Flasks
The top clones from each ranking (TTC- and titer-based) were
further evaluated in duplicates in 125mL shake ﬂasks without
MSX selection. Cells were seeded at 4 105 cells/mL in 40mL
CDCHOmedium, supplemented with GSEMand 2mL/mL anti-
clumping agent. Cells were incubated at 37 C, 5% CO2 at
120 rpm (25mm shaking amplitude). VCD, viability, and
etanercept titers were measured daily. Cultures were discon-
tinued when viability dropped below 50%.2.7. Viability and VCD
When cells were grown in 96-well HDW plates, viability and
VCD were determined by a combined Hoechst and PI stain on
the Celígo Imaging cytometer as previously described.[20]
Viability and VCD of cells in 6-well plates and 125mL shake
ﬂasks were determined on the NucleoCounter NC-200 Cell
Counter (Chemometec, Allerod, Denmark) using Via1-Cassettes
and the “Viability and Cell Count Method 2” assay.2.8. Titer Measurements
Etanercept titers were determined in supernatants by bio-layer
interferometry using protein A biosensors and an Octet RED96
system (ForteBio, Pall, Menlo Park, CA) as previously
described,[21] with an increased shaking speed of 1000 rpm.
The absolute titers of etanercept were calculated using a
calibration curve generated from a dilution series of Enbrel
(Pﬁzer, New York City, NY; Lot R51698) and absolute
quantiﬁcation was validated by Coomassie-stained SDS-PAGE
gels as previously described (data not shown).[22]2.9. Statistical Analyses
All statistical analyses were performed using GraphPad Prism 7
software (GraphPad Prism Software Inc., La Jolla, CA). To
analyze the correlation between two variables, either linear
regression or nonlinear regression was used. Nonlinear
regression was used when data points were not equally scattered
across the entire y range, and nonlinear regression was
performed by applying a straight line or a line through origin
model with relative weighting. When nonlinear regression was
used, outliers were identiﬁed and excluded using the ROUT
method,[23] where maximum false discovery rate (FDR) was set© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 10)
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(p< 0.05) between the data points of two groups, different
unpaired parametric or nonparametric t-tests were performed.
Nonparametric Mann–Whitney test was used when data points
were not normally distributed according to the D’Agostino–
Pearson test. When variances from two populations were not
equal according to F-test, Welch’s correction was used.3. Results and Discussion
In this study, we set out to compare how product titer as well
as product titer normalized to conﬂuence (TTC) of suspen-
sion-adapted clones in static cultures perform as earlyFigure 1. Study design: evaluating surface labeling enrichment and comparin
An etanercept-producing polyclonal pool was established by nucleofection of C
(GS) on Day 1 and methionine sulfoximine (MSX) selection was subsequen
sorted and bulk sorted for: a) propidium iodide(PI)-negative cells (non-enric
intensity (top 5%-enriched). Bulk sorted cells were expanded and their sp
Following 15 days of static incubation in the absence of MSX, single-cell colo
static incubation without MSX selection, clones were screened for titer and co
clones were ranked according to titer and titer-to-confluence (TTC) ratio. Fo
deepwell (96-HDW) plates: 1) randomly picked top 5%-enriched clones, 2) ran
titer-selected clones. Surface labeling enrichment was evaluated by comparing
(μ), qp and volumetric productivity) in batch suspension cultures between TT
First, between groups 1), 3), and 4) in 96-HDW plates, and second, between a
flasks. The measurements obtained in 96-HDW plates and shake flask batc
Biotechnol. J. 2018, 13, 1700216 1700216 (4
20reporters for growth rate, speciﬁc and volumetric productivity
of CHO cell suspension batch cultures (see Figure 1 for details
on the study design). We hypothesized that the titer-based
ranking is biased toward clones with a fast-growing phenotype
in static cultures. Since the growth proﬁle changes dramati-
cally when moving clones from static to suspension culturing
conditions,[11,12] this type of ranking could give rise to poor
predictability of the ﬁnal clone performance in batch cultures.
However, by normalizing titer to conﬂuence (TTC-based
ranking), high qp clones would be selected instead. Since qp in
our experience is generally less prone to variations between
growth formats, we hypothesized that TTC-based selection
had the potential to not only select clones with high qp, but
also with high volumetric productivity.g clone performance obtained by TTC- and titer-based selection strategies.
HO-S cells with a plasmid encoding etanercept and glutamine synthetase
tly applied. The polyclonal pool was then surface labeled and single-cell
hed control) and b) PI negative-cells in the top 5% of anti-IgG fluorescent
ecific productivity (qp) evaluated in a 6-well plate under MSX selection.
nies were transferred from 384-well to 96-well plates. Following 3 days of
nfluence by bio-layer interferometry and image cytometry, respectively. All
ur groups were selected for further evaluation in suspension in 96-half-
domly picked non-enriched clones, 3) top TTC-selected clones, and 4) top
qp between groups 1) and 2). Clone performance (specific cell growth rate
C- and titer-based selection was compared twice without MSX selection.
reduced number of highest ranking clones from groups 3) and 4) in shake
h cultures were compared. SC, single-cell; D1, Day 1.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 10)
Figure 2. Surface labeling combined with FACS enriches for etanercept-producing clones with high specific productivity (qp). Etanercept-expressing cell
pool was stained with an anti-human IgG Alexa Fluor 488 antibody (surface labeling) and cells were bulk and single-cell sorted for top 5% highest Alexa
Fluor 488 fluorescence. A) Evaluation of qp for bulk sorted non-enriched and top 5%-enriched cells. Subsequent to FACS sorting, cells were recovered
andmaintained in methionine sulfoximine (MSX)-containing medium and qp was assessed in 2-days batch cultures (Day 39–41 after nucleofection) in a
6-well plate in technical triplicates. Statistical significance was calculated using unpaired t-test (bars represent mean). B) Evaluation of qp for single-cell
sorted, randomly picked non-enriched (n¼ 44) and randomly picked top 5%-enriched (n¼ 43) clones. qp was assessed in 2-days batch cultures
(Day 44–46 after nucleofection) without MSX selection in a 96-half-deepwell (96-HDW) plate. Statistical significance was calculated using
Mann–Whitney test (bars represent median with interquartile range (IQR)).
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qp Using Surface Labeling Combined with FACS
After etanercept-producing polyclonal cell line was established
during 14 days of MSX selection (Figure S2, Supporting
Information), the polyclonal pool was subjected to surface
labeling combined with FACS,[18] to enrich for clones with high
qp. A total of 1920 single cells with PI-negative gating (non-
enriched cells) and 8448 single cells with double, PI-negative and
top 5% highest anti-IgG ﬂuorescence gating (top 5%-enriched
cells) were single-cell sorted. Fifteen days after sorting, 10% of
the single-cell sorted cells were recovered (n¼ 852). Sorting for
top 5%-enriched cells gave rise to a threefold increase in qp both
for bulk and single-cell sorted cells (Figure 2A and B,
respectively). This is consistent with previous reports that have
also demonstrated enrichment for clones with high qp.
[6,18,24]
Moreover, the inherent heterogeneity in etanercept expression
obtained from random genomic integration of plasmids was
observed both before and after surface labeling-based enrich-
ment (Figure 2B). When comparing the staining proﬁle at the
time of the sorting with obtained qp values for all surface labeled,
single-cell sorted cells (non-enriched and top 5%-enriched), a
positive correlation was observed (R2¼ 0.35; R2¼ 0.47 without
outliers; Figure S3, Supporting Information). These results show
that surface-labeling combined with FACS is capable of
enriching for clones with high qp despite an imperfect
correlation between staining intensity and qp.3.2. High-Throughput Titer and Confluence Screening of
Etanercept-Producing Clones in Static Culture
Screening efforts encompassing several growth formats are
usually required to isolate a stable cell line with the desiredBiotechnol. J. 2018, 13, 1700216 1700216 (5
21properties from inherently heterogeneous cell pools. To assess qp
in the early phase of CLD, we developed a 96-well screening
platform where IgG or Fc-fusion protein titer and conﬂuence of
suspension-adapted cells are determined in a HT and automa-
tion-friendly manner (Figure S4, Supporting Information).
These two measurements can be used to calculate the TTC
ratio as a proxy for qp. Similarly, Porter et al.
[11] used TTC ratio
(referred to as “speciﬁc activity”) when assessing clones in
96-well plates. Whereas “speciﬁc activity” relied on visual
inspection of conﬂuence, conﬂuence was determined by image
cytometry in the present study (Figure S5, Supporting
Information). In addition, a clear linear relationship was
observed between conﬂuence and cell numbers (Figure S6,
Supporting Information), suggesting that conﬂuence is a valid
proxy for cell numbers. A total of 852 surviving clones were
cultured statically and screened for titer and conﬂuence within a
single day. Approximately 80% of the 852 screened clones had
detectable etanercept titers (n¼ 672) and consequently had a
positive TTC value assigned. All clones were then ranked twice,
either according to their TTC or titer values. This initial titer- and
TTC-based ranking was used throughout the study in order to
evaluate the performance of titer and TTC as early reporters for
volumetric productivity (Table S4, Supporting Information).
Calculated TTC values were spanning from 0.1 to 94.5 (arbitrary
units) and measured titer values were ranging from 0.05 to
2.8 μg/mL.3.3. Characterization of Selected Clones in Suspension in
96-Half-Deepwell Plates
To maximize the number of clones being evaluated in
suspension, we characterized the selected clones in the
previously described System Duetz 96-HDW plates.[20,25] Top© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 10)
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clones) in the TTC and titer category, respectively, and 48
randomly picked top 5%-enriched clones were selected for
further evaluation (Figure 1). 40 of the 56 TTC-selected clones
and 55 of the 57 titer-selected clones survived expansion into
96-HDW plates, whereas 43 of 48 randomly selected clones
survived. The difference in survival rate between the TTC- and
titer-selected is probably explained by the lower conﬂuence of
TTC-selected clones and by the fact that the majority of the
non-surviving clones had relatively low conﬂuence (Figure S7,
Supporting Information). Sixteen clones were overlapping
between the TTC and titer categories giving rise to 24 and 39
unique TTC- and titer-selected clones, respectively.
In 2-day batch cultures in 96-HDW plates, TTC-selected
clones on average initially grew slower compared to both titer-
selected clones and randomly selected clones (Figure 3A).
However, clones in the TTC category were more frequently
seeded at a lower cell density, which correlated with low growth
rates (Figure S8, Supporting Information). By comparing onlyFigure 3. TTC- and titer-selected clones achieve higher specific and volumet
Selected clones were transferred from static culture to suspension in 96-ha
growth rate (μ) and specific productivity (qp) were assessed in 2-days batch cu
batch cultures in 96-HDW plates. A) Comparison of specific growth rate in a 2
clones (n¼ 43), top TTC clones (n¼ 38) and top titer clones (n¼ 54). Statistic
top 5%-enriched clones vs. top TTC clones; randomly picked top 5%-enriche
clones) (bars represent mean interquartile range (IQR)). B) Comparison
5%-enriched clones, top TTC clones and top titer clones. Statistical significan
IQR). C) Correlation analysis of qp and TTC ratio for all the clones in 96-HDW
straight line model. R2 values without and with relative weighing and elimin
randomly picked top 5%-enriched clones, top TTC clones and top titer clone
represent median with IQR). Δ, p-value reported for comparison between gro
seeding density above 1 105 cells/mL were analyzed. Overlapping clones m
clones top 5%-enriched” that are also present in either “top TTC clones” a
Biotechnol. J. 2018, 13, 1700216 1700216 (6
22the clones seeded above 4 105 cells/mL, we observed no
difference in growth rate between TTC- and titer-selected clones
(Figure S9A, Supporting Information). Hence, predominantly
TTC-selected clones seeded at a lower cell density (<4 105
cells/mL) probably experienced a longer lag phase with a
possible negative effect on the cell growth rate during the 2 days
of culture. Similarly, TTC-selected clones generally had
signiﬁcantly higher qp compared to titer-selected clones
(Figure 3B). However, when comparing the clones with seeding
density above 4 105 cells/mL, no difference in qp between the
TTC- and titer-selected clones was observed (Figure S9B,
Supporting Information). Independent of seeding density, the
randomly selected clones had signiﬁcantly lower qp compared to
both the TTC and titer categories (Figure 3B). While a poor
correlation was observed between conﬂuence (static cultures)
and speciﬁc cell growth rate (suspension cultures) (Figure S10,
Supporting Information), a clear correlation was observed
between TTC and qp (Figure 3C). Thus, while growth rate
clearly responds to changes in culture conditions consistent withric productivity than randomly selected clones in 96-half-deepwell plates.
lf-deepwell (HDW) plates. Forty-six days after nucleofection, specific cell
ltures in 96-HDW plates. In parallel, maximum titer was assessed in 7-days
-days batch culture experiment between randomly picked top 5%-enriched
al significance was calculated using Mann–Whitney test (randomly picked
d clones vs. top titer clones) or Welch’s t test (top TTC clones vs. top titer
of qp in a 2-days batch culture experiment between randomly picked top
ce was calculated using Mann–Whitney test (bars represent median with
plates with positive TTC values (n¼ 138) using nonlinear regression with a
ation of outliers are reported. D) Comparison of maximum titer between
s. Statistical significance was calculated using Mann–Whitney test (bars
ups without the clones present in both groups (n¼ 16). Only clones with a
arked with green color in panels B and D are clones present in “random
nd/or “top titer clones.”
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when going from static incubation to suspension culture.
In order to estimate volumetric productivity (maximum titer)
in long-term batch suspension cultures in a HT manner, the
selected clones were again cultivated in 96-HDW plates. This
time, however, all cultures were maintained longer until more
than 50% of the clones had viability below 65%. As expected,
randomly selected clones had lower maximum titers compared
to both the TTC- and titer-selected clones (Figure 3D). However,
no signiﬁcant differences in maximum titers were observed
between TTC- and titer-selected clones independent of whether
the 16 overlapping clones were included or excluded from the
analysis (Figure 3D). In addition, seeding density did not seem to
have a clear impact on the maximum titer as opposed to cell
growth rate (Figure S8, Supporting Information). Due to the
viability-based termination point, viability of clones was different
at the end of the experiment. In fact, 47% and 30% of the clones
had viability above 65% in the TTC and titer categories,
respectively, suggesting that maximum achievable titers were
underestimated to a larger degree for the TTC-selected clones
compared to the titer-selected clones.
3.4. Characterization of Highest Ranking Clones in Shake
Flasks and Comparison to 96-Half-Deepwell Data
To assess the performance of the TTC- and titer-selected clones
more thoroughly, the top 12 of the surviving clones in both
categories were subjected to a standard batch culture experiment
in shake ﬂasks. Four of these clones were overlapping between
the two categories, giving rise to eight unique clones in both
categories. Clone IDs were assigned to each clone in shake ﬂask
batch culture and the clone IDs with the corresponding ranks
can be seen in Table S4, Supporting Information.
Speciﬁc growth rates of TTC- and titer-selected clones were not
signiﬁcantly different from Day 0 to 2 in shake ﬂasks, whether or
not overlapping clones were included in the comparison
(Figure 4A, left panel; growth curves in Figure S11, Supporting
Information). Similarly, no differences in growth rates were
observed when comparing the same set of top 12 TTC and titer
clones in 96-HDWplates (Figure S12A, Supporting Information).
Overall, speciﬁc growth rates of the top 12 TTC and titer clones
were consistent between the 96-HDW plates and shake ﬂasks
except for clones 10 and 11 (Figure 4A, right panel), which were
seededat a lowerdensity in96-HDWplates (FigureS8, Supporting
Information). Interestingly, clones 10 and 11 in shake ﬂasks had
comparable cell growthrates to theremaining top12TTCandtiter-
selected clones. This is consistent with the previously mentioned
notion that theseclonespotentiallyhada longer lagphase in the96-
HDW plates due to lower seeding density. Importantly, we have
previously observed similar growth proﬁles of CHO-S cells
between shake ﬂasks and 96-HDW plates.[20] Thus, the 96-HDW
plate seems to be a suitable microscale vessel for comparison of
clones in batch cultures when seeding densities are aligned.
TTC- and titer-selected clones on average achieved similar qp in
different stages of batch culture (Day 0–2 andDay 3–5),whether or
not overlapping clones were included in the comparison
(Figure 4B, left panel; growth curves in Figure S11, Supporting
Information). Similarly, we observed no differences in qp when
comparing the top12TTCand top12 titer clones in96-HDWplatesBiotechnol. J. 2018, 13, 1700216 1700216 (7
23(Figure S12B, Supporting Information). Comparison of qp
between HDW plates and shake ﬂasks from Day 0 to Day 2
demonstrated a positive correlation (Figure 4B, right panel)
(R2¼ 0.58; R2¼ 0.71 without one outlier), suggesting qp was
largely unaffected by different seeding densities or formats.
However, qp of the clones was decreasing through the time course
of the experiments in the present study (Figure 2 and 4B, right
panel). In our attempt to do an unbiased evaluation of TTC- and
titer-basedselection,MSXselectionpressurewasnot reintroduced
after single-cell sorting in order to keep themediumunchanged in
all cell culture vessels (Figure 1). The decrease in qp is likely a
consequence of no MSX selection pressure after FACS similar to
what has been observed for CHO clonal cell lines obtained by
dihydrofolate reductase/methotrexate-based selection[26] and/or
the presence of post-transcriptional bottlenecks.[27] Thus, it is
important to note that the evaluation of the TTC- and titer-based
selection is most likely affected by this loss of productivity. Future
studies are warranted to investigate whether TTC- or titer-based
selection enriches for clones with stable productivity.
Like qp, similar average maximum titers were achieved by the
TTC- and titer-selected clones (Figure 4C, left panel). When
comparing maximum titers obtained in HDW plates and shake
ﬂasks, the values correlated moderately (Figure 4C, right panel)
(R2¼ 0.52). This moderate correlation is likely a combined
consequence of difference in seeding density (Figure S8,
Supporting Information) and the viability-based termination
point in the 96-HDW plates.
Despite not being able to increase the frequency of isolating
clones with higher qp, the two clones with the highest qp and
volumetric productivity in the shake ﬂask experiment were
uniquely found by TTC-based selection. These two clones (clone
ID: 2 and 11) were ranked as 2nd and 11th highest TTC clone
(151st and 557th highest titer clone, respectively) during the
initial screening in static culture. As expected, clone 11, having
the highest qp and volumetric productivity also had the lowest
growth rate in the early phase (Day 0–2) of the batch culture
(μ¼ 0.027 h1) and the lowest accumulated IVCD (1.8 107
cellsday/mL). This clone exhibited quite an extraordinary
phenotype in comparison to the other highest ranking TTC and
titer clones in shake ﬂasks, having a remarkably higher qp,
especially from Day 3 to 5 (Figure 4B, left panel). Interestingly,
the two clones (clone ID: 13 and 17) with highest volumetric
productivity in the titer category were likewise uniquely found by
titer-based selection and ranked as ﬁrst and ﬁfth highest titer
clones (113th and 126th highest TTC clone, respectively) during
the initial screening of statically cultured clones. The titer-
selected clone with highest volumetric productivity had one of
the highest growth rates from Day 0 to 2 (μ¼ 0.039 h1) and the
highest accumulated IVCD (3.9 107 cellsday/mL) in the entire
clone panel. In addition, higher variation in the TTC category
was observed for both qp (Figure 4B, left panel) and volumetric
productivity (Figure 4C, left panel). This suggests that clones in
the TTC category are phenotypically more diverse compared to
titer-selected clones. Overall, these observations support the
notion that high volumetric productivity can be achieved through
high IVCD of clones selected by titer-based ranking or through
high qp of clones selected by TTC-based ranking.
It has previously been reported that performance in batch
cultures does not necessarily predict the performance in ﬁnal© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 10)
Figure 4. Top TTC- and titer-based clones achieve similar final volumetric productivity in shake flask batch cultures. Top 12 TTC- and titer clones were
transferred from 96-half-deepwell (HDW) plates to shake flasks. Sixty-six to seventy-four days after nucleofection, specific cell growth rate (μ), specific
productivity (qp) and maximum titer were assessed in batch cultures. Clone performance was compared between 96-HDW plates and shake flask batch
cultures. A, left panel) Comparison of specific growth rate from Day 0 to 2 in shake flask batch cultures between top titer-to-confluence (TTC) clones
(n¼ 12) and top titer clones (n¼ 12). Statistical significance was calculated using unpaired t-test (bars represent mean SD). A, right panel) Correlation
analysis of specific growth rates of clones from Day 0 to 2 between 96-HDW plates and shake flask batch cultures (n¼ 18), using regression through the
origin model. B, left panel) Comparison of qp from Day 0 to 2 and Day 3 to 5 of shake flask batch cultures between top TTC clones and top titer clones.
Statistical significance was assessed using Welch’s t-test (Day 0–2) and Mann-Whitney test (Day 3–5) (bars represent median interquartile range
(IQR)). B, right panel) Correlation analysis of specific productivity (qp) of clones from Day 0 to 2 between 96-HDW plates and shake flask batch cultures,
using regression through the origin model. R2 values without and with relative weighing and elimination of an outlier are reported. C, left panel)
Comparison of maximum titer in shake flask batch cultures between top TTC clones and top titer clones. Statistical significance was assessed using
unpaired t test (bars represent mean SD). C, right panel) Correlation analysis of maximum titer of clones between 96-HDW plates and shake flask
batch cultures, using regression through the origin model. R2 with relative weighing is reported. Δ, p-value for comparison between groups without the
clones present in both groups (n¼ 4). Correlation analysis was only performed for clones with seeding density>1 105 cells/mL in 96-HDW plates. IDs
ranging from 1 to 20 were assigned to clones in shake flask batch cultures and the corresponding titer- and TTC-based ranks can be seen in Table S4,
Supporting Information.
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are contributing to major changes in culture conditions,
inﬂuencing cell growth, speciﬁc and volumetric productivity
of clones.[11,28] Due to these unpredictable differences in clonal
behavior between batch culture and fed-batch culture, it might
be an advantage to have a panel of phenotypically diverse high-
producer clones to test in fed-batch cultures. Such a panel seems
achievable by employing a dual titer- and TTC-selection strategy.
Accordingly, it seems likely that clones ﬁt-for-purpose for already
established commercial protein production processes are
present in such diverse clone panels, speeding up the process
of cell line commercialization.4. Conclusions
A thorough analysis of the heterogeneity in a polyclonal pool was
accomplished by HT screening of 852 clones, using selection of
clones based on either titer or TTC. Despite poor correlation
observed between conﬂuence of statically cultured clones and
cell growth rate of clones in suspension, we observed that qp
remains largely unaffected. We were able to show that TTC as a
proxy for qp is not a precise reporter for high volumetric
productivity in suspension consistent with previous reports.[11,12]
However, TTC-based ranking was used to identify clones with
high volumetric productivity, which would not have been found
if using titer-based ranking. We therefore suggest TTC-based
selection as an addition to titer-based selection, because it
increases the possibility of selecting clones in the early phase of
CLD with high qp as well as volumetric productivity. Further-
more, the presented screening platform has been developed to
isolate etanercept-producing clones and is therefore applicable
for other Fc-fusion proteins as well as IgG variants, which
currently constitute the majority of biopharmaceuticals on the
market.[29]Abbreviations
CHO, Chinese hamster ovary; CLD, cell line development; FACS,
fluorescence-activated cell sorting; GS, glutamine synthetase; HDW,
half-deepwell; HT, high-throughput; IVCD, integral of viable cell density;
MSX, methionine sulfoximine; PI, propidium iodide; qp, specific
productivity; TTC, titer-to-confluence; VCD, viable cell density.Supporting Information
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Rationale 
Stable and predictable expression of recombinant genes in mammalian cells is crucial for             
studies of gene functions in basic research, for gene therapy, as well as for biotherapeutics               
production in industry. Traditionally, recombinant gene-expressing cell lines are generated          
by random integration of a recombinant gene into the genome, yielding clones with a wide               
range of expression, growth and stability characteristics. When applying targeted integration           
of recombinant gene into defined, safe harbor integration sites, homogenous expression           
levels with minimal clonal variation have been observed ​(16, 65)​. However, recombinant            
gene expression patterns in a characterized integration site are highly dependent on the             
expression cassette being used. To the best of our knowledge, no method has been developed               
that would allow systematic evaluation of site-specific recombinant gene expression levels           
modulated by different expression cassette components in mammalian cells. Such method           
would provide an excellent opportunity for the development of CHO cell lines with             
predictable and desired recombinant gene expression in defined integration sites. 
 
In the present study, we developed a CRISPR/Cas9-based toolbox that allows the            
construction of CHO cell lines with a site-specifically integrated landing pad, containing a             
recombinant gene under defined 5’ proximal regulatory elements. For this purpose we used             
three different integration sites - two well-characterized integration sites, used routinely           
in-house, and one novel integration site, identified in the stable Rituximab high-producing            
clone, generated with a clone screening method, presented in ​Chapter 1​. We then             
recombined several different expression cassettes (​i.e. 5’ proximal regulatory         
element-recombinant gene) into the site-specifically integrated landing pad of a genetically           
identical (isogenic) cell line. Using the developed toolbox, we were able to systematically             
analyze the interplays between the different layers contributing to the final recombinant gene             
expression level.   
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 Abstract 
Many branches of biology depend on stable and predictable recombinant gene expression,            
that has been achieved in the recent years through targeted integration of the recombinant              
gene into defined integration sites. However, transcriptional levels of recombinant genes in            
characterized integration sites are controlled by multiple components of the integrated           
expression cassette. Lack of readily available tools has inhibited meaningful experimental           
investigation of the interplay between the integration site and the expression cassette            
components. Here we show in a systematic manner how multiple components contribute to             
final net expression of recombinant genes in a characterized integration site. We develop a              
CRISPR/Cas9-based toolbox for construction of mammalian cell lines with site-specifically          
integrated landing pad, containing a recombinant gene under defined 5’ proximal regulatory            
elements. Generated site-specific recombinant cell lines can be used in a streamlined            
recombinase-mediated cassette exchange for fast screening of different expression cassettes.          
Using the developed toolbox, we show that different 5’ proximal regulatory elements            
generate distinct and robust recombinant gene expression patterns in defined integration           
sites of CHO cells with a wide range of transcriptional outputs. This approach facilitates the               
generation of user-defined and product-specific gene expression patterns for programmable          
mammalian cell engineering.  
 
Introduction 
The ability to precisely control and maintain the level of recombinant gene expression is              
crucial to mammalian cell engineering. To ensure that recombinant genes are stably            
expressed in the host cells, genomic integration is needed, which is typically still conducted              
in a random or semi-random manner (​i.e. insertion of cassettes into actively transcribed             
regions of the genome). When random or semi-random integration is applied, unpredictable            
and heterogenous transgene expression is observed due to variability in gene copy numbers             
and the nature of the chromosomal integration site (so-called position effect) ​(1, 2)​.             
Accordingly, laborious screening for the desired expression levels is required ​(3, 4)​. In             
contrast, methods applying targeted integration into predefined loci pave the way toward            
rational design of cells with predictable transgene expression ​(5)​. The use of the type II               
CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9       
(CRISPR-associated protein 9) system has enabled more efficient and precise genome           
editing ​(6)​. Harnessing the homology-directed repair (HDR) mechanism, error-free targeted          
integration of an exogenous DNA donor template into the genome can be achieved following              
a double-strand break induced by Cas9 ​(7)​. HDR-mediated gene targeting has been used             
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 extensively in mammalian cell engineering with applications ranging from         
biopharmaceutical production, gene therapy to gene function studies ​(8)​. What these fields            
have in common is that they are all struggling to overcome the obstacles of variable               
transgene expression, clonal variation, and oncogenic transformation (chromosomal        
rearrangements).  
Therapeutic glycoproteins are traditionally produced using Chinese hamster ovary (CHO)          
cells, where the final yield and stability of the protein production are important aspects of               
cost-effective production pipelines ​(9)​. To achieve predictable and desirable protein          
production, protocols for CRISPR/Cas9-based site-specific integration ​(5, 10–12) and         
recombination-based site-specific integration ​(13–18) have been developed, sometimes used         
in combination ​(19–21) that ensure controlled genome integration into predefined loci.           
Recombination-based systems require a prior establishment of master cell lines containing a            
marker gene with recombinase recognition sites, referred to as landing pads, allowing for             
recombinase-mediated cassette exchange (RMCE). CRISPR/Cas9-based targeted integration       
and RMCE result in predictable and desirable recombinant gene expression patterns when            
employed into previously characterized, safe genomic loci (​i.e. safe harbors). Safe harbors are             
genomic sites which are: a) positioned in open chromatin areas that are generally             
transcriptionally active, b) immune to mono- or biallelic disruption of the target locus upon              
transgene integration, and c) not receptive to transcriptional perturbations of endogenous           
genes upon transgene integration ​(22)​. There are a few widely used safe harbors provided for               
engineering in the human genome, such as AAVS1, CCR5 and ROSA26 ​(23)​. However, there              
is a continually growing repository of integration sites supplied for mammalian cell            
engineering ​(12, 20, 24)​, albeit, their proper validation as safe harbors is needed.  
Apart from the chromosomal context, the nature of the expression construct used to generate              
recombinant cell lines has an equally important impact on protein yield and stability ​(25)​. A               
range of vector elements can modulate transgene expression, ranging from          
chromatin-modifying elements (such as matrix attachment regions (MARs), insulators,         
ubiquitously acting chromatin opening elements (UCOEs) and stabilizing anti-repressors         
(STARs)) to natural and engineered promoters ​(26)​. Site-specific expression levels with           
diverse vector elements have been studied in different fields of biology ​(14, 27, 28)​. When               
applying targeted integration into predefined loci, these studies have confirmed that the            
expression level of the transgene is highly dependent on the interplay between the promoter              
and the target genomic locus. Since methods that would predict the interaction of the              
integrated cassette with the genome are not available, both, safe harbor sites and             
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 performance of different expression cassettes in such chromosomal contexts can currently           
only be verified experimentally.  
To the best of our knowledge, no available toolbox has been published so far that would allow                 
streamlined evaluation of site-specific stable gene expression levels under different          
expression cassettes. To this end, we present a modular toolbox for systematic screening of              
vector elements in predefined integration sites, using the CHO-S cell line as a model. By               
studying different expression cassette designs in newly discovered safe harbors using           
targeted integration, we demonstrate that desired (​e.g. ​high or stable) expression levels in             
defined chromosomal loci are restricted to a specific cassette design. We explore four             
different layers contributing to the final net expression level, namely clonal background,            
chromosomal context, vector design, and type of recombinant protein by studying five            
parental clones, three integration sites, six 5’ proximal regulatory elements and three            
recombinant proteins, respectively. This renders a total of 270 possible combinations           
between the four features, and we here examine 66 (25%) of those combinations             
experimentally. A more detailed understanding of the performance of vector elements when            
embedded in a defined chromosomal context is not only of general interest to the              
mammalian cell engineering community, but is also critical knowledge when designing           
suitable expression cassettes for engineering more complex expression patterns.         
Furthermore, since there is a need to further diversify elements for gene expression, this tool               
allows for identification of a wide range of robust gene expression patterns providing means              
toward programming mammalian cells with dynamic functionalities. 
 
Material and methods 
Identification of integration sites  
Site A was identified in a monoclonal cell line with randomly integrated Rituximab (C6_2),              
generated with an in-house developed clone screening platform ​(29)​. For more information            
regarding the C6_2 cell line generation, refer to the Supplementary data. The C6_2 cell line               
was outsourced to Cergentis B.V. (Utrecht, The Netherlands), where integration site A was             
first identified using the proprietary ‘Targeted Locus Amplification’ (TLA) technology ​(30)​.           
Site A was re-analyzed with an in-house targeted MiSeq deep-sequencing protocol. The            
integrated construct and flanking genomic regions were amplified from genomic DNA           
(gDNA) obtained from the C6_2 cell line and was prepared for Illumina Miseq             
DNA-sequencing using the Nextera XT v2 set A kit (Illumina) according to the             
manufacturer’s instructions. Sequencing was performed in a pooled run (2 x 150 bp            
paired-end). The resulting reads were mapped to a draft reference sequence encompassing            
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 the inserted heterologous plasmid sequence using CLC Genomics Workbench (version 8.5).           
Analysis of broken mapped reads was used to manually reconstruct the sequence junctions             
and thereby the anticipated sequence of the integrated construct and genomic context. Sites             
T2 and T9 were predicted based on transcriptomic data and model predictions. ​Briefly,             
regions between genes with consistently high expression profiles in a previously published            
RNA-Seq dataset from CHO-S during exponential and stationary phase ​(31) were identified.            
A region between two highly expressed genes (site T2) and between two highly expressed              
genes, one of which (​Rrm1​) is essential (site T9), were chosen as integration sites, ​with the                
assumption that the surrounding chromatin would remain open, and so it would be less              
likely that transgenes integrated at those sites would be silenced​. The assumption of             
essentiality was based on literature ​(32) and ​in silico predicted lethality when simulating a              
Rrm1 knockout in the genome-scale model of CHO cell metabolism ​(31)​. ​We utilized flux              
balance analysis ​(33) to predict essential genes. For this, model simulations used the default              
uptake and secretion constraints provided previously ​(31)​. To account for the possibility that             
the cells could change which metabolites are being catabolized or secreted, we did not force               
secretion or uptake of any metabolites ​in order to exclude false positive predictions of              
essentiality. The percentile ranks from expression levels of T2 and T9 neighboring genes             
across the 40 RNA-Seq samples are provided in the ​Supplementary Figure S1. Integration             
regions and the accompanying chromosomal and epigenetic information for all three sites,            
obtained from the new Chinese hamster reference genome ​(34) and the CHO-Epigenome            
database ​(35)​, respectively, are available in the Supplementary Table S1.  
  
Plasmid design and construction 
The CHO codon optimized Cas9 and sgRNA expression vectors with the same design as              
previously described ​(36) were used. sgRNA target sequences (available in Supplementary           
Table S2) with the shortest possible distance to the identified genome-plasmid breakpoints            
(site A) or to the identified high-expressing locus (site T2 and T9) were designed either using                
the CRISPy tool ​(36) (site A) or manually (site T2 and T9). 5’ and 3’ homology arms were                  
selected to flank each sgRNA target sequence with the length of 750 bp each, and were                
amplified from CHO-S genomic DNA. The sequences of both homology arms for each site are               
provided in the Supplementary Table S2. Donor plasmids with the landing pad and donor              
recombinase-mediated cassette exchange (RMCE) plasmids were constructed via the         
uracil-specific excision reagent (USER) cloning method as previously described ​(21) with a            
minor adjustment. Donor landing pad plasmids were designed with mCherry coding           
sequence together with EF1α promoter being flanked by ​loxP at the 5’ end and ​lox2272 at the                 
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 3’end (Figure 1a). Consequently, donor RMCE plasmids contained both the GOI and            
promoter of interest in-between ​loxP at the 5’ end and ​lox2272 at the 3’ end. Plasmids used                 
to PCR amplify expression cassettes of mCherry, eGFP and CHO codon-optimized           
erythropoietin (EPO) have previously been described ​(21, 37, 38)​. Cre recombinase was            
expressed from the commercial PSF-CMV-CRE recombinase expression vector (Sigma         
Aldrich; OGS591). The weak and strong Kozak sequences used here have previously been             
described ​(38)​. All the plasmids used in the present study are depicted in the Supplementary               
Figure S2 and all the primers used are in the Supplementary Table S3. The sequences of the                 
GOIs, promoters, terminators and Kozaks used in this study are listed in the Supplementary              
Table S4. Assembled PCR fragments were transformed into ​E. coli Mach1 competent cells             
(Life Technologies). All constructs were verified by sequencing of the expression cassettes            
(Eurofins Scientific​) and purified using NucleoBond Xtra Midi EF (Macherey-Nagel)          
according to manufacturer’s instructions.  
  
Cell cultivation 
CHO-S cells (Thermo Fisher Scientific) were maintained in CD CHO medium (Gibco)            
supplemented with 8mM L-glutamine (Thermo Fisher Scientific) and 2 µL/mL          
anti-clumping agent (Life Technologies) and cultivated in 125 mL Erlenmeyer flasks. Cells            
were incubated at 37°C, 5% CO​
2
at 120 rpm (25mm shaking amplitude) and passaged every               
2-3 days, unless otherwise stated. Viable cell density (VCD) and viability were monitored             
using the NucleoCounter NC-200 Cell Counter (ChemoMetec, Denmark), using         
Via1-Cassettes and the “Viability and Cell Count Method 2” assay. 
 
Platform cell line generation using CRISPR/Cas9 
CHO-S cells were transfected with the sgRNA plasmid and landing pad donor plasmid             
(EF1α-mCherry) for the corresponding integration sites, together with a Cas9 plasmid,           
according to a previously described protocol ​(21)​. Stable cell pools were established with             
G418 selection (500 µg/mL) as previously described ​(21)​. To establish monoclonal platform            
cell lines (PCLs), G418-selected pools were subjected to single-cell cloning using BD            
FACSJazz cell sorter (BD Biosciences). Double ZsGreen1-DR negative/mCherry positive         
single cells (​i.e. cells with targeted integration only) were seeded in flat-bottom 384-well             
plates (Corning, Sigma Aldrich) with 30 µL of CD CHO medium supplemented with 8 mM               
L-Glutamine, 1.5% HEPES (Gibco) and 1x Antibiotic-Antimycotic (Gibco). Two weeks after           
the sorting, surviving single-cell derived colonies were transferred to flat-bottom 96-well           
plates (Corning) with 200 µL of CD CHO medium supplemented with 8 mM L-Glutamine              
and 1x Antibiotic-Antimycotic using an epMotion 5070 liquid handler (Eppendorf).          
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 Subsequently, cells were expanded in suspension and verified by mCherry fluorescent           
analysis, 5’ and 3’ junction PCR and copy number analysis by qPCR. 
  
Fluorescent level analysis 
The generated mCherry PCLs were analyzed using an Xcyto 10 image cytometer            
(Chemometec), applying unstained suspension cells on the slide and examining mCherry           
fluorescence intensity in 20,000 - 40,000 individual cells of the population. Only PCLs with              
homogenous mCherry expression (≥ 98% of mCherry positive cells) were selected.   
  
Confirmation of landing pad integration 
For 5’ and 3’ junction PCRs, crude gDNA was extracted from the cell pellet using               
QuickExtract​TM DNA extraction solution (Epicentre, Illumina) according to the         
manufacturer’s instructions. 1-2 µl of gDNA mixture was used as template for touchdown             
PCR using 2x Phusion Master Mix (Thermo Fisher Scientific) and the following conditions:             
98°C for 30 s; 98°C for 10 s; 68-58°C [-1°/cycle] for 30 s; 72°C for 2 min; 30 x: 98°C for 10 s;                       
58°C for 30 s; 72°C for 2 min; 72°C for 10 min. PCR primers for 5’/3’ junction PCRs are listed                    
in the Supplementary Table S3 and were designed as shown previously ​(5)​. PCR products              
were visualized on 1% agarose gels.  
  
Copy number analysis using qPCR  
qPCR was conducted to determine the relative copy numbers of the integrated mCherry gene              
and the Neomycin selection marker (NeoR). GeneJET Genomic DNA Purification Kit           
(Thermo Fisher Scientific) was used for extraction of gDNA according to manufacturer’s            
instruction. qPCR was run on a QuantStudio 5 Real-Time PCR System (Agilent            
Technologies). Amplification was performed under the following conditions: 50°C for 2 min,            
95°C for 10 min; 40x: 95°C for 15 s, 60°C for 1 min. Copy numbers of mCherry and NeoR                   
were determined with ​C1GALT1C1 (​COSMC​) as an internal control gene for normalization            
(39) using TaqMan​TM Gene Expression Master Mix and custom-made TaqMan​TM probes for            
all three genes (Thermo Fisher Scientific). Primers and probes are listed in the             
Supplementary Table S5 and were validated by melting curve analysis and primer efficiency             
test. A delta-delta threshold cycle (ΔΔCt) method was applied to calculate the copy number              
of mCherry/NeoR integrated using two previously generated PCLs with a single-copy of            
mCherry landing pad integrated within ​COSMC ​gene and T2 site (single-copy calibrators) ​(5,             
38)​. Each experiment included no template control and negative control (CHO-S wt as a              
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 template) with technical triplicates. Only PCLs with a single copy of both, mCherry and NeoR               
were expanded and banked.  
  
Batch cultivation with single-copy PCL clones 
Cells were seeded at density 1 x 10​5 cells/mL in 40 mL volume of CD CHO medium                 
supplemented with 8 mM L-Glutamine and 2 µl/mL anti-clumping agent in 125 mL flasks.              
VCD and viability were measured daily, as described above. 2 x 10​6 cells were harvested on                
day three in the mid to late exponential phase by centrifugation (200 g, 5 min, RT). Cell                 
pellets were stored at -80°C. On day three, mCherry fluorescent analysis was performed             
using Xcyto 10 image cytometer, as described above. Cultures were discontinued when            
viability dropped below 60%. 
  
Subpopulation generation by recombinase-mediated cassette exchange (RMCE)       
and bulk sorting  
mCherry PCL clones A-D1, T2-C9 and T9-G4 were randomly selected from the panel of              
single-copy monoclonal PCLs for site A, T2 and T9, respectively. These three clones were              
used for recombination experiments, unless otherwise stated. PCLs with a VCD of 1 x 10​6               
cells/mL were transfected with an RMCE donor (with desired 5’ proximal regulatory            
element-GOI) and a Cre recombinase vector, as previously described ​(21)​. After transfection,            
cells were passaged for two weeks in order to minimize transient transgene expression,             
followed by bulk sorting of the recombined cell population. When RMCE donor encoded             
eGFP, double mCherry negative/eGFP positive cells were considered recombined and were           
bulk-sorted. When RMCE donor encoded EPO, mCherry negative cells were considered           
recombined and were bulk-sorted. Cells (0.5-1 x 10​5 cells/well) were sorted in flat-bottom             
96-well plates using a BD FACSJazz cell sorter. Non-recombined PCLs were used for gating              
the mCherry negative cells. Bulk-sorted cells were expanded in suspension (to 125 mL flasks)              
and further used either in a long-term cultivation experiment (eGFP populations) or            
short-term productivity assay (EPO populations). Independent set of experiments         
comprising recombination, bulk sorting and long-term cultivation were performed twice in           
the same original PCL (​i.e. ​for A-CP-eGFP, A-SV40-eGFP and T2-CP-eGFP) accounting for            
two independent replicates for these three conditions. 
  
Copy number analysis on bulk-sorted populations using dPCR 
To ensure that bulk-sorted populations on average harbor a single copy of the recombined              
GOI (eGFP or EPO), relative copy number analysis with digital PCR (dPCR) was performed              
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 using a QuantStudio​TM 3D Digital PCR System (Applied Biosystems). Copy numbers of eGFP             
and EPO were determined using ​COSMC as an internal control gene for normalization, with              
custom-made TaqMan​TM probes used for all three genes (Thermo Fisher Scientific). Primers            
and probes are listed in the Supplementary Table S5 and were validated by melting curve               
analysis and primer efficiency test. gDNA of bulk-sorted populations, isolated with GeneJET            
Genomic DNA Purification Kit, together with the QuantStudio™ 3D Digital PCR Master Mix             
v2 was loaded onto QuantStudio™ 3D PCR Chips. Amplification was performed under the             
following conditions: 96°C for 10 min; 39x: 60°C for 2 min, 98°C for 30 s; 60°C for 2 min. A                    
previously generated monoclonal PCL with a single copy of EPO integrated within T9 site              
was used as a single-copy EPO control ​(21)​. Additionally, a titration experiment was             
performed to ensure the reliability of the obtained results. gDNA of a bulk-sorted sample              
(A-CP-strong kozak-eGFP) was spiked into CHO-S wt gDNA comprising 0%, 10%, 20%, 50%,             
and 80% of the total gDNA. The corresponding target-to-reference ratio was subsequently            
determined for each titration mixture. Each experiment included a no template control. The             
final analysis of the target-to-reference ratio was performed with the QuantStudio™ 3D            
Analysis Suite Cloud Software.  
 
Relative mRNA expression level using RT-qPCR 
Total RNA was extracted from 1-2 x 10​6 cells using the RNeasy Plus Mini Kit (Qiagen)                
according to the manufacturer’s instructions. RNA concentration was measured with Qubit           
fluorometric analysis (Life technologies) and the purity/quality was assessed with Nanodrop           
(Thermo Fisher Scientific) and 1% agarose gel visualization. cDNA was synthesized from            
1.5-3 µg of total RNA using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR with                
dsDNAse treatment (ThermoFisher Scientific). RT-qPCR analyses were performed on the          
QuantStudio 5 Real-Time PCR System using TaqMan​TM Multiplex Master Mix (Thermo           
Fisher Scientific) in triplexes (GOI and two normalization genes) using the following            
amplification conditions: 50°C for 2 min, 95°C for 10 min; 40x: 95°C for 15 s, 60°C for 1 min.                   
Custom-made Taqman assays were used for mCherry, eGFP and EPO, as well as             
normalization genes ​Gnb1 ​and ​Fkbp1a ​(40)​. All the primers and probes are listed in the               
Supplementary Table S5 and were validated by melting curve analysis and primer efficiency             
test. Using the ΔΔCt method, the relative expression levels of GOIs were calculated by              
normalization to the geometric mean of expression levels of the two normalization genes.             
Each experiment included controls with no template and was performed using technical            
triplicates.  
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 Long-term cultivation 
eGFP bulk-sorted populations were recovered after cell sorting and expanded in suspension            
(6-9 passages), and transferred to 6-well plates (Greiner) after which long-term cultivations            
were initiated in complete media containing 1x Antibiotic-Antimycotic. Cells were passaged           
every 2-3 days and kept in culture for two months. Cells from passage 2 (week 1), passage 11                  
(week 4) and passage 23 (week 8), as counted from the start of the long-term cultivation,                
were analyzed for eGFP fluorescence levels using FACS and relative eGFP mRNA expression             
levels using RT-qPCR. The BD FACSJazz cell sorter was calibrated each time using Rainbow              
Calibration Particles (8 peaks) 3.0 - 3.4 µm (BD Biosciences), followed by the use of constant                
photomultiplier settings for eGFP and mCherry detection. A total of 100,000-200,000           
events were collected in the analysis. Data analysis was performed with FACSDiva Software             
(BD Biosciences) and FlowJo 10 (FlowJo LLC). Median fluorescence intensities (MFIs) of            
bulk-sorted populations at each time point were normalized to MFI of the T2-EF1α sample              
for the ease of representation. For the analysis of eGFP mRNA expression levels, 1-2 x 10​6                
cells/mL cells at late exponential phase were centrifuged (200​g​, 5 min, RT) and cell pellets               
were stored at -80°C. RNA samples were prepared as described above. eGFP mRNA             
expression levels of bulk-sorted populations at each time point were normalized to the levels              
of the T2-EF1α sample at the first time point (week 1; internal calibrator).  
  
Short-term productivity assay and titer measurements 
A three day batch culture was performed to determine specific productivity of EPO in              
mid-exponential phase for different bulk-sorted populations. Cells were seeded at density 5 x             
10​5 cells/mL in 25 mL volume of CD CHO medium supplemented with 8 mM L-Glutamine               
and 2 µl/mL anti-clumping agent in 125 mL flasks. VCD and viability were measured daily,               
as described above. On day three, EPO titers were determined in supernatants by bio-layer              
interferometry (ForteBio, Pall, Menlo Park, CA) using Streptavidin biosensors (Fortebio          
18-5021, Pall), functionalized with the anti-EPO V​
H​H biotin conjugate (Life Technologies,           
cat.no: 7103372100), as previously described ​(37)​. Absolute EPO titers were calculated using            
a 7-point calibration curve generated from a dilution series of commercially available EPO             
(Genscript, Piscat-away, NJ, USA). Specific productivity of EPO was calculated using titer            
and integral viable cell density (IVCD) values as described elsewhere ​(41)​. On day three 2 x                
10​6 cells were harvested for mRNA analysis by centrifugation at 200​g for 5 min at RT and                 
cell pellets were stored at -80°C, and mCherry fluorescence analysis was performed using             
Xcyto 10 image cytometer, as described above. EPO mRNA expression levels of bulk-sorted             
populations were normalized to the levels of the T2-EF1α sample (internal calibrator).  
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Statistical analyses  
All statistical analyses were performed using GraphPad Prism 7 software (GraphPad Prism            
Software Inc., La Jolla, CA). ​Statistical significance of log2-transformed mCherry mRNA           
level differences between the integration sites was calculated using an ordinary one-way            
analysis of variance (ANOVA) with Turkey’s multiple comparisons test (​n ​= 5 clones/site)             
where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. To analyse the correlation                  
between the two variables, linear regression was used and R​2​ together with p value reported.  
  
Results 
Carefully studied integration sites constitute preferable genome safe harbors for          
recombinant gene expression. Therefore, this study set out to identify putative safe harbors             
in CHO-S cells to use them for systematic characterization of their capacity for stable              
recombinant gene expression and thereby provide them to the mammalian cell engineering            
community. Next, to systematically assess recombinant gene expression patterns in these           
newly defined integration sites, we developed a modular CRISPR/Cas9-based toolbox.          
Specifically, this toolbox was designed to inspect the interactions between the four layers             
influencing the final level of recombinant gene expression: cell host, the integration site, the              
vector construct and the type of recombinant protein. We inspected 66 randomly-selected            
combinations between the four layers, and named the samples after all the integrated             
components from each layer.    
 
Identification of putative safe harbor integration sites in the CHO-S genome 
To increase the number of well-characterized genomic loci for stable and predictable            
recombinant expression, we chose a combined strategy of identifying sites; the sites were             
identified based on either experimental expression stability or ​in silico approach. Site A             
derives from a low-copy, relatively high-producing cell line with randomly integrated           
Rituximab, generated using our in-house developed clone screening platform ​(29)​. This cell            
line exhibited stable and relatively high Rituximab productivity over two months of culturing             
during which no gain or loss in Rituximab gene copy number was observed (Supplementary              
Figure S3). Proprietary TLA technology was used to identify the genomic loci of integration              
in this cell line ​(30)​, unveiling site A. Full integration of intact Rituximab expression cassette               
in site A was independently confirmed with targeted MiSeq deep-sequencing          
(Supplementary Figure S4). The results here validated that the integration event did not             
disrupt the host genome in the proximity of integration (​i.e. chromosomal rearrangement)            
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 and therefore this locus can be used for targeted reverse engineering. On the other hand,               
sites T2 and T9 were selected based on transcriptomic data of neighboring genes and model               
predictions and were previously used as integration sites in our studies ​(21, 38)​. By analyzing               
published RNA-seq datasets from CHO-S cell line ​(31) and identifying regions with            
consistently high expression profiles across 40 samples, sites T2 and T9 were chosen as              
integration site candidates. We hypothesized that these two sites would be good integration             
sites owing to consistent chromatin accessibility for transcription. Site T2 is positioned            
in-between two highly expressed genes and site T9 is in proximity of a highly expressed gene                
Rrm1 ​, that is metabolically essential for DNA synthesis ​(32)​, as additionally confirmed by the              
genome-scale CHO metabolic model (35). The percentile ranks from expression levels of T2             
and T9 neighboring genes across the 40 RNA-Seq samples are provided in the             
Supplementary Figure S1, demonstrating that T2 and T9 neighboring genes are consistently            
among the highest expressed genes in this cell line. The integration loci information is              
available in the Supplementary Table S1, together with the corresponding Chinese           
hamster-derived chromosome numbers and the surrounding epigenetic marks. The features          
of these three integration sites can in the future help towards defining the general              
characteristics of safe harbors in CHO cells. 
 
Modular toolbox for generation of mCherry-encoding platform cell lines with a           
poly(A) trap-based RMCE landing pad  
Having identified three sites of interest, a modular CRISPR/Cas9-based toolbox was           
developed allowing for systematic quantification of recombinant gene expression levels in           
these sites modulated by different 5’ proximal regulatory elements (​Figure 1A​). In the first              
part of the toolbox, platform cell lines (PCLs) with landing pads flanked by unique ​lox sites                
are generated for each integration site of interest via HDR and G418 selection, as previously               
described ​(21)​. The PCLs are designed with EF1α-mCherry inside the landing pad and             
poly(A) outside of the landing pad (poly(A) trapping). By employing a panel of parental              
clones for each integration site, a number of individual PCLs are generated. This allows for               
investigating the effects on gene expression originating from the cell host and the integration              
site, respectively. In the second part of the toolbox, generated PCLs with the poly(A) trap can                
be subjected to RMCE to replace EF1α-mCherry with desired 5’ proximal regulatory elements             
followed by the gene of interest (GOI). The RMCE facilitates fast integration of the desired               
expression cassettes into the same PCL, allowing for investigation of the effects originating             
from the vector elements and type of recombinant protein integrated. 
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 In conclusion, this platform was designed to interrogate site-specific expression levels of any             
recombinant protein with any 5’ proximal regulatory element in a controlled and streamlined             
manner. Moreover, due to its design, it can be used for direct comparison and benchmarking               
of different expression contexts and different integration sites of interest.  
 
Validation of generated mCherry-encoding platform cell lines 
Following the workflow of the toolbox, we generated PCLs with mCherry integrated in site A,               
T2 and T9. To account for clonal variation originating from the heterogeneous polyclonal             
pool, five independent PCLs were generated for each of the three sites. 5’ and 3’ junction                
PCRs were performed for confirmation of specific integration into the three integration loci             
(Supplementary Figure S5). The frequency of clones with correctly targeted integration           
events post-G418 selection ranged from 21% for site A and 25% for site T2 to 30% for site T9.                   
Following junction PCRs, the PCLs were confirmed to harbor a single copy of the landing pad                
expression cassette by copy number analysis using qPCR (Supplementary Figure S6).           
Furthermore, ≥ 98% of the total cell population was mCherry positive for all 15 PCLs,               
indicating that the mCherry expression is relatively homogeneous, despite the generated           
PCLs being in different growth phases (Supplementary Figure S7).  
Using the established CRISPR/Cas9-based platform, we successfully generated a panel of           
PCLs with the mCherry expression cassette in the three selected integration sites. These             
PCLs were selected as cell line models for studying both clonal variation and interactions              
between integration site and vector regulatory elements for different recombinant proteins.  
  
Minimal clonal variation at defined integration sites 
To characterize the effect of the cell host background on site-specific gene expression levels,              
the 15 generated PCLs (5 PCLs per integration site) were analyzed in batch cultures. Since               
the expression cassette in the landing pad was identical in all clones (EF1α-mCherry), we              
were able to examine the two factors contributing to the differences in expression levels:              
clonal background and the site of integration.  
The five PCLs for each integration site demonstrated different growth profiles (see            
Supplementary Figure S8), probably because they were derived from a genetically           
heterogeneous cell pool of host cells. Despite different growth profiles, mCherry median            
fluorescence intensities (MFIs) in the mid exponential phase were uniform between the PCLs             
of one site as evaluated by the small coefficient of variation (CV) (site A: CV = 10.9%; site T2:                   
CV = 10.9%; site T9: CV = 4.1%) (​Figure 1B​). When comparing the CVs in mCherry MFI                 
within each PCL, we observed much larger values ranging between 42% and 70%. Large CVs               
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 observed in mCherry MFI within the clone indicate the presence of clone-specific            
fluctuations in mCherry expression on account of transcriptional and translational bursts.           
However, we observed no differences in clone-specific fluctuations between the three sites,            
as evaluated by the mean CV of each site. Furthermore, mCherry mRNA expression levels              
correlated with the MFIs, suggesting that mCherry fluorescence can be used as a proxy for               
transcription and expression levels (R​2 ​= 0.62, p = 0.0005) (​Figure 1C​). The variation in               
mCherry mRNA expression levels observed between the five independent PCLs of each site             
was relatively small, as seen with the MFI values (site A: CV = 24%; site T2: CV = 15%; site                    
T9: CV = 13%). When comparing mCherry mRNA expression levels between the integration             
sites, we observed significant differences in how the EF1α promoter responds to the genetic              
context (p = 0.0015 for A vs T2 and p = 0.0059 for T2 vs T9). Sites A and T9 yielded                     
approximately 1.5-fold higher mCherry expression levels than site T2 (Figure 1B and 1C),             
indicating the local chromatin environment and possible neighboring enhancers of site A and             
T9 provide an increased transcriptional output from EF1α promoter.   
Overall, these results demonstrated that when controlled, targeted integration into putative           
safe harbor loci is employed, the generated clones display minimal variation in recombinant             
gene expression levels, despite having different growth profiles. Moreover, it was           
reconfirmed that the promoter activity is governed by its spatial positioning (​i.e. position             
effect) within a defined genomic landscape. Based on these results, one representative PCL             
for each integration site was randomly selected from the generated panel for the following              
recombination experiments.   
 
Proof-of-principle recombination into poly(A) trap elicited tunable eGFP        
expression patterns  
To compare expression from different vector elements in different integration sites​, we            
needed to confirm that EF1α-mCherry can be successfully recombined with another 5’            
proximal regulatory element-GOI and can be functionally transcribed from the poly(A) trap.            
To this end, the EF1α-mCherry cassettes in the landing pads of the three representative PCLs               
were exchanged with four different eGFP constructs. The eGFP constructs were designed            
with either a composite promoter (CP; comprised of mCMV enhancer, hEF1α and 5’UTR             
HTLV) or the viral SV40 promoter together with a strong or weak Kozak sequence ​(38)​.  
One week post-recombination, double mCherry negative/eGFP positive populations were         
observed, indicating successful recombination and eGFP transcriptional output from the          
poly(A) trap (​Figure 2A​), thereby confirming the functionality of our platform. When            
comparing MFIs of the recombined cells, an approximately 13-fold difference was observed            
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 between strong and weak Kozak sequences across all three sites and both promoters (Figure              
2A). However, the same constructs recombined in different sites yielded approximately           
2-fold higher eGFP fluorescence levels in site A and T9 in comparison to T2, for both                
promoters with either a weak or strong Kozak sequence. This confirmed the trend observed              
with the 15 PCLs where site A and T9 gave rise to increased mCherry expression levels with                 
the EF1α promoter. 
Next, we wanted to investigate whether the observed double mCherry negative/eGFP           
positive populations were a result of specific recombination of mCherry with a single copy of               
eGFP. Only then, these double mCherry negative/eGFP positive populations could be used            
for analyzing the effect of integration sites and vector constructs on expression levels. Hence,              
we bulk-sorted five double mCherry negative/eGFP positive populations with strong Kozak           
sequences and conducted copy number analysis using digital PCR (dPCR). All bulk-sorted            
populations displayed a 1:1 target-to-reference ratio, confirming that on average these           
populations harbored a single copy of eGFP (​Figure 2B​). A 1:1 ratio was also found in a                 
confirmed single-copy monoclonal RMCE cell line producing EPO, generated in our previous            
study ​(21) (Supplementary Figure S9). Furthermore, a control titration experiment was           
performed where incrementally increasing amounts of gDNA from A-CP-strong Kozak-eGFP          
bulk-sorted population were spiked into CHO-S wt gDNA. A linear relationship was            
confirmed between the eGFP spike-ins and the target-to-reference ratio (R​2 = 0.98, p =              
0.0002)(Supplementary Figure S10). 
Overall, our proof-of-principle experiment confirmed three important objectives, needed for          
the following systematic evaluation of site-specific expression patterns. First, poly(A)          
trapping enabled functional output post-recombination. Second, recombined populations        
were sufficiently homogenous (​i.e. single copy) to be reliably used for comparative analysis             
without the need to establish monoclonal cell lines. Third, different 5’ proximal regulatory             
elements (promoters and Kozak sequences) elicited tunable and context-dependent gene          
expression patterns demonstrating that stable recombinant gene expression is both          
construct-dependent and site-dependent. 
 
Observation of site-dependent and construct-dependent eGFP expression       
patterns  
Following the successful proof-of-principle experiment, we set out to conduct a systematic            
evaluation of site-specific gene expression patterns with all 5’ proximal regulatory elements            
in our panel. We therefore generated eGFP constructs with four different promoters - two              
viral promoters (CMV and SV40), a constitutive promoter (EF1α) and a composite promoter             
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 (CP), all followed by a strong Kozak sequence. By recombining them into the three              
representative PCLs, we were able to quantify the combined effect of these promoters and              
the three identified genomic loci on the expression levels from stably integrated eGFP. 
Two weeks post-recombination, the recombined population (​i.e. mCherry negative/eGFP         
positive population) was observed in all 12 samples, while samples were largely devoid of the               
transient eGFP expression (​i.e. mCherry positive/eGFP positive population) (​Figure 3A​).          
The percentage of successfully recombined cells varied between 2% to 8%. By comparing the              
MFI of these recombined populations, the promoter giving rise to the highest expression             
level was CP in all three sites, followed by the EF1α and SV40 promoters. For all three                 
promoters, sites A and T9 generated approximately a 2-fold higher output than site T2,              
consistent with the results seen in the analysis of the mCherry expression levels in 15 PCLs                
(Figure 1C). While CP and SV40 promoter demonstrated higher cell-to-cell variation (wider            
distribution of the fluorescence levels, ​i.e. CV), constitutive EF1α promoter displayed lower            
intrinsic noise with a relatively tight and unimodal expression pattern (site A: CV = 37.1%;               
site T2: CV = 38.8%; site T9: CV = 33.6%). Surprisingly, CMV, generally thought of as one of                  
the strongest exogenous promoters ​(42, 43)​, generated the lowest levels of fluorescence in all              
three sites. While CMV in combination with site T2 generated the strongest MFI when              
compared to the other two sites, this promoter performed particularly poorly in site T9 with               
a 30-fold lower MFI compared to CP. Overall, CMV generated the highest cell-to-cell             
variation in all three sites (site A: CV = 69.5%; site T2: CV = 63.7%; site T9: CV = 108%),                    
indicating that the variation primarily originates from the promoter itself and not the             
integration site.  
To confirm the results seen in the initial fluorescence analysis, where the cell population              
consisted of a small portion of the recombined cells and a large pool of non-recombined               
(mCherry positive) cells (Figure 3A), bulk-sorting of the recombined populations was           
performed. After recovery, copy number analysis was conducted, confirming the presence of            
a single eGFP copy in all recombined populations (Supplementary Figure S11). Next, eGFP             
expression levels were determined at the mRNA and protein level (​Figure 3B​). A clear              
agreement was observed between the fluorescence measurements (Figure 3A and 3B),           
confirming that the initial MFI measurements prior to bulk sorting give a good proxy for the                
eGFP expression level. Consistent with the analysis of mCherry expression levels (Figure 1C),             
a significant linear correlation was observed between eGFP fluorescence and mRNA levels            
(Figure 3B, R​2 ​= 0.59; p = 0.0008). Despite normalizing the data, the discrepancies that we                
observe between generally lower mRNA levels and higher corresponding protein levels might            
be on account of slow degradation rates of long-lived proteins such as eGFP that can limit the                 
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 ability to track rapid mRNA fluctuations. Both the analyses (at mRNA and protein level)              
confirmed the strength of the promoters in the three sites, observed at the time of bulk                
sorting (Figure 3A). Moreover, similar gene expression patterns were generated when RMCE            
and bulk-sorting were repeated (independent replicates named A-CP_Rep2, T2-CP_Rep2,         
A-SV40_Rep2), indicating that data generated by the poly(A) trap platform is reproducible            
and robust.  
In conclusion, these results facilitated ranking of the promoter strength in a site-specific             
manner. A wide range of site- and promoter-specific expression levels was observed whereby             
elements have been identified for predictable and tunable gene expression patterns. Finally,            
it has been shown that commonly used promoters, such as EF1α and CMV, function in a                
position-dependent mechanism.  
 
Similar clone-specific eGFP expression patterns across all three integration         
sites 
To explore if the findings mentioned above are only specific to the particular PCL used,               
RMCE was performed with the same set of eGFP constructs into two additional PCLs per               
site. FACS analysis was performed two weeks post-recombination and the generated MFIs            
were closely following the trend obtained with the original three PCLs (​Figure 3C​). These              
results further supported our observations with the mCherry-encoding PCLs, that gene           
expression patterns are prevalently site- and promoter-specific when controlled targeted          
integration is performed. The cell host background, despite additional round of RMCE-based            
generation of a subpopulation, did not seem to contribute substantially to the differences in              
gene expression levels in the three selected putative safe harbor sites. 
 
Long-term stability of eGFP expression achieved in all three integration sites  
To explore the long-term stability of recombinant gene expression under the selected set of              
promoters when integrated in site A, T2 and T9, a two-month cultivation experiment of              
eGFP-encoding bulk-sorted populations was performed. eGFP fluorescence and mRNA levels          
were measured in the beginning (week 1), in the middle (week 4) and at the end (week 8) of                   
the cultivation. None of the bulk-sorted populations displayed a demonstrable loss of the             
eGFP expression during 8 weeks of culturing (​Table 1​), retaining the initial values observed              
in Figure 3B.  
These results indicate that the three integration sites characterized in this study provide             
robust gene expression patterns over long-term culturing. Therefore, these sites seem to            
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 constitute safe harbors in the CHO-S genome for integration of transgenes, with varying             
strength of expression levels dependent on the construct integrated.  
 
Site-specific gene expression characterization for a secreted biotherapeutic 
To demonstrate the usefulness of our toolbox for recombinant protein production in            
mammalian cell lines, we aimed to characterize the expression levels of a secreted             
biopharmaceutical, EPO. The RMCE was performed in the three representative PCLs with            
EPO constructs comprising three different promoters (CMV, EF1α and CP) and the            
previously described strong Kozak sequence. Two weeks post-recombination, bulk sorting          
was performed on mCherry negative cells for all 9 conditions (​Figure 4A​). The mCherry              
negative cells were deemed as correctly recombined cells expressing EPO and these            
populations constituted 1% to 5% of all cells. Bulk-sorted cells were recovered and using              
dPCR analysis the presence of a single copy of EPO was confirmed in these populations               
(Supplementary Figure S9). This was followed by a three-day batch culture in 125 mL shake               
flasks where specific EPO productivity and mRNA expression levels were measured in the             
mid-exponential phase of the culture. Specific EPO productivity and EPO mRNA levels            
displayed a high level of correlation (​Figure 4B; R​2 ​= 0.98). The ranking of the promoters                
for the expression of the secreted EPO was similar to the intracellular eGFP. The strongest               
promoter in all integration sites was CP, reaching 3 pcd/EPO copy in sites T9 and A. The                 
EF1α promoter construct generated a 3-fold lower output and approximately the same            
amount of protein in all three sites (1 pcd/EPO copy). Interestingly, the CMV promoter gave               
rise to higher EPO mRNA levels and specific productivity values in sites A and T2 compared                
to the levels provided in these sites for eGFP, but remained the weakest promoter in site T9                 
(7-fold lower pcd than T9-CP-EPO).  
These results demonstrate that our toolbox can be successfully used to modulate the             
expression levels of a secreted biotherapeutic. Furthermore, we were able to show that             
promoters can generate protein-specific gene expression patterns at characterized genomic          
loci, advocating for testing of the desired vector constructs for both, the site of interest and                
the protein of interest.  
  
Discussion 
Tight control of recombinant gene expression is a major quest in different fields of biology,               
ranging from gene therapy, functional genetics studies in basic research, biopharmaceutical           
production to synthetic biology. In order to adapt to ever changing environmental stimuli,             
eukaryotic cells have complex systems in place for dynamic and flexible regulation of their              
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 transcriptional and translational processes. Thus, heterologous gene networks with         
predictable and desirable outputs are difficult to install in eukaryotic cells when random             
integration is applied. Molecular tools for site-specific integration are therefore crucial to            
move this field forward; however, increased specificity and efficiency of these tools have to be               
achieved for routine applications ​(44)​. We and others have developed CRISPR/Cas9-based           
targeted integration protocols for ​in vitro gene editing in mammalian cells ​(5, 10–12, 19–21)​.              
In this study we wanted to further expand the CRISPR/Cas9 applications by developing a              
CRISPR/Cas9-based modular toolbox for systematic evaluation of site-specific recombinant         
expression patterns modulated by different 5’ proximal regulatory elements. Here, we           
describe a systematic and streamlined analysis of stable gene expression patterns resulting            
from the interplay between the four contributing layers: the cell host, the integration locus,              
the inserted vector elements and the type of recombinant protein being expressed. By             
precisely quantifying the resulting expression profile, the objective of this toolbox is to pave              
the way toward generation of mammalian cell lines with fine-tuned and user-defined gene             
expression patterns. 
First, we characterized three candidate safe harbor integration sites in the CHO-S genome,             
one in an intragenic, specifically intronic region (site A), and two in intergenic regions (site               
T2 and T9)(Supplementary Table S1) with the objective of further expanding the growing             
repository of available sites for programmable mammalian cell engineering ​(12, 20, 24)​.            
These sites were selected either on the basis of experimental data with sites showing stable               
expression or ​in silico analysis identifying sites with high and stable expression profiles of              
neighboring genes. All three sites identified here are positioned in open chromatin areas that              
are generally transcriptionally active (Supplementary Table S1). High expression levels of           
transgenes when integrated into regions with high transcriptional activity and chromatin           
accessibility were recently reported ​(45)​. Being in transcriptionally active regions of the            
genome, these newly proposed regions are possibly less noisy, exhibiting lower cell-to-cell            
variability in gene expression patterns. Our study indeed unveiled that all three sites             
generated relatively robust gene expression patterns with minimal clonal variation and           
approximately 2-fold higher transcriptional output in sites A and T9 in comparison to T2.              
We have previously shown that minimal clonal variation can be achieved when targeted             
integration is applied ​(5, 21)​. Moreover, since the chromosome regions surrounding the            
integration sites seem to support relatively stable long-term transgene expression, the           
regions around site A, T2 and T9 might be less prone to genomic rearrangements from               
transcriptionally active regions of euchromatin into closed heterochromatin. We therefore          
believe that these three sites can be considered safe harbors for programmable transgene             
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 expression in CHO-S cells. However, further studies are warranted to confirm whether these             
sites give rise to gene expression patterns as robust as seen in other established safe harbors,                
such as ROSA26. 
Second, we developed a toolbox for generation of PCLs using a novel approach with poly(A)               
trap-based RMCE landing pads. Poly(A) traps have been previously used, however, in a             
different setting for gene trapping purposes ​(46)​. The toolbox allows users to generate PCLs              
with their own integration site of interest and use them for rapid evaluation of site-specific               
gene expression patterns resulting from any desired 5’ proximal regulatory elements. After            
PCLs with the sites of interest are established, the timeline to optimize site-specific             
expression profiles of any given recombinant protein is two to four weeks from transfection              
(as measured by fluorescence or protein levels, respectively). This brings the timeline of             
expression optimization closer to that of transient expression-based experiments.   
Third, employing the developed toolbox, we analyzed site-specific expression profiles of           
genes under transcriptional control of some of the commonly used promoters in mammalian             
cell engineering. Using eGFP and EPO expression cassettes, we observed that the gene             
expression is heavily influenced by the interplay between the integration site and the             
promoter of interest, generating up to a 30-fold dynamic range in protein expression. All the               
promoters tested here were dependent on the site of integration featuring highly genetic             
context-specific transcriptional regulation. Viral promoters, such as CMV, have previously          
been shown to be prone to the local epigenetic regulation and silencing ​(47–51)​. Our study               
showed that the otherwise potent CMV promoter gave rise to the overall lowest and the most                
stochastic transgene expression levels of the four promoters studied here. As the transgene             
copy number is low in our studied populations (​i.e. one copy), bursts in             
transcription/translation can lead to easily detectable differences between otherwise         
genetically identical cells ​(52)​. Therefore, the lower the amount of transcript (​e.g. CMV at              
site T9), the higher the intrinsic noise, since low copy number together with low              
transcription rates can limit the precision of gene regulation ​(53)​. On the other hand, we               
observed that the SV40 viral promoter allowed for relatively high and stable transgene             
expression levels in our integration loci, suggesting the genomic context of these sites is              
favorable towards high transcription rates under the SV40 promoter. The SV40 promoter            
has previously been reported to be more resistant to transcriptional silencing than CMV ​(43,              
54) and is usually included in vector systems to drive the selection marker expression ​(26)​.               
For the purpose of finding high-producing clones it is therefore of utmost importance to              
carefully devise the expression cassettes of both the GOI and the selection marker by              
considering the strength, but also general responsiveness of the promoter to the local             
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 environment. The strongest promoters in our study were CP (composed of the mCMV             
enhancer, hEF1α promoter and 5’UTR HTLV) and EF1α promoter, making them desirable            
for the applications where high expression levels are needed. However, for multi-gene            
engineering strategies, their usage might be limited due to a few reasons. Firstly, both CP               
and EF1α are large promoters that would in turn generate very large multi-gene vectors that               
might not be efficiently transfected or integrated. Moreover, if either of these promoters             
would be used successively or if used together (high similarity between the two promoters)              
for multiple genes, there might be a higher risk of promoter interference when competing for               
the same endogenous transcription factors ​(55)​. This constitutes an important consideration           
for mammalian synthetic biology, where the more attractive solution might be the            
integration of a completely synthetic system (​i.e. a pair of non-mammalian transcription            
factor and regulatory elements with its cognate binding sites) with minimal host cell             
interactions ​(56)​. All in all, these findings stress the importance of having a toolbox to               
empirically interrogate site-specific gene expression patterns modulated by a range of           
desired regulatory elements. The toolbox facilitates site- and application-specific design of           
expression cassettes, preventing the risk of unpredictable loss of promoter functionality,           
even from increasingly more utilized built-for-purpose synthetic promoters ​(55, 57, 58)​. 
Numerous studies have been conducted to improve the levels of stable recombinant            
expression by optimization of expression constructs ​(42, 43, 59–65)​. However, the           
performance of different vector designs cannot be reliably compared between these studies,            
since the analyses were conducted: a) in different cell hosts; b) in randomly or              
semi-randomly integrated, stable cell pools or clones with high variability in gene copy             
numbers; and c) under antibiotic selection and in overall different culture conditions. Only a              
few studies so far have explored different vector constructs in a site-specific manner ​(14, 27,               
28)​, confirming that the strength of the expression cassette is defined by its chromosomal              
context. However, to the best of our knowledge, no systematic evaluation has been             
performed wherein the performance of different 5’ proximal regulatory elements were           
benchmarked against each other in a controlled manner. In our system, a single copy of 5’                
proximal regulatory element-GOI is integrated in a defined, retargeted genomic site. Further,            
comparisons are done without the presence of antibiotic selection, thereby considerably           
reducing cell-extrinsic factors causing dynamic transcriptional regulation ​(66)​. In fact, by           
aligning all three main sources of transcriptional regulation (cell-extrinsic, cell type-specific           
and genomic-loci intrinsic ​(67)​), the contribution of any 5’ proximal regulatory element to             
the final transgene expression level can be precisely determined.  
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 Further studies are warranted to explore how the local genomic environment in the three              
presented sites interacts with the exogenous promoters, to decipher how the regulatory            
elements affect the transgene expression in these sites. Similarly, it remains to be explored              
whether any perturbations have been inflicted upon host cell transcriptome after targeted            
integration in the three putative safe harbors. Generally, transgene integration into a safe             
harbor should cause little to no transcriptional alterations to the endogenous genes and             
should not disrupt the host genome in the proximity of integration (​i.e. genomic             
rearrangements). Moreover, the preferred promoters for predictable transgene expression         
should not be inducing changes in the host cell transcriptome by titrating away the              
endogenous transcription factors from endogenous genes ​(68) and should not be as prone to              
position effects and corresponding epigenetic mechanisms ​(55)​. 
There are many potential implications of this toolbox, overall enabling identification of            
parameters determining robust gene expression patterns and fidelity over long-term          
culturing. By using this toolbox for mammalian cell line engineering, the inherent            
stochasticity of gene expression can be minimized and predictable transgene expression           
profiles can be achieved. Predictable and tunable transgene expression profiles are a            
requirement for programming more complex cell behaviors, such as expressing entire           
metabolic pathways with dynamic expression patterns and high temporal precision ​(69)​,           
building reliable synthetic circuits ​(70)​, or engineering the optimal effector gene expression            
levels ​(71)​. We employed this toolbox to increase the expression levels of a secreted              
biotherapeutic (EPO), demonstrating the applicability of our workflow for CHO cell line            
engineering. Similar approaches could be undertaken to optimize the expression context of            
other recombinant proteins in any integration site of interest across different expression            
platforms, including a variety of human cells and cell lines.  
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Figure 1: Generation of mCherry platform cell lines with a poly(A) trap-based recombinase-
mediated cassette exchange (RMCE) landing pad in putative safe harbors yields homogeneous 
mCherry expression patterns across different parental clones 
(A) Five independent mCherry platform cell lines (PCLs) in each of the three putative safe harbors (A, T2 and 
T9) were generated with CRISPR/Cas9-based targeted integration via homology-directed repair (HDR) using 
site-specific landing pad (LP) donor and sgRNA plasmid, together with a Cas9 vector. LP donor vector 
consisted of mCherry and selection marker (NeoR) expression cassettes, flanked by 750 bp long 5’ and 3’ arms, 
homologous to the site of interest, and ZsGreen1-DR expression cassette outside of homology arms to exclude 
random integrants. After HDR-based targeted integration, a 14-day G418-based selection was performed to 
enrich for cells with a successful integration of the LP donor.  This was followed by single-cell cloning of double 
mCherry positive/ZsGreen1-DR negative cells by FACS to isolate monoclonal cell lines with targeted 
integration of the LP donor. The LP donors contained loxP and lox2272 recombination sites, flanking EF1α-
mCherry, providing a poly(A)-containing LP (i.e. poly(A) trapping) for recombinase-mediated cassette 
exchange (RMCE). EF1α-mCherry was upon co-transfection of Cre recombinase and RMCE donor exchanged 
with a range of different expression cassettes. RMCE donors consisted of different genes of interest (GOIs) 
under different 5’ proximal regulatory elements (i.e. promoters and Kozak/translation initiation sequences 
(TIS)). Two weeks post-recombination, successfully recombined cells were detected by FACS and bulk sorted 
(mCherry negative cells for EPO and double mCherry negative/GFP positive cells for eGFP) to isolate an 
RMCE-generated cell pool comprising targeted integrants. To assess site-specific expression strength resulting 
from specific regulatory elements, the pools were further analyzed by measuring the GOI’s mRNA (by RT-
qPCR) and protein levels (by FACS or bio-layer interferometry for eGFP and EPO, respectively). Further, eGFP 
expression profiles at the mRNA and protein level were measured during two month long-term cultivation to 
assess the expression stability of both, the integration site and the promoter of interest. (B) mCherry 
fluorescence levels of the generated mCherry-encoding PCLs (n = 5 clones/site) were measured in mid to late 
exponential phase in batch cultures. Coefficient of variation (CV) and median fluorescence intensity (MFI) are 
shown for each clone, by analyzing 20,000 - 40,000 cells per clone. (C) mCherry mRNA levels were also 
assessed in mid to late exponential phase in batch cultures in the generated mCherry-encoding PCLs. mCherry 
mRNA levels were normalized to T2-C9 clone. Statistical significance between relative mRNA expression levels 
of five clones with targeted site A, T2 and T9 was calculated using unpaired t test. A linear regression-based 
correlation analysis of relative mCherry MFIs from Figure 1b (normalized to mCherry MFI of T2-C9 clone) and 
relative mCherry mRNA expression levels is shown. 
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Figure 2: Proof-of-principle RMCE experiment with different eGFP constructs confirms 
functionality of poly(A) trap and generates single-copy populations with tunable expression 
patterns 
(A) Three representative PCLs (A-D1, T2-C9 and T9-G4) were randomly selected for site A, T2 and T9, 
respectively, and subjected to RMCE with four different eGFP constructs with composite promoter (CP) or 
SV40 promoter, preceded by either a weak or strong Kozak sequence. One week post-RMCE, mCherry and 
eGFP fluorescence were measured by FACS (100,000 - 200,000 cells) with MFIs of successfully recombined 
populations (i.e. mCherry negative/eGFP positive cells) reported. (B) Recombined populations with eGFP 
under CP or SV40 promoter and strong Kozak only were bulk sorted and their eGFP copy number measured 
using digital PCR (dPCR). Using COSMC as an internal one-copy control gene, obtained eGFP/COSMC reads 
(%) are reported for five bulk-sorted populations. The error bars represent 95% confidence intervals, averaged 
between the technical replicates (n = 2). 
 
- Chapter 2 - 
57
 - Chapter 2 - 
58
Figure 3: Screening of the promoter-eGFP panel generates site-dependent and construct-
dependent expression patterns with up to 30-fold dynamic range and minimal clonal variation   
(A) A panel of eGFP constructs with four differents promoters (EF1α, CMV, CP and SV40 promoter) preceded 
by a strong Kozak sequence was recombined into A-D1, T2-C9 and T9-G4 PCLs. Two weeks post-RMCE, FACS 
analysis (100,000 - 200,000 cells) for all 12 conditions was performed assessing MFI and CV of successfully 
recombined eGFP populations (i.e. mCherry negative/eGFP positive cells). (B) All 12 recombined populations 
were bulk sorted and their eGFP fluorescence and mRNA levels measured. eGFP MFIs and mRNA levels were 
normalized to the values of T2-EF1α population (internal calibrator). A linear regression-based correlation 
analysis of relative eGFP MFIs and relative eGFP mRNA expression levels is shown. RMCE, bulk sorting as 
well as eGFP fluorescence and mRNA levels measurements were repeated for three PCL-promoter 
combinations (Rep2 samples). (C) Heatmap with relative MFIs for 36 eGFP recombined populations, 
measured with FACS (100,000 - 200,000 cells). The panel of eGFP constructs with four promoters and a 
strong Kozak sequence was recombined into three different parental PCLs for each site. eGFP MFIs of all 
populations were normalized to the value of T2-C9-EF1α population.   
 
 
 
 
 
Table 1: Long-term stability of eGFP expression is ensured in all three newly discovered safe 
harbors regardless of the expression cassette used 
Heatmap with relative MFIs and relative mRNA expression levels for 12 eGFP recombined populations (from 
Figure 3a and b) at week 1, week 4 and week 8 from the start of long-term cultivation. Three bulk-sorted 
populations (namely A-CP, A-SV40 and T2-CP) were generated twice, independently (for more details refer to 
Material and Methods, subsection: Subpopulation generation by recombinase-mediated cassette exchange 
(RMCE) and bulk sorting), and the corresponding MFIs are reported as relative mean MFIs between the two 
biological replicates. eGFP MFIs and mRNA levels were normalized to the values of T2-C9-EF1α population at 
the first time point (week 1; internal calibrator).   
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Figure 4: Expression level characterization for a secreted biotherapeutic (EPO) demonstrates 
protein-specific patterns under different expression cassettes 
(A) A panel of erythropoietin (EPO) constructs with three differents promoters (EF1α, CMV promoter and CP) 
preceded by a strong Kozak sequence was recombined into A-D1, T2-C9 and T9-G4 PCLs. Two weeks post-
RMCE, FACS analysis (100,000 - 200,000 cells) for all 9 conditions was performed assessing percentage of 
successfully recombined EPO populations (i.e. mCherry negative cells).  (B) All 9 recombined populations 
were bulk sorted and EPO protein and mRNA levels measured. Specific productivities of EPO (pcd; pg 
protein/cell day) were correlated with relative EPO mRNA expression levels using linear regression. EPO 
mRNA levels were normalized to the value of T2-EF1α population. 
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Improving Recombinant Protein Production by 
Ectopic Expression of Effector Genes - A Review 
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 Rationale 
In this chapter, a review is presented of the state of the art with respect to engineering                 
effector genes, beneficial for resolving the secretory bottlenecks (​q​
p​) in the production of             
recombinant proteins in CHO cells. We discuss the different experimental and cellular            
factors, such as the expression platform, the gene dosage and origin, the clonal variation and               
the host cell, contributing to and affecting the results observed when overexpressing the             
effector gene of interest. The review underpins the importance of considering these factors             
and provides guidance for the future engineering of novel effector genes.  
 
The many factors discussed here are examined and the guidelines applied in a study,              
presented in ​Chapter 4​, where novel effector genes with ​q​
p​-increasing function are            
discovered. 
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Chinese hamster ovary (CHO) cells are themost frequently used cell
host for biopharmaceutical production of glycoproteins (Walsh, 2014).
Besides being the host cell used for the ﬁrst approval of a recombinant
biopharmaceutical produced in mammalian cells in 1986 (Wurm,
2004), CHO cells are the preferred choice for a number of reasons.
First, CHO cells can easily be adapted for high-density suspension
growth in a chemically deﬁned, serum-free medium in large-volume
cultures (Kim et al., 2012; Sinacore et al., 2000). Second, gene ampliﬁca-
tion methods have been established for CHO cells, leading to high spe-
ciﬁc productivity (qp) of recombinant protein (r-protein) in stable cell
lines (Durocher and Butler, 2009). Third, CHO cells are less prone to
virus infection than other mammalian production cell lines and are
therefore regarded as a safe host for the production of human therapeu-
tics (Berting et al., 2010). Last, CHO cells and other mammalian cells are
the platform of choice for the production of human recombinant glyco-
proteins because of their ability to correctly make human-like post-
translational modiﬁcations (PTMs), in particular glycosylation (Butler
and Spearman, 2014). Human-like PTMs turn r-protein products into
functional drug molecules with reduced immunogenicity, prolonged
serum half-life and high pharmacological efﬁcacy in the human body
(Walsh and Jefferis, 2006).
The production of r-proteins in CHO cells in optimized bioprocesses
can reach qp of 50–90 pg per cell per day (pcd) (Hacker et al., 2009). As
previously pointed out by Khan and Schröder (2008), professional se-
cretory plasma cells are capable of secreting IgM at a rate of 200–
400 pcd (Fazekas et al., 1980; Randall et al., 1992). This clearly indicates
that nature's physiological limit not yet has been reached and thus, in-
tracellular rate-limiting steps in protein production remain to be re-
solved. Indeed, post-transcriptional rate-limiting steps in the
biosynthetic pathway of r-proteins have been reported multiple times
in CHO cells (Johari et al., 2015; Kallehauge et al., 2016; S.J. Kim et al.,
1998; Ku et al., 2008; Schröder et al., 1999) as well as in other mamma-
lian cells (Barnes et al., 2004; Fann et al., 1999). The presence of a post-
transcriptional bottleneck suggests that there aremany opportunities to
improve the secretory pathwaymachinery in CHO cells. Moreover, arti-
ﬁcial protein scaffolds such as fusion proteins are becoming more pop-
ular in the biopharmaceutical industry with increasing market shares
(Aggarwal, 2014). These non-native scaffolds are in general more
prone tomisfolding (Lee et al., 2007). Thus, the cost-efﬁcient production
of these difﬁcult-to-express fusion proteinswillmost likely require sub-
stantial engineering of the folding machinery in the secretory pathway.
EngineeringCHOcells by the ectopic expression of transgenes (here-
after referred to as effector genes) is an attractive solution to improve
the secretory capacity of CHO cells. In many cases, such engineering ef-
forts have led to positive effects on qp on a variety of r-proteins (see re-
cent reviews (Fischer et al., 2015; Hussain et al., 2014; Nishimiya,
2013)). Thismultitude of studies showing positive effects clearly under-
pins the potential of expressing effector genes. However, as previously
pointed out (Hussain et al., 2014; Kim et al., 2012; Mohan et al.,
2008), some effector genes are ﬂawed by inconsistent effects. To exem-
plify this, all published studies on r-protein productivity (volumetric
productivity or qp) in CHO cells with the ectopic expression of thewide-
ly studied protein disulphide isomerase (PDI) are listed in Table 1. PDI is
an endoplasmic reticulum (ER)-resident enzyme conferring disulphide
isomerase activity (Hatahet and Ruddock, 2009). Moreover, PDI forms
and reduces disulphide bonds in nascent polypeptides in the lumen of
the ER and in parallel inhibits the aggregation of folding intermediates64through its function as a chaperone (Appenzeller-Herzog and Ellgaard,
2008). The reported effects of overexpressing PDI on volumetric pro-
ductivity and qp vary from a two-fold decrease through no effect to a
1.4-fold increase. This inconsistency, can to some extent, be explained
by product speciﬁcity, as several different r-proteins have been used
as model proteins. In fact, PDI overexpression only increased qp for
one of four monoclonal antibody (MAb) variants in a parallel experi-
mental setup (Pybus et al., 2014). However, many cellular and experi-
mental factors are at play when examining how an effector gene
affects volumetric productivity and qp (Fig. 1). Thus, it is likely that fac-
tors other than product speciﬁcity are involved in the inconsistency of
PDI's effect on volumetric productivity and qp of r-proteins.
In contrast to PDI, the effect of many effector genes on volumetric
productivity or qp has only been reported once (Hussain et al., 2014;
Nishimiya, 2013). Notwithstanding product speciﬁcity, it is likely that
a considerable number of these effects are conditional – for example,
speciﬁc to the monoclonal cell line or the expression platform being
used. The applicability of such conditional effects is often limited to
the research group in question and not to the CHO engineering ﬁeld in
general. Here, cellular and experimental factors that potentially affect
the outcome when studying effector genes will be described and
discussed. If these factors are appreciated, the risk of unintentionally in-
vestigating conditional effects can beminimized and the chance of ﬁnd-
ing true positive effects can be increased.
2. CHO host cell lines
In 1957, the immortalized, original CHO cell line (the common an-
cestor for all CHO cell lines) was established from the ovaries of an out-
bred female Chinese hamster (Puck, 1957; Wurm, 2013). This original
cell linehas led to amultitude of commercially available andproprietary
CHO cell lines (Wurm, 2013). Being an immortalized cell line, the ge-
nome of CHO cells is inherently unstable (Frye et al., 2016). Moreover,
dihydrofylate reductase deﬁciency (DHFR) in the widely used DXB11
and DG44 cell lines was achieved by subjecting cells to radiation- and
chemical-mediated mutagenesis, respectively (Urlaub et al., 1983;
Urlaub and Chasin, 1980). Thus, host CHO cell lines constitute a
genomically diverse family in termsof single nucleotide polymorphisms
(Lewis et al., 2013), copy-number variations (Kaas et al., 2015) and kar-
yotypes (Wurm and Hacker, 2011). Moreover, it has recently been sug-
gested to regard CHO host cell lines as ‘quasispecies’, emphasizing the
extensive genetic heterogeneity residing in the CHO host cell family
(Wurm, 2013).
When CHO host cell lines are compared, they are found to be not
only genetically divergent but also phenotypically diverse. For example,
it has been shown that the ER size in the CHO-K1 host cell line is larger
compared to a DXB11-derived host cell line, and the mitochondrial
mass was also found to be higher in CHO-K1 cells (Hu et al., 2013).
These phenotypic differences might explain the approximately 10-fold
lower qp observed for the DXB11-derived host cell line compared to
CHO-K1 cells, which was obtained for two different MAbs from stable
gene-ampliﬁed clones (Hu et al., 2013). In a recent CHO bibliome
study by Golabgir et al. (2016), a meta-analysis of bioprocess studies
showed that the speciﬁc growth rate and qp of DXB11- compared to
DG44-derived cell lines were signiﬁcantly higher and lower, respective-
ly. Although the bibliome data consist of a range of process conditions
and experimental setups, both DG44 and DXB11 are DHFR-deﬁcient
cell lines. Consequently, the gene-ampliﬁcation process and clone selec-
tion are therefore comparable, warranting the comparison of qp.
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Fig. 1.Cellular and experimental factors affecting the biosynthetic pathway of r-proteins in
CHO cells. Graphical representation of a CHO cell co-expressing an r-protein (gene, mRNA,
polypeptide and protein in red letters) and an effector gene (gene and protein in blue
letters). Effects from external factors are indicated with dashed arrows. Effector protein-
mediated effects are shown with thin line arrows, and whether these effects are direct
or indirect through interactions with an unknown DNA or protein molecule (element X)
are illustrated. Nucleus, ER, Golgi and transport vesicles are depicted in the upper half of
the cell. Since localization of effector proteins is gene-dependent, cytoplasmic organelles
are not depicted in the lower half of the cell. PTM, post-translational modiﬁcation.
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DG44-derived cells in the bibliome study. The observed differences be-
tween CHO-K1, DXB11 and DG44 host cells clearly illustrate the pheno-
typic diversity that resides within the family of CHO host cells.
Being such a diverse family of cell lines, the following question
arises: Are effects on qp of an effector gene transferable across CHO
host cell lines? In the PDI example, at least four CHO host cell lines
(DXB11, DG44, CHO-K1 and CHO-S) have been used (Table 1). Because
of product speciﬁcity and other factors, it is not possible to make any
conclusion on the inﬂuence of CHO host cell lines on PDI as an effector
gene. As for the spliced form of X-box-binding protein 1 (XBP-1S), it
has been shown that ectopic XBP-1S expression was able to increase
the volumetric productivity of erythropoietin (EPO) in CHO-K1 as well
as in the murine NS0 myeloma cell line (Ku et al., 2008). Moreover,
Tastanova et al. (2015) found that the CHO-derived transcription factor
Yin Yang 1 (YY1) improved the volumetric productivity of a MAb (Ri-
tuximab) upon co-transfection in a transient expression setup in CHO-
K1 and CHO-S cells. Moreover, YY1 expression also improved the volu-
metric productivity of MAb in DG44- and DXB11-derived stable cell
lines. In a transient expression setup using the human orthologue, the
positive effect of YY1 on volumetric productivity was also observed in
human embryonic kidney (HEK) cells, human cervical cancer cells
(HeLa) and human ﬁbrosarcoma cells (HT-1080), which are immortal-
ized cell lines with genomes vastly different from CHO cells. Future
studies will show whether the generic effect of YY1 and XBP-1S be-
tween genomically distinct cell lines is an exception that proves the
rule.3. Clonal variation
Phenotypic heterogeneity is observed not only between CHO host
cell lines but also within the cell population of CHO host lines. In fact,
CHO cells are known for being able to adapt to changes in process con-
ditions, which has been exploited in the industry to generate clonally66derived cell lines with enhanced manufacturing capabilities (Frye et
al., 2016). Moreover, themajority of cells in host cell lines seem to be in-
trinsically incapable of high production of MAb, and universally compe-
tent cells are likely relatively rare cases (O'Callaghan et al., 2010).
Functional heterogeneity residing in the host cell population is typically
referred to as clonal variation (Fig. 2). Although not CHO cells, howclon-
al variation is generated (phenotypic drift) has been elegantly demon-
strated in the murine cell line NS0 (Barnes et al., 2006). Three rounds
of limiting dilution were performed, and variation in cell growth rate
was observed after each round of subcloning. This phenomenon has
subsequently been observed in subclones of a CHO-K1-derived host
cell line (Davies et al., 2013). The cell growth rate changed for approxi-
mately half of the clones during extended culture time, demonstrating
that both static (inheritable) phenotypes and phenotypic drift were ob-
served. Moreover, the initial cell growth rate of the subclones varied
substantially, which demonstrates the presence of clonal variation
within the host cell line. When analysing single cells in a monoclonal
cell line culture, large variation in transgene expression has been ob-
served, which could not be attributed to variables such as cell cycle
and cell size (Pilbrough et al., 2009). Since this variation was shown to
ﬂuctuate within a relatively short period, phenotypic drift may partly
originate from non-genetic diversity. However, a comprehensive ge-
nome and epigenome characterization of a CHO-K1 host cell line
adapted to growth in three differentmedia showed high variation in ge-
nome sequence both as a result of media adaptation and under constant
culture conditions over time (Feichtinger et al., 2016). Based on these
observations and as previously stressed by Frye et al. (2016), absolute
genetic homogeneity in a cell culture does not seem achievable because
of the genomic plasticity inherent in immortalized mammalian cell
lines.
Clonal variation for recombinant CHO cell lines does not originate
only from functional heterogeneity in the host cell line, as genetic het-
erogeneity is also introduced during the generation of recombinant
cell lines (Fig. 2). For example, chromosomal aberrationswere observed
in 10 of 16 stable gene-ampliﬁed GFP-expressing cell lines not observed
in the DG44 host cell line (Derouazi et al., 2006). In addition, signiﬁcant
differences in speciﬁc growth rate and qp of subclones from a gene-am-
pliﬁed MAb-producing clonally derived DG44 CHO cell line have been
observed (N.S. Kim et al., 1998). Thus, recombinant monoclonal cell
lines generated by gene ampliﬁcation are genetically and phenotypical-
ly diverse.
Does an observed phenotypic difference between two recombinant
cell lines originate from clonal variation or from stable expression of
an effector gene? If only one control cell line and one effector gene-ex-
pressing cell line (bothmonoclonal) are being investigated, it is not pos-
sible to rule out that an observed phenotypic difference originates from
clonal variation (Stockholm et al., 2007). Instead, this would require a
number of monoclonal cell lines in both categories to demonstrate
that the difference is a consequence of expressing the effector gene. In
the PDI example, only single clonally derived producer cell lines have
been used as host cell lines when analysing the effect of constitutively
expressing PDI (Table 1). These monoclonal producer cell lines have
then been used as hosts to generate either quasi-monoclonal ormono-
monoclonal PDI-expressing lines (see Fig. 2 for deﬁnitions). Thus, the
observed effects of PDI expression are likely biased by clonal variation,
as quasi-polyclonal and mono-monoclonal cell lines in general do not
represent the average phenotype in the host cell line. This bias can be
addressed if employing polyclonal producer cell lines (see ‘Clonality
and clonal variation’ in Section 7).
In summary, caution must be exercised when investigating the ef-
fects of expressing effector genes in clonally derived producer cell
lines. At a minimum, quasi-polyclonal or mono-monoclonal cell lines
from two but preferably three different monoclonal producer cell lines
should be examined. Alternatively, transient expression or stable epi-
somal expression of the r-protein product circumvents the bias originat-
ing from clonal variation (see Section 7).
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Fig. 3. Secretion bottleneck and ER stress. A) Schematic depiction of a secretion bottleneck
upon co-expression of an r-protein and an effector gene. The black solid line shows the
relationship between translation rate of an r-protein and qp. The grey solid line
illustrates that expression of certain effector genes gives rise to a positive effect on qp
only when a secretion bottleneck is present. The grey and black dashed lines indicate
the onset translation rate for a secretion bottleneck with and without expression of a qp-
increasing effector gene, respectively. B) Schematic graph showing how secretion
bottlenecks affect ER stress levels. Same colour code as in panel A is used except for the
red line, which indicates the threshold between anti- and pro-apoptotic ER stress levels.
Fig. 2. Clonal variation in stable CHO cell lines. A typical process of generating a clonally derived stable CHO cell line co-expressing an r-protein and an effector gene is illustrated. CHO cells
are depicted as circles, and the red circle is a high-producer cell clone selected for transfection of the effector gene. To depict the heterogeneitywithin the cell pools, the qp level of each cell
is illustrated as black and greypie charts for transient and constitutive expression of the r-protein, respectively. Clonality of eachphase is indicated.Quasi-polyclonal andmono-monoclonal
mean that the polyclonal cell line and monoclonal cell line, respectively, both originate from amonoclonal r-protein producer cell line. Whether cells have adapted to expression of the r-
protein is indicated (see ‘ER stress’ in Table 2). The extent of clonal variation throughout the process is depicted and is deﬁned as the possible phenotypic difference from an average cell in
the host cell line. Transfection-mediated stress is depicted (see ‘Transfection stress’ in Table 2). SCS: single-cell sorting.
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The main application of CHO cells in the biopharmaceutical industry
is to produce human-like glycoproteins. Although humanized, some
MAb biopharmaceuticals are chimeric molecules of mouse and human
amino acid sequences (Ahmadzadeh et al., 2014). Thus, human and, to
some extent, murine-derived polypeptide sequences are expressed in
a heterologous CHO-based context. In view of this, should the origin of
an effector gene be human, CHO or mouse? In the PDI example (Table
1), all three origins have been reported, although human PDI is overrep-
resented (four of six studies). This observation is consistent with an
overall preference for the human origin of effector genes (Fischer et
al., 2015).
The argument for using a human effector gene would be that the ef-
fector gene protein is expected to directly interact with the r-protein. In
other words, it is thought to facilitate a favourable interaction between
two autologous (human) molecules that is less likely to take place be-
tween two heterologousmolecules (direct effect; see Fig. 1). In contrast,
the argument for using a CHO effector gene would be that an effector
gene is expected to interact with host cell molecules (indirect effect
through element X; see Fig. 1). For example, an effector gene-encoded
transcription factor and a chaperone are expected to interact with
host cell molecules (DNA) and the r-protein, respectively. Thus, the
choice of effector gene origin depends on the function of the effector
gene.
The inﬂuence of effector gene origin on CHO cell line engineering has
not been systematically investigated. However, it has been shown that
both CHO- and human-derived PDI can improve qp of human MAb-re-
lated r-proteins in CHO cells (Johari et al., 2015; Mohan et al., 2007;
Pybus et al., 2014) (Table 1). Moreover, XBP-1S has been shown to in-
crease volumetric productivity and qp in CHO cells – both the human
(Becker et al., 2008; Cain et al., 2013; Pybus et al., 2014) and murine
(Hansen et al., 2015; Ku et al., 2008) orthologues. In contrast, only the
CHO-derived and not the human orthologue of YY1was able to increase
volumetric productivity in CHO cells and vice versa in human cells
(Tastanova et al., 2015). As pointed out by the authors, this clearly indi-
cates that interaction with host-speciﬁc co-factors was required.
Although there might be a few cases where a human effector gene
orthologue is needed, CHO orthologues are more likely to be functional
because they will be present in a non-foreign (autologous) cellular con-
text like YY1. Thus, using CHO-derived effector genes likely increases
the chances of identifying true positive effects and at the same time
minimizing the risk of false negative effects. Furthermore, applying
CHO-derived effector genes would enable direct comparisons of the ex-
pression level between the recombinant effector gene and the endoge-
nous gene. Accordingly, this would entail comparisons of effector gene
doses across experiments and studies (see Section 6).67Cloning CHO and Chinese hamster gene sequences has recently be-
come a more straightforward task owing to the drafts of Chinese ham-
ster and CHO cell line genomes (Brinkrolf et al., 2013; Lewis et al.,
2013; Xu et al., 2011). Moreover, efforts to improve the quality of the
Chinese hamster genome and to reﬁne annotations are currently ongo-
ing (Kremkow et al., 2015). The availability of correctly annotated Chi-
nese hamster gene sequences is likely to facilitate the autologous,
ectopic expression of effector genes in CHO cells in future CHO cell
line engineering studies.
5. Secretion bottleneck and ER stress
A non-linear relationship between the transcript level and qp in CHO
cells shows that there is a post-transcriptional bottleneck in the biosyn-
thetic pathway of r-proteins. Such a bottleneck has been reported in
CHO cells upon transient expression of an Fc-fusion protein (Johari et
al., 2015) and EPO (Ku et al., 2008), although only EPO titer and not qp
was reported for the latter example. In addition, a post-transcriptional
bottleneck has been reported in stable MAb-producing CHO cells (S.J.
Kim et al., 1998) andNS0myeloma cells (Barnes et al., 2004).Moreover,
a post-translational rate-limiting step (hereafter referred to as a ‘secre-
tion bottleneck’; Fig. 3A) has been demonstrated in stable CHO cell lines
expressing antithrombin III (Schröder and Friedl, 1997) as well as in
baby hamster kidney cells constitutively expressing activated protein
C (Fann et al., 1999). In these two cases, a non-linear relationship
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demonstrates that the bottleneck was downstream of translation and
likely also translocation and therefore within the secretory pathway
(ER, Golgi and secretory transport vesicles). Most intracellular whole
MAb molecules in stable CHO cell lines have been found to be in the
early part of the secretory pathway (between ER and cis-Golgi) for cell
lines with and without a secretion bottleneck (O'Callaghan et al.,
2010). The study by O′Callaghan et al. also demonstrated that bottle-
necks in the biosynthetic pathway of the same MAb molecule are cell
line-speciﬁc, irrespective of qp. For example, in one cell line with qp of
7 pcd, the folding and assembly rate of MAb was particularly slow,
whereas in another cell linewith qp of 8 pcd, secretionwas the rate-lim-
iting step.
The unfolded protein response (UPR) is a homeostatic transcription-
al program that is induced when the capacity of folding and processing
incoming nascent polypeptides in the ER is exceeded (Moore and
Hollien, 2012;Walter and Ron, 2011). This protein folding perturbation
is called ER stress. The UPR seeks to restore cellular homeostasis, how-
ever, if high levels of ER stress conditions persist, theUPRwill eventually
becomepro-apoptotic (Jäger et al., 2012;Moore andHollien, 2012; Sano
and Reed, 2013). ER stress originating from r-protein expression has
been observed several times. For example, expression levels of certain
r-proteins have been shown to correlatewith ER stress levels upon tran-
sient expression (Johari et al., 2015; Ku et al., 2010). Once post-tran-
scriptional and/or secretion bottleneck conditions were established,
ER stress levels increased abruptly upon a higher expression level of r-
protein (Fig. 3B). Moreover, cell lines expressing seemingly difﬁcult-
to-express r-proteins have been shown to have increased levels of ER
stress compared to cell lines expressing easy-to-express r-proteins
(Johari et al., 2015; Le Fourn et al., 2014; Sommeregger et al., 2016).
These examples show that ER stress and secretion bottlenecks are inti-
mately linked.
In two studies by Ku et al., a post-transcriptional bottleneck was
identiﬁed at high gene doses of transiently expressed EPO (Ku et al.,
2008, 2010). Ectopic expression of XBP-1S was found to improve the
volumetric productivity of EPO only at gene doses causing ER stress
and with a post-transcriptional bottleneck phenotype (Ku et al.,
2008). Consequently, some ER-related effector genes – such as XBP-1S
– can improve volumetric productivity and/or qp only in conditions
where a post-transcriptional bottleneck is present (Fig. 3A). Being an
ER-localized protein, the effects of PDI on qp likely depend on whether
such bottlenecks are present. However, the presence of a post-tran-
scriptional bottleneck has been investigated for only two of eleven r-
proteins (Table 1). Preferably, non-secretion bottleneck aswell as secre-
tion bottleneck conditions should be established when analysing effec-
tor genes, which would minimize the risk of obtaining false negative
results. Indeed, an inadequate conclusion would have been drawn if
only a low gene dosage of EPO had been used by Ku et al. (2008).
Obtaining positive effects on qp of effector genes in conditions with-
out post-transcriptional bottlenecks is an interesting supposition. To the
knowledge of the authors, no studies have methodically investigated
this topic. Although not investigated, it seems likely that a post-tran-
scriptional bottleneck was not present when expressing Rituximab in
CHO-S cells in the study by Tastanova et al. (2015), as we have obtained
a N10-fold higher qp in a comparable transient expression setup in
shake ﬂasks (Hansen et al., 2015). Nevertheless, a three-fold increase
in Rituximab titer was obtained upon YY1 overexpression in CHO-S
(Tastanova et al., 2015). In a stable CHO-DG44-derived clone expressing
MAb, the positive effect of YY1 was also observed, and this effect could
not be ascribed to an increase in the cell growth rate or transcript level
of MAb heavy and light chains. The increase in qp combinedwith an un-
changed transcript level suggests that the secretion rate per transcript
must be three-fold higher, indicating that the effect is post-transcrip-
tional. Differences in the translation rate have been predicted between
stable monoclonal CHO cell lines expressing the same MAb by mathe-
matical modelling (O'Callaghan et al., 2010), suggesting that the effect68of YY1 could be an increased translation rate. Alternatively, it could be
a decreased degradation of folding intermediates mediated by the ER-
associated degradation pathway (Hussain et al., 2014; Merulla et al.,
2013) or autophagy- and lysosomal-mediated degradation (Kim et al.,
2013). Nevertheless, the YY1 example implies that a secretion bottle-
neck phenotype does not seem to be a prerequisite for improving qp.6. Effector gene dosage
Whether an effector gene is able to improve qp depends not only on
the presence of the effector gene-encoded protein but also on the ex-
pression level. In other words, the outcome of expressing an effector
gene on qp depends on the effector gene dosage (Brown and James,
2015; Xiao et al., 2014). In a study byDavis et al. (2000), CHO clones sta-
bly expressing an Fc-fusion protein with different expression levels of
PDI (‘low PDI’, ‘medium PDI’ and ‘high PDI’) were used (Table 1).
Whereas the low PDI clone had no apparent effect on product titer,
the medium PDI had increased intracellular levels of the Fc-fusion pro-
tein but no effect on titer and the high PDI clone had increased intracel-
lular levels of Fc-fusion protein and a two-fold decrease in titer. If
leaving clonal variation out of consideration, this example shows that
the folding machinery can be overwhelmed when an ER-localized en-
zyme exceeds an optimal expression level range. Like ER-resident en-
zymes, gene dosage titration is also important when investigating
transcription factors as effector genes. Johari et al. (2015) observed in-
creased volumetric productivity of two MAb variants when expressing
either XBP-1S or cleaved activating transcription factor 6 (ATF6c) at
lower gene doses and no effect at the highest gene dosage. Moreover,
the gene dosage for both effector genes inversely correlated with cell
growth, suggesting that the expression of XBP-1S and ATF6c generated
a ﬁtness cost. When Tastanova et al. (2015) investigated how the gene
dosage of the transcription factor YY1 affected the volumetric produc-
tivity of a variety of MAb molecules and CHO cell lines, an optimal
gene dosage range of YY1 was observed. These examples demonstrate
the importance of gene dosage titration.
Two complementary strategies were employed to titrate the YY1
gene dosage by transient expression: the ﬁller plasmid (empty vectors)
principle and promoters with different strengths (Tastanova et al.,
2015). Filler plasmids are used to titrate the effector gene-encoding
plasmid (Estes et al., 2015; Rajendra et al., 2012, 2015), whereas
promotors with different strengths drive transcription at different
rates (Brown and James, 2015; Qin et al., 2010). The ﬁller plasmid prin-
ciple is a cost-efﬁcient solution in transient expression-based setups, as
no additional cloning work is needed besides a single plasmid prepara-
tion of the ﬁller plasmid. Moreover, a linear relationship between the
transfected plasmid load and mRNA can be expected at relatively low
gene doses (Johari et al., 2015; Ku et al., 2008; Rajendra et al., 2015).
When controlling the expression level of stably integrated effector
genes, using a set of promotors with different strengths is the preferred
choice (Brown and James, 2015).
Only a single gene dosage has been used when investigating the ef-
fect of PDI expression on nine of eleven r-proteins (Table 1). This means
that, in nine of eleven cases, it is unknown whether an optimal or ad-
verse gene dosage was used. This indicates that a substantial number
of studies on ectopic expression of effector genes have only employed
a single gene dosage, suggesting that the gene dosage space for many
studied effector genes remains to be explored.
In summary, a wide range of effector gene doses should preferably
be used in the attempt to ﬁnd an optimal range of expression.Moreover,
the expression level of the effector gene and the endogenous gene
should be compared to facilitate comparisons across studies, which re-
quires that CHO-derived effector genes be used (see Section 4). These
efforts would facilitate higher chances of drawing valid conclusions as
well as higher chances of identifying conditions where effector genes
improve qp.
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There are several different platforms for the ectopic expression of r-
proteins in CHO cells. r-proteins can be expressed either transiently
from a non-integrated plasmid or from a gene stably integrated into
the genome. Transient gene expression (TGE) is a widely used technol-
ogy for the rapid production of r-proteins, usually during a 2–10 day
batch or fed-batch process (Baldi et al., 2007). TGE is the preferred pro-
duction method during the early stages of drug development for pre-
clinical studies, as a sufﬁcient quantity of r-protein can be obtained
within a short period of time (Kim et al., 2012). However, the lower pro-
tein yield achieved with TGE in CHO cells has historically been a major
drawback compared to the substantially higher yields obtained with
stable gene expression (SGE). Thus far, extensive efforts to improve
TGE yields in CHO cells have beenmade by optimizing the culture envi-
ronment (Galbraith et al., 2006; Ye et al., 2009), transfection efﬁciency
(Mozley et al., 2014; Rajendra et al., 2012, 2015), vector systems (Cho
et al., 2001; Mariati et al., 2010) and host cell line (Cain et al., 2013;
Daramola et al., 2014; Macaraeg et al., 2013). Therefore, TGE has be-
come a robust and ﬂexible system, applicable tomultiple r-proteins, ex-
pression volumes and bioprocesses with substantially increased yields
of up to 3 g/L for MAb-producing CHO cells (Liu et al., 2015).
SGE is a prerequisite for the stable, large-scale manufacturing of r-
proteins as biologics for clinical applications (Noh et al., 2013; Wurm,
2004). Stable cell lines are typically generated using selection based
on a selective marker expressed on the same plasmid as the r-protein
(Priola et al., 2016). If desired, the gene encoding the r-protein can be
ampliﬁed to increase qp, although gene-ampliﬁcation in general reduces
the stability of volumetric productivity and qp in extended culture con-
ditions (Chusainow et al., 2009). The twomost widely used gene ampli-
ﬁcation systems are the DHFR system and the glutamine synthetase
system (Noh et al., 2013). Nowadays, companies report titers of
N10 g/L forMAbproduction (Gronemeyer et al., 2014). As an alternative
to random transgene integration, piggyBac or sleeping beauty-mediated
transposition can be used,where transgene integration into highly tran-
scribed regions of the host genome is favoured. This leads to a generally
higher rate of transgene transcription compared to the random integra-
tion of plasmids (Ding et al., 2005; Galvan et al., 2009; Wilson et al.,
2007). Consequently, higher qp and stability compared to stable produc-
er clones obtained by random integration have been achievedwithMAb
titers of up to 7.6 g/L (Matasci et al., 2011; Rajendra et al., 2016).
Inducible expression (IE) platforms support the idea of a regulated,
biphasic r-protein expression throughout the production phase, e.g.,
being turned off during growth and turned on only during the late expo-
nential and stationary phase. The inducible nature of the IE platform
provides a powerful expression system for r-proteins that might confer
toxicity when being expressed by constitutive promoters. Several sys-
tems with either repressor or activator conﬁgurations have been devel-
oped for mammalian cells to achieve tight control of gene expression.
Among many, there are i) antibiotic-based regulation systems, such as
the Tet-Off-On system regulated by tetracyclin (Gossen and Bujard,
1992; Mohan et al., 2007), the Pip system regulated by streptogramin
(Fussenegger et al., 2000) and the E.REX system regulated by
macrolides (Weber et al., 2002); ii) an aptamer-based regulation system
(Werstuck andGreen, 1998); and iii) the cumate gene-switch (Gaillet et
al., 2010; Mullick et al., 2006). All these inducible systems have been
successfully used in CHO cell lines, and a 0.24 g/L titer of an Fc-fusion
protein has been reported for this system (Gaillet et al., 2010).
Expression from replicating episomes in CHO cells reduces the loss
of plasmid and thereby prolongs the nuclear retention time of the plas-
mid after cell divisions (Van Craenenbroeck et al., 2000). Episomal rep-
lication can be achievedusing, e.g., the Polyomavirus large T gene (PyLT)
and its origin of replication (PyOri) (Heffernan andDennis, 1991),while
plasmid maintenance and segregation can be accomplished using Ep-
stein-Barr virus nuclear antigen-1 (EBNA-1) and its origin of replication
(OriP) (Lupton and Levine, 1985; Yates et al., 1984). Using these two69sets of complementing viral components, the episomal platformwas re-
ported to increase and prolong TGE yields of a growth hormone and
MAb in CHO cells in comparison to non-replicating plasmid controls
(Codamo et al., 2011; Kunaparaju et al., 2005). Without antibiotic-
based selection, expression from replication-proﬁcient episomes can
be regarded only as a quasi-stable gene expression platform, as epi-
somes eventually will be lost with a half-life of approximately 8–
9 days (Silla et al., 2006). Without selection, titers of up to 2 g/L MAb
have been reported (Daramola et al., 2014). However, if antibiotic-
based selection is applied, a stable pool of cells can be obtained that sta-
bly replicates and segregate episomes for more than two months (Silla
et al., 2006). Thus, when combined with selection, the system can be
regarded as stable episomal expression (SEE).
Although all the described expression systems have been used suc-
cessfully to express r-proteins in CHO cells, each expression platform
has advantages and disadvantages when used for effector gene expres-
sion. In Table 2, four selected expression systems are compared as plat-
forms for analysing how effector genes affect qp. It is important to note
that other expression systems are available – such as stable pools and
monoclonal cell lines obtained by lentiviral vector-mediated gene trans-
fer (Oberbek et al., 2011) or stable pools obtained by piggyBac transpo-
sons (Matasci et al., 2011). In addition, the four expression systems can
be combined in different ways – such as using IE (Chung et al., 2004) or
TGE (Hayes et al., 2010) in a monoclonal stable producer cell line. Nev-
ertheless, the selected expression platforms serve to highlight impor-
tant aspects to consider when choosing a platform and interpreting
the ﬁnal data.
7.1. Duration – from transfection to answer
The preparation of plasmids carrying effector and r-protein genes
takes approximately the same time for all four expression platforms.
However, the time span from transfection to an answer varies substan-
tially. TGE is clearly the fastest track, as experiments are typically done
within two to three days (Hansen et al., 2015; Johari et al., 2015; Ku et
al., 2008). SEE is also relatively fast, as antibiotic-based selected SEE
cells can be obtained within two weeks (Silla et al., 2006). In contrast,
both IE and SGE platforms require generation and characterization of
monoclonal cell lines that take months to perform (Noh et al., 2013).
7.2. Gene dosage and combining genes
In terms of gene dosage titration (Rajendra et al., 2012) and combin-
ing genes (Nishimiya et al., 2013), TGE offers complete ﬂexibility, as a
variety of different plasmids (ﬁller plasmid and/or plasmids carrying
different effector genes) can be co-expressed. This is not the case for
SEE, as the copy numbers of two plasmids with different genes
expressed, in some cases, will drift towards selection for the plasmid/
gene giving rise to the lowest ﬁtness cost (personal communication
with Dr. Mikael Rørdam Andersen, Technical University of Denmark).
To avoid this drift, the r-protein gene and effector gene must be co-
expressed from the same plasmid. Relatively few cell lines are manage-
able to maintain in parallel, which decreases the throughput of gene
combinations for the IE and SGE platforms. Because the effector gene
is constitutively expressed in the described IE and SGE platforms
(Table 2), the effector gene dosage is not titratable in these platforms.
Notably, recent advances in promoter engineering in CHO cells make
it possible to precisely control the gene dosage in TGE and possibly
also in SEE, IE and SGE platforms spanning over two orders of magni-
tude (Brown et al., 2014).
7.3. Transfection stress and variability
A considerable drawback of TGE is the cytotoxic effect from transfec-
tion, here termed ‘transfection stress’ (Fig. 2). Different transfection re-
agents induce different levels of cytotoxicity in terms of impeded cell
Table 2
Selected expression platforms available for analysing how effector genes affect qp in CHO cells.
Transient gene expression (TGE)a Stable episomal expression (SEE)b Inducible expression (IE)c Stable gene expression (SGE)d
Time from transfection to answer 2–3 dayse ~2 weeks N2 months N2 months
Gene dosage easily titrated Yes No Yes No
Genes easily combined Yes No No No
Transfection stress and variability Yes No No No
Cells adapted to ER stress No (No)f No Yes
Secretion bottleneck easily obtained Yes (Yes)g No Yes
Clonality Polyclonal Polyclonal Mono-monoclonalh Mono-monoclonalh
Clonal variation No No Yes Yes
Validation by SGE needed Yes Yes Yes No
a Transient, plasmid-based co-expression of r-protein and effector genes. Examples: Hansen et al. (2015), Johari et al. (2015), Ku et al. (2008), and Tastanova et al. (2015).
b Stable episomal co-expression of r-protein and effector genes after antibiotic-based selection (without selection resembles TGE). No published examples of co-expression are avail-
able, but the expression system is described here: Kunaparaju et al. (2005) and Silla et al. (2006). The r-protein gene and effector gene must be co-expressed from the same plasmid to
prevent a drift in copy number between the two genes (see ‘Gene dosage and combining genes’ in Section 7 for details).
c Inducible expression of a stably integrated gene encoding the r-protein in a clonally derived cell line constitutively expressing an effector gene of interest. No reported examples of this
speciﬁc setup are available to the best of the authors' knowledge, but examples of the expression system are described here: Mohan et al. (2007) and Mohan and Lee (2010).
d Constitutive (stable) co-expression of stably integrated genes encoding r-protein and effector genes in clonally derived cell lines. Examples: Dreesen and Fussenegger (2011), Haredy
et al. (2013), and Tastanova et al. (2015).
e Features regarded as advantages are highlighted in boldface type.
f See ‘ER stress’ in Section 7 for details.
g See ‘Secretion bottleneck’ in Section 7 for details.
h Quasi-polyclonal cell lines can also be used; however, mono-monoclonal cell lines are commonly used. For deﬁnition of quasi-polyclonal andmono-monoclonal cell lines, see Fig. 2.
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aswell as the inhibition of protein synthesis (Underhill et al., 2003). No-
tably, transfection stress can be reduced through process or cell engi-
neering optimization (Johari et al., 2015; Macaraeg et al., 2013; Majors
et al., 2008). In addition, variability in transfection efﬁciency is an inher-
ent problem for TGE (Hansen et al., 2015; Liu et al., 2008); however, op-
timization and careful selection of the transfection method can reduce
variability substantially (Davies et al., 2013). For the SEE, IE and SGE
platforms, transfection stress is most likely not an issue because of the
lengthy (≥2 weeks) antibiotic-based selection processes.7.4. ER stress
The expression of r-proteins is inducible for the TGE (transfection)
and IE (addition of inducing agents) platforms. In contrast, r-proteins
are constitutively expressed during the selection processes in the SEE
and SGE platforms. Whereas the effector gene and the r-protein are
co-expressed during the selection process in the SEE platform, the r-
protein is typically ﬁrst integrated into the genome (monoclonal cell
line; Fig. 2) and subsequently the effector gene (quasi/mono-monoclo-
nal cell line; Fig. 2) in the SGE platform. Thus, in contrast to the TGE,
IE and SEE platforms, the SGE platform subjects cells to high expression
level of the r-protein before investigating whether the effector gene of
interest can alleviate the ER stress originating from r-protein expres-
sion. In other words, some cells with a high r-protein expression level
and consequently a high level of ER stress will likely not survive during
the selection processes (Hu et al., 2013) (Fig. 3B). These highly relevant,
stressed cells will therefore not be part of the effector gene test case, in
contrast to the TGE and IE platforms. This could introduce a bias towards
cells with lower level of ER stress or cells inherently capable of coping
with high levels of ER stress. It is important to note that stable producer
cells adapted to a permanent increase in ER stress levels can be obtained
(Sommeregger et al., 2016); however, the ER stress levels in these
clones are not high enough to induce apoptosis. Instead, conditions
with pro-apoptotic levels of ER stress are more likely to be established
by TGE and IE because of the inducible nature of the two systems. Nota-
bly, the SEE platform does not allow for pro-apoptotic levels of ER stress
to persist throughout the selection process. However, it does enable an
effector gene of interest to alleviate pro-apoptotic levels of ER stress, be-
cause the effector gene and r-protein are co-expressed throughout the
entire process.707.5. Secretion bottleneck
Post-transcriptional and secretion bottlenecks have been reported in
CHO cells for TGE (Johari et al., 2015; Ku et al., 2008) and SGE platforms
(O'Callaghan et al., 2010). To thebest of the authors' knowledge, a secre-
tion bottleneck has not been reported in CHO cells for IE platforms,
which likely is a result of a presumably low transcription rate of the r-
protein gene compared to the TGE and SGE platforms. Naturally, the oc-
currence of a secretion bottleneck is protein-speciﬁc, and it is likely that,
for some difﬁcult-to-express proteins, a secretion bottleneck can be
readily obtained. A post-transcriptional bottleneck in CHO cells has
been reported upon expression from replicating episomes (Pybus et
al., 2014); however, this was without antibiotic-based selection and is
therefore not regarded as SEE (Table 2). A relatively high average qp
(10 pcd for MAbs) can be obtained using the SEE platform (personal
communication with Dr. Meelis Kadaja, Icosagen Cell Factory Ltd., Esto-
nia), implying that post-transcriptional and/or secretion bottleneck
conditions can be established using the SEE platform.
7.6. Clonality and clonal variation
Whenusing TGE and SEE platforms, a representative pool of cells from
the host cell line is being tested (polyclonality), whereas clonally derived
cells are typically used in the IE and SGE platforms (monoclonality).
Whilst polyclonal cells represent an average phenotype of all cells in the
host cell line, monoclonal cell lines typically represent a favoured pheno-
type identiﬁedwithin the functionally heterogeneous pool of cells (Fig. 2).
Thus, different questions are being put forward when expressing effector
genes in polyclonal and monoclonal cells. If qp is increased upon effector
gene expression in polyclonal cells, this ﬁnding can likely be transferred
to the majority of cells within the host cell line. This is not necessarily
the case for clonally derived cell lines expressing effector genes (mono-
monoclonal; see Section 3). Thus, ﬁndings from a clonally derived cell
line might be conditional; that is, the effect only applies to the cell line
in question (O'Callaghan et al., 2010).
7.7. Validation
Since SGE is the preferred production platform for therapeutic pro-
teins in the industry (Noh et al., 2013), any effector gene should prefer-
ably be validated in a SGE context – that is, in high-producer
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times transferable to a SGE context (Tastanova et al., 2015) and some-
times not (Mohan and Lee, 2010). The need for validation is obviously
a drawback of the TGE, SEE and IE platforms. However, if measures de-
scribed here are taken – such as applying different effector gene doses
and establishing conditions with and without post-transcriptional
and/or secretion bottlenecks – the success rate of validating effector
genes is likely to increase.
In summary, TGE is the preferred platform for screening effector
genes because effector genes can readily be combined, gene dosage
can easily be titrated and post-transcriptional and/or secretion bottle-
necks can be obtained; in addition, TGE is not hampered by clonal vari-
ation and adaptation to ER stress (Table 2). A considerable drawback is
the presence of transfection stress and transfection variability, which,
however, can be addressed to some extent through process optimiza-
tion. Once combinations of effector genes and gene doses have been
identiﬁed, they need to be validated, preferably in multiple stable
mono-monoclonal cell lines derived from different host cell lines.
8. Product quality
Although volumetric productivity and qp are important measures,
the ability to enhance product quality is equally important in the bio-
pharmaceutical industry (Gramer, 2014). Volumetric productivity is
the mass of produced r-protein per volume per culture time in cell-
free supernatants. However, a signiﬁcant fraction of the protein mass
can be misfolded or incorrectly processed variants of the r-protein
(Kunert and Reinhart, 2016). In such cases where product quality is im-
paired, an increase in product titer does not necessarily correlate with
an increase in the yield of bioactive r-protein. Quality attributes deﬁning
the overall product quality aremolecularly diverse features of the r-pro-
tein, such as misfolding/aggregation, incorrectly processed propeptides,
enzymatic degradation and amino acid sequence variations (Gramer,
2014). Moreover, glycosylation is probably the most important quality
attribute of therapeutic glycoproteins, because the pharmacokinetic ef-
fects of undesired glycosylation patterns can be decreased drug efﬁcacy
or increased antigenicity (Bertozzi et al., 2009; Butler and Spearman,
2014). Recent advances in glycoengineering and descriptions of how ef-
fector genes can be used tomodulate glycosylation have been described
in recent reviews (Bennun et al., 2016; Dicker and Strasser, 2015; Spahn
and Lewis, 2014). Because of scope limitations, only misfolding/aggre-
gation and propeptide processing in relation to effector genes will be
described here.
Some secreted proteins are expressed as inactive proprotein precur-
sors containing one or more inhibitory propeptides that need to be pro-
teolytically cleaved off by propeptidases before full activity is achieved
(Wiederanders et al., 2003). Since these propeptides in general are es-
sential for protein folding (Chen and Inouye, 2008), propeptide-con-
taining r-proteins need to be expressed as proproteins to prevent
misfolding and degradation. However, there are multiple examples of
insufﬁcient cleavage of propeptides of r-proteins expressed in CHO
cells, leading to the secretion of a mixture of inactive proprotein and
mature, correctly processed r-protein (Preininger et al., 1999;
Sathyamurthy et al., 2012, 2015; Wasley et al., 1993). In these studies,
the ectopic expression of effector genes encoding propeptidases in-
creased the percentage of correctly processed r-proteins. This demon-
strates that the propeptidase machinery within CHO cells can be the
bottleneck for the production of propeptide-containing r-proteins. Solv-
ing this type of bottleneck is unique to propeptide-containing r-proteins
and is therefore not generally applicable for enhancing qp of other types
of r-proteins.
Product quality in terms of misfolding and aggregation is intimately
linked to the secretory pathway. Schröder et al. (2002) demonstrated
that increasing the r-protein expression level of antithrombin III
through gene ampliﬁcation in stable clonally derived CHO cells gave
rise to the formation of disulphide-bonded aggregates. Similarly,71lowering the gene dosagewhen transiently expressing an Fc-fusion pro-
tein in HEK cells has also been shown to reduce aggregate formation
(Estes et al., 2015). In the PDI example (Table 1), the product quality
has been investigated in only one of eleven examples. Here, a 1.2-fold
increase in qp of an Fc-fusion protein was observed upon PDI overex-
pression (Johari et al., 2015). However, PDI overexpression was found
to impair product quality through a 1.4-fold increase in the formation
of highmolecular aggregates. Thus, the overall effect of PDI overexpres-
sion was a decrease in the number of correctly folded Fc-fusion protein
molecules produced per cell per unit time. This study elegantly illus-
trates the importance of analysing quality attributes when studying
how effector genes affect qp.
9. Concluding remarks and future directions
A desirable goal of engineering the secretory capacity of CHO cells is
to generate a universally competent cell line (‘super-CHO’) capable of
manufacturing all r-proteins in demand. In general, this seems difﬁcult
to achieve because of product speciﬁcity (McLeod et al., 2011). For ex-
ample, it has been reported that host cell line subclones being able to
produce a MAb at relatively high qp levels compared to the host cell
pool were not able to produce high levels of an Fc-fusion protein
(O'Callaghan et al., 2015). Moreover, two similar antibody fragments
have been shown to differentially inﬂuence the cell's physiology in
terms of different proteomic responses in a product-speciﬁc manner
(Sommeregger et al., 2016). Similarly, effector genes have been shown
to increase qp in a MAb-variant-speciﬁc manner (Pybus et al., 2014).
However, some effector genes can increase qp for different types of r-
proteins in CHO cells. For example, XBP-1S was able to increase qp
and/or product titer for secreted alkaline phosphatase (SEAP) and vas-
cular endothelial growth factor (VEGF) (Tigges and Fussenegger,
2006), EPO (Ku et al., 2008), MAb (Becker et al., 2008; Cain et al.,
2013; Pybus et al., 2014), an Fc-fusion protein (Johari et al., 2015) and
α1-antitrypsin and C1 esterase inhibitor (Hansen et al., 2015). Similarly,
YY1 expression was able to increase product titer for SEAP, VEGF and
MAb (Tastanova et al., 2015). This type of general effector genes seems
to be able to traverse product speciﬁcity. It is important to note that gen-
eral effector genesmost likely alsowill fall shortwhen it comes to r-pro-
teins that require specialized modiﬁcations, such as the cleavage of
propeptides (Sathyamurthy et al., 2015) andγ-carboxylation of clotting
factors (Kumar, 2015). Thus, positive effects of general effector genes
are likely not generally valid per se, but the effect may be retrieved
once specialized post-translation modiﬁcations are no longer constitut-
ing a bottleneck.
The function of proteins encoded by general effector genes is proba-
bly conceptually different compared to effector gene-encoded proteins
with more product-type speciﬁc effects (i.e. not general effector
genes). In order to traverse product-speciﬁcity, the effect of general ef-
fector genes is probably multifaceted. Such multifaceted effects can be
the result of simultaneously changing the expression level of several
genes. Several cellular processes and/or molecules are able to confer
such effects; for example phosphorylation (Rajesh et al., 2015),
microRNAs (Barron et al., 2011; Hackl et al., 2012), transcription factors
(Adachi et al., 2008; Harding et al., 2003) and histone marks
(Dahodwala and Sharfstein, 2014). Themolecules involved in these pro-
cesses do not interact directly with the r-protein and the effects are
therefore indirect (Fig. 1). An attractive advantage of using general ef-
fector genes is the possibility of modulating the expression level of
more genes than is currently possible when co-expressing multiple sin-
gle effector genes. However, some effects from general effector genes
may also be adverse due to pleiotropic, undesired regulation of a subset
of genes (Stearns, 2010). Thus, investigating and eliminating these po-
tential adverse effects of a general effector gene of interestmay improve
the desired phenotype.
Although single general effector genes seem to be part of the answer,
multiple (general) effector genes are likely a more coherent and robust
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Seth et al., 2007). In fact, multiple reactions within the biosynthetic
pathway of MAb seem amenable for improvement (O'Callaghan et al.,
2010). This notion is supported by non-limiting examples of studies
demonstrating an increase in volumetric productivity or qp in CHO
cells upon the expression of effector genes related to translation and
translocation (Le Fourn et al., 2014), ER folding processes (Borth et al.,
2005; Chung et al., 2004; Hwang et al., 2003) and protein transport
and secretion (Florin et al., 2009; Peng et al., 2011; Peng and
Fussenegger, 2009) (Fig. 1). Several reports have demonstrated syner-
gistic effects on the volumetric productivity or qp of co-expressingmul-
tiple genes in CHO cells (Cain et al., 2013; Le Fourn et al., 2014; Mohan
and Lee, 2010; Peng and Fussenegger, 2009), demonstrating the poten-
tial of combining effector genes. In addition to effector gene overexpres-
sion, downregulating or knocking out endogenous genes might be
equally important for increasing qp (Feichtinger et al., 2016;
Harreither et al., 2015). Finally, supplementing small-molecule chemi-
cal chaperones combined with effector gene overexpression has been
shown to exceed the limits of functional heterogeneity present in the
CHO-S host cell line (Johari et al., 2015).
Whenmodulating the expression of multiple effector genes, the rel-
ative stoichiometry between gene transcripts (gene dosage) becomes
an important aspect to consider to obtain an optimal effect on qp (Xiao
et al., 2014). However, qp is not the only relevant factor: the time inte-
gral of viable cell density (accumulated viable cell number) and product
quality attributes are important measures to control in production
bioprocesses for increasing the product yield (Gramer, 2014; Kim et
al., 2012). This is not a simple task, because process parameters (for ex-
ample metabolite concentration and osmolality) in a bioreactor can
change throughout a bioprocess (Justice et al., 2011). These dynamic
changes affect the overall physiology andﬁtness of the cell and are likely
to affect transcription rates in a promoter-speciﬁc manner (Brown and
James, 2015). Such bioprocess-dependent variables can therefore inter-
fere with the gene dosage of single and multiple effector genes. Thus,
highly context-speciﬁc promoter designs are needed to simultaneously
control the expression level of multiple effector genes during produc-
tion bioprocesses (see recent review (Brown and James, 2015)). In com-
bination with improved designs of vector elements, site-speciﬁc
integration of expression cassettes into so-called safe harbour sites
(Papapetrou et al., 2011) in the CHO genome has the potential of en-
abling predictable and stable expression levels of effector genes in clon-
ally derived cell lines. Based on the game-changing clustered regularly
interspaced short palindromic repeat (CRISPR)/CRISPR-associated
(Cas) genome editing technology (Mali et al., 2013), site-speciﬁc inte-
gration into CHO cells is nowpossible at a relatively low costwith appli-
cable efﬁciencies (Lee et al., 2015, 2016).
The global cellular view of systems biology and 'omics-based ap-
proaches holds a unique potential to identify pathways and gene net-
works comprising novel effector genes (Datta et al., 2013; Gutierrez
and Lewis, 2015; Kildegaard et al., 2013). These networks would most
likely be tedious to identify using a classical reductionist's approach
where typically only a few genes are being tested. Indeed, as recently
stated by Clarke and Lee (2014), the CHO community is currently gen-
erating 'omics data at an ever-increasing rate. This is supported by the
following non-exhaustive examples on CHO 'omics studies: genomics
(Lewis et al., 2013; Xu et al., 2011), transcriptomics (Becker et al.,
2011; Doolan et al., 2008), translatomics (Courtes et al., 2013;
Kallehauge et al., 2016, in press), proteomics (Baycin-Hizal et al.,
2012; Carlage et al., 2009), metabolomics (Selvarasu et al., 2012; Zang
et al., 2011) and integrative 'omics (Clarke et al., 2012). Moreover, a
consensus genome-scale reconstruction of CHO cell metabolism has
now been established (Hefzi et al., 2016) which potentially opens up
new designs of CHO cell lines (Kaas et al., 2014). In fact, using the ge-
nome-scale model to assess resource utilization suggests modulating
expression of effector genes related to the secretory pathway is a
more efﬁcient way of improving qp compared to typical bioprocess72treatments such as sodium butyrate and hypothermia (Hefzi et al.,
2016).
As mentioned by Hussain et al. (2014), some CHO 'omics studies
have probably been hampered by clonal variation (Fig. 2), because
only a few clonally derived cell lines were compared. As previously de-
scribed, CHO cells – even within a host cell line – are functionally and
genomically diverse and only a fraction of the cells are universally com-
petent in terms of r-protein production (O'Callaghan et al., 2010).More-
over, the 'omics proﬁle of gene-ampliﬁed clonally derived high
producer cells are probably vastly different compared to before trans-
fection, due to, for example, adaptation to ER stress. Thus, an 'omics pro-
ﬁle of a high producer might comprise information on the end point of
coping with a high secretion load. However, the proﬁle does not neces-
sarily contain any information on the cellularmechanism(s) involved in
coping with the initial secretion load that the cell is subjected to right
after transfection and/or gene ampliﬁcation events. Instead, the intrinsic
capability for coping with the initial secretion load is more likely to be
found in non-transfected cells (non-adapted cells; Fig. 2). In fact,
Harreither et al. (2015) were able to show that the capability to obtain
high qp from transient expression is reﬂected in the native tran-
scriptome of host cell line subclones. Besides being a potential source
of novel candidate effector genes, 'omics-based proﬁling of non-adapted
monoclonal cells holds the potential to give fundamental insight into
the functional heterogeneity of CHO cells.
Historically, the CHO lineage was not generated for r-protein pro-
duction but for the investigation of molecular and classical cell genetics
(Wurm, 2013). Moreover, CHO cells do not originate from dedicated se-
cretory tissues like plasma cells and β-cells. By default, CHO cells there-
fore seem to be a suboptimal cell line for r-protein production, with
many opportunities for improvement. The signiﬁcant advances
achieved through the ectopic expression of effector genes (Fischer et
al., 2015) are likely only the tip of the iceberg, as relatively few of the ap-
proximately 20,000 genes in the Chinese hamster genome (Kremkow et
al., 2015; Lewis et al., 2013) have been investigated. Furthermore, com-
bining effector genes increases the number of possible test conditions
dramatically. However, the number of possible test conditions can be
reduced through systems biology- and 'omics-based approaches. De-
spite valuable guidance from systems biology, several novel effector
genes (single genes and combinations) remain to be investigated. In
conclusion, the cellular and experimental factors described here will
likely aid future investigations of effector genes and thereby accelerate
the development of CHO cell lines with optimized secretory capacity.
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Rationale 
Thorough analysis of cellular pathways important for bioprocessing has the potential to            
unravel novel beneficial effector genes that can be overexpressed to generate superior CHO             
cell factories. In this chapter, we have screened a panel of candidate effector genes, identified               
previously through network-based secretory pathway reconstruction and transcriptomic        
analysis of IgG-producing CHO cell lines. The objective of this study was to find novel               
effector genes with positive effects on ​q ​
p ​of IgG-producing cells and to understand the              
cellular mechanisms giving rise to the increase of ​q​
p​. 
 
The novel effector genes were examined using the guidelines we proposed and carefully             
reviewed in ​Chapter 3​. We explored a variety of factors, contributing to the observed              
phenotype, by also investigating the two stable IgG (Rituximab) high-producing clones           
generated with the clone screening method described in​ Chapter 1​.  
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1. Introduction 
CHO cells remain the main cell factory for production of glycosylated biotherapeutics, with             
IgGs (including bispecifics and biosimilars) dominating the market now and most likely in             
the foreseeable future ​(1, 2)​. Protein synthesis and secretion processes are important aspects             
for the production of biotherapeutics, however, they are often suboptimal in CHO cells for              
recombinant proteins (r-proteins) due to their ovarian cell type origin, inherently not            
possessing as high secretory activity as ​e.g. secretory plasma cells ​(3, 4)​. Therefore,             
establishing high-producing cell lines through antibiotic selection and gene amplification          
(5–7)​, efficient high-producer clone screening methods ​(8)​, cell media optimization ​(9) and            
expression vector engineering ​(10, 11) are needed strategies to achieve increased r-protein            
synthesis in CHO cells. However, increased r-protein synthesis can quickly result in reaching             
the limit of r-protein secretion, ​i.e. a secretion bottleneck. Secretion bottleneck is a             
non-linear relationship between the intracellular levels of r-protein molecules and specific           
productivity (​q​
p​). The occurrence of the secretion bottleneck is r-protein-specific and is more             
readily obtained for difficult-to-express (DTE) r-proteins. DTE r-protein is a protein that is             
difficult to express due to intracellular challenges (​i.e. transcription, protein folding,           
post-translational processing, secretion) or to its biophysical properties ​(12)​. Cell line           
engineering efforts have been employed to improve ​folding, transport and secretion of            
r-proteins to enhance ​q ​
p​. Target genes (from here on referred to as effector genes) that are                
related to the protein secretory pathway have previously been overexpressed, such as protein             
disulfide isomerase (PDI) ​(13, 14)​, Sly1 ​(15)​, Munc18b ​(16) and SNARE proteins ​(17)​.             
Further, r-protein expression can due to high expression levels or difficult expression            
capability (DTE r-proteins) generate ER stress by exceeding the protein folding and            
processing capacity of the ER ​(18–20)​. Resulting r-protein secretion bottlenecks and           
increased ER stress can in turn induce the unfolded protein response (UPR) ​(21)​. To enhance               
r-protein production, effector genes with transcription factor functions that are involved in            
the UPR have previously been overexpressed, such as X-box binding proteins (XBP1)            
(22–24) and activating transcription factor 4 (ATF4) ​(25)​. Collectively, these studies           
demonstrate that r-protein secretion bottlenecks can be effectively targeted with rational           
effector gene engineering approaches. Moreover, extensive engineering of cell host is           
sometimes indeed needed to alleviate expression bottlenecks, especially for production of           
DTE r-proteins ​(12)​. However, it is increasingly more evident that not only r-protein-specific,             
but also cell line-specific engineering are required for the positive effects of effector genes to               
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be observed ​(26, 27)​, given the intrinsic genetic and functional heterogeneity of CHO cells              
(28)​.  
In this study, we identified a panel of candidate effector genes through a previously              
performed network reconstruction of the CHO secretory pathway, combined with CHO           
transcriptomic data ​(29)​. We set out to identify effector genes from the candidate panel that               
would increase ​q ​
p
and the volumetric productivity of IgG in CHO cells with the objective of                
using these genes as engineering targets to improve the secretory capacity of CHO cells.              
Therefore, we transiently co-expressed a panel of candidate effector genes and an IgG1             
molecule (Rituximab), using an established microscale screening platform ​(30)​, and          
identified three novel effector genes that increased ​q ​
p
​of CHO-S cells under the used              
conditions. Following the identification of the novel effector genes, a thorough investigation            
of intracellular and experimental conditions supporting the positive ​q ​
p
phenotype was           
conducted.  
All in all, we demonstrated that positive effects of the novel effector genes identified in this                
study occur in a relatively narrow range of conditions. Increased ​q​
p
​of CHO-S cells upon               
effector gene overexpression was observed for several IgG1 molecules, however, exclusively           
when IgG1 molecule was transiently expressed and when it was delivered in the expression              
cassette with a heavy chain (HC) under the CMV promoter and a light chain (LC) under the                 
EF1α promoter. Therefore, this case study serves as a reminder of the many complexities of               
the ectopic expression of effector genes for increasing the secretory capacity of CHO cells, as               
exemplified in our review ​(31)​.  
2. Material and methods 
2.1 Plasmid design and construction  
All the plasmids were constructed via uracil-specific excision reagent (USER) cloning           
method, using flexible assembly sequence tags, uracil-containing primers and Phusion U           
Hot-Start Flex polymerase (New England Biolabs), as previously described ​(32)​. Expression           
cassettes of the three IgG1 plasmids (Rituximab B, Adalimumab and Trastuzumab) consisted            
of CMV-HC-BGHpA-EF1α-LC-BGHpA expression cassette and the vector backbone with         
neomycin selection marker. Whereas Rituximab A consisted of the same expression cassette,            
however, with a vector backbone, lacking a functional mammalian selection marker. Plasmid            
Rituximab B - swap derives from Rituximab B with heavy chain (HC) and light chain (LC)                
under the swapped promoters (EF1α-HC-SV40pA-CMV-LC-BGHpA). Plasmids encoding       
Rituximab were previously described ​(33)​. Etanercept plasmids consisted of an expression           
cassette (CMV or EF1α-Etanercept-BGHpA), with a previously published vector backbone          
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(34) and Etanercept cds sequence ​(35)​. Adalimumab and Trastuzumab coding sequences are            
based on the amino acid sequence with accession number DB00051 and DB00072,            
respectively, from the DrugBank database ​(36) and were CHO codon optimized (GeneArt,            
Life Technologies). Effector genes were either amplified from cDNA template or synthesized,            
based on Mus Musculus RefSeq IDs. All effector genes encode amino acid sequences with a               
known Uniprot ID (more information about the cloning of effector genes in the             
Supplementary Table S1). Effector genes were cloned into the ​EF1α-PacI/Nt.BbvCI-SV40pA          
vector backbone ​(the empty vector), as previously described ​(34)​. ​The empty vector without             
any coding sequence was used for all mock transfections. ​All the plasmids are depicted in the                
Supplementary Figure S1. Assembled PCR fragments were transformed into ​E.coli Mach1           
competent cells (Life Technologies). All constructs were verified by sequencing of the            
expression cassettes (Eurofins Scientific​) and purified using NucleoBond Xtra Midi EF           
(Macherey-Nagel) according to manufacturer’s instructions.  
2.2 Cell cultivation 
CHO-S cells (Life Technologies) and CHO-S-derived E9_2 and C6_2 stable Rituximab           
producing cells were grown in 30 mL volume of CD CHO medium (Gibco) supplemented              
with 8 mM L-Glutamine and 2 µL/mL anti-clumping agent (Gibco) in 125 mL Erlenmeyer              
flasks (Corning). E9_2 and C6_2 stable producers were established with Rituximab B            
plasmid, generated using a previously published clone screening platform ​(35)​, as described            
in our manuscript in Chapter 2. CHO-K1-derived stable Rituximab-producing cells (kindly           
provided by Prof. Gyun Min Lee) were grown in 30 mL volume of PowerCHO medium               
(Lonza), supplemented with glutamine synthetase expression medium supplement (GSEM;         
Sigma–Aldrich), 2 µL/mL anti-clumping agent and 25 µM MSX (Sigma–Aldrich; Cat.           
M5379) in 125 mL Erlenmeyer flasks. Cells were incubated at 37°C, 5% CO​
2
at 120 rpm                
(25mm shaking amplitude) and passaged every 2-3 days.  
2.3 Transfection and 3-day batch cultivation in 96-half-deepwell plates 
CHO-S cells were co-transfected with effector gene- and r-protein-encoding plasmids in           
pre-sterilized polystyrene 96-square System Duetz half-deepwell-microplates (CR1496c,       
Enzyscreen, Haarlem, Netherlands) capped with autoclaved low-evaporation sandwich Duetz         
covers (CR1296a, Enzyscreen) as described previously ​(30) with the following exceptions: A            
20% : 80% effector gene : r-protein-encoding plasmid mix was employed instead of 50% :               
50%. Anti-clumping agent was added one day after transfection, instead of three hours after.              
- Chapter 4 - 
81
The 96 half-deepwell plates were incubated in an S41i incubator shaker at the following              
conditions: 325 rpm, 25 mm shaking amplitude, 5% CO​
2​, 37°C.  
2.4 Transfection and 3-day batch cultivation in 6-well plates 
One day prior transfection, the medium was changed to remove the anti-clumping agent. For              
transfection, cells were seeded at density 1 x 10^6 cells/mL in 3 mL volume of CD CHO                 
medium supplemented with 8 mM L-Glutamine (CHO-S cells) or PowerCHO medium,           
supplemented with GSEM and 25 µM MSX (CHO-K1 cells) in a 6-well flat-bottom plate              
(Falcon). Every experiment included a pmaxGFP transfection for assessment of transfection           
efficiency. A total plasmid load was constant, that is 3.75 µg of DNA per well being diluted in                  
OptiPRO™ SFM (Gibco). A plasmid load consisted of 80% model protein and 20% effector              
gene for transfections in CHO-S wt, and 80% empty vector and 20% effector gene for               
transfections in stable producing cell lines, unless otherwise stated. Mock samples were            
transfected with 80% model protein and 20% empty vector in CHO-S wt cells, and with               
100% empty vector in stable cell lines. Rituximab was titrated in duplicates (independent             
transfections) using 0%, 8%, 20%, 33%, 66% and 100% plasmid dose of Rituximab A in a                
3.75 µg of total plasmid DNA load, with the remainder of DNA being the empty vector.                
FreeStyle™ MAX Reagent (Gibco) was diluted in OptiPRO™ SFM according to           
manufacturer’s instructions and added to diluted plasmid mixture for 8 min of incubation.             
Transfection mixture was added to cells and four hours post-transfection 2 µL/mL of             
anti-clumping agent was added to cell suspension. Viable cell density (VCD) and viability             
were measured daily, as described below. Every day 150-300 µL of cell suspension was              
centrifuged at 1000 g, 5 min and supernatant stored at -80°C for titer measurements.              
Integral of viable cell density (IVCD) and ​specific productivity (​q​
p​)(pg protein/cell/day; pcd)            
for each condition were calculated as described elsewhere ​(27)​. On day two GFP fluorescent              
analysis for transfection efficiency assessment was performed, as described below. 1 x 10^6             
cells were harvested on day three by centrifugation at 200 g, 5 min. Cell pellets were stored                 
at -80°C for RNA extraction. Each experiment included two independent mock transfections.  
2.5 Viability, VCD and transfection efficiency determination 
When cells were grown in 96-half-deepwell plates and 6-well plates, viability and VCD were              
determined by a combined Hoechst and PI stain on the Celígo image cytometer (Nexcelom              
Bioscience, Lawrence, MA) as previously described ​(30)​. pMaxGFP transfection efficiency          
was assessed through Hoechst and GFP fluorescence measurements using Celígo image           
cytometer. Viability and VCD of cells in 125 mL shake flasks were determined on the               
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NucleoCounter NC-200 Cell Counter (Chemometec, Allerod, Denmark) using Via1-Cassettes         
and the “Viability and Cell Count Method 2” assay. 
2.6 Relative mRNA expression levels using RT-qPCR 
Total RNA was extracted from 1 x 10^6 cells using RNeasy Plus Mini Kit (Qiagen) according                
to the manufacturer’s instructions. RNA concentration was measured with Qubit          
fluorometric analysis (Life technologies) and the purity/quality was assessed with Nanodrop           
(Thermo Fisher Scientific) and 1% agarose gel visualization. cDNA was synthesized from 1 µg              
of total RNA according to manufacturer’s instructions using either TURBO DNA-free™ kit            
(Invitrogen) followed by qScript™ Flex cDNA kit (Quantabio) or Maxima First Strand cDNA             
Synthesis Kit for RT-qPCR with dsDNAse treatment (ThermoFisher Scientific). The          
RT-qPCR was run on the QuantStudio 5 Real-Time PCR System using TaqMan​TM Multiplex             
Master Mix (Thermo Fisher Scientific) in a triplex and the following amplification            
conditions: 50°C for 2 min, 95°C for 10 min; 40x: 95°C for 15 s, 60°C for 1 min.                  
Custom-made Taqman assays were used for genes encoding Rituximab heavy chain (HC),            
Rituximab light chain (LC), BiP and HERP, as well as normalization genes ​Actb ​and ​Gapdh​.               
All the primers and probes are listed in the Supplementary Table S2 and were validated by                
melting curve analysis and primer efficiency test. BiP and HERP TaqMan probes were             
previously validated (unpublished data) using tunicamycin (ER stress inducer) treatment.          
Using the ΔΔCt method, the relative expression levels of genes of interest were calculated by               
normalization to the expression levels of the two normalization genes. Each experiment            
included controls with no template and was performed with technical triplicates. mRNA            
expression levels were normalized to the mean level of two mock samples or to 100% dose of                 
Rituximab in experiments where Rituximab-encoding plasmids were titrated (internal         
calibrators). 
2.7 Titer measurements  
Rituximab, Adalimumab, Trastuzumab and Etanercept titers were determined in         
supernatants by bio-layer interferometry (ForteBio, Pall, Menlo Park, CA) using Protein A            
biosensors (Fortebio 18-5012, Pall), as previously described ​(37)​. Absolute titers of           
Rituximab, Adalimumab and Trastuzumab were calculated using a calibration curve from a            
dilution series of purified human IgG (Genscript, Cat: #A01006) and absolute Etanercept            
titers were calculated using a calibration curve generated from a dilution series of             
commercially available Enbrel (Pfizer, New York City, NY; Lot R51698). 
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3. Results 
First, we wanted to use a set of effector genes with published positive effects on IgG ​q ​
p
in                  
CHO cells, either transiently or constitutively expressed, that would serve as positive controls             
for ​q​
p
enhancement (data on 15 ‘positive control’ effector genes available in Supplementary             
Table S3). The only protein included in this panel with no reported positive effects on ​q ​
p
for                 
IgG is CHOP, however its positive effect on IgG volumetric productivity was previously             
reported ​(38)​. Second, in our previous study we have manually reconstructed the mouse             
secretory pathway and by applying a comparative genomic approach, we were able to identify              
important secretory components and regulators in CHO-K1 genome ​(29)​. Using this           
reconstruction together with the transcriptome data from CHO non-producing and          
IgG-producing cells, we selected several new candidate engineering targets for improving the            
q​
p
of CHO cells for IgG production (data on 20 candidate effector genes available in               
Supplementary Table S4). The candidate effector genes were selected on the combined basis             
of their predicted function in the reconstructed secretory pathway and their mRNA fold             
changes between non-producing and IgG-producing cell lines. And third, we were interested            
in identifying novel effector genes from the panel of candidate targets that increase overall              
IgG volumetric yield by increasing the ​q ​
p​. Further, we set out to understand the cellular               
mechanism giving rise to the observed increase, so that the novel ​q ​
p​-increasing targets could              
be used to engineer CHO cells’ secretory capacity.  
3.1 Initial screen identifies three novel effector genes that increase ​q ​
p
of            
transiently expressed Rituximab in CHO-S cells 
A panel of candidate effector genes alongside ‘positive control’ effector genes and CHOP, all              
of murine origin, were initially screened in 96-half-deepwell plates when transiently           
expressing an IgG (Rituximab A) in CHO-S cells (​Figure 1​), using an established screening              
platform ​(30)​. By applying a 80% IgG : 20% effector gene plasmid dosage, the screen               
uncovered only a few beneficial effector genes from the ‘positive control’ group, namely             
CHOP and ​Xbp1s with approximately 2.5-fold and 3.5-fold increase in ​q​
p
of Rituximab,             
respectively. This result reconfirms the inconsistency of observed effects across different           
studies and underpins the importance of understanding that both cellular and experimental            
factors are able to modulate the outcome when testing effector genes, as exemplified in our               
review ​(31)​. On the other hand, from the panel of newly proposed targets, overexpression of               
three effector genes demonstrated increased ​q​
p
of Rituximab in our initial setting: ​Epas1 ​,             
Mafb​ and ​Nfe2 ​with approximately 2-fold, 3-fold and 1.5-fold increase, respectively.  
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Figure 1: Screen of ‘positive control’ and candidate effector genes using transient            
expression-based screening platform in 96-half-deepwell plates 
CHO-S cells were transiently co-transfected with Rituximab and effector gene of interest (80% : 20%               
plasmid dosage, respectively) or Rituximab and empty vector (mock) (80% : 20% plasmid dosage,              
respectively). Three days post-transfection, q ​
p
was assessed for each condition and normalized to the              
mock value. Values of each transfection replicate are shown (​n​ = 8).  
3.2 Novel effector genes increase ​q​
p
exclusively when transiently co-expressed          
with Rituximab in a CMV-HC and EF1α-LC composition 
The three ​q​
p​-increasing effector genes, newly identified in the initial screening, were further             
examined together with the established ​Xbp1s effector gene (positive control) to precisely            
define the conditions under which their positive effects would be reproducibly observed. We             
identified and explored several underlying cellular and experimental factors that could be            
affecting the effector genes: a) different IgG vector compositions, b) different IgG expression             
platforms (transient and stable), c) different CHO host cell lines, d) different stable             
producing cell lines, e) different IgG secretion levels and f) different effector gene dosages.  
Since the positive effects of these effector genes were first observed when being transiently              
co-expressed with Rituximab (20% : 80% dosage, respectively) in CHO-S cells, the same             
experiment was reproduced in a 6-well format using three different Rituximab plasmids. To             
test whether co-expression of a selection marker gene would have an effect on ​q ​
p​, we have                
tested two plasmids, both consisting of the HC- and LC-coding sequences downstream of a              
CMV and EF1α promoter, respectively (Rituximab A and Rituximab B). Whereas the third             
plasmid had swapped promoters for the HC- and LC-coding sequences (Rituximab B - swap).              
A 2- to 5-fold ​q​
p
increase was observed for all four overexpressed effector genes for               
Rituximab in the CMV-HC-EF1α-LC composition (​Figure 2A​), especially prominent for          
Epas1 and ​Mafb ​overexpression. Intriguingly, when promoters were swapped, the three           
novel effector genes had no positive effect on ​q ​
p ​of Rituximab, while ​Xbp1s retained              
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approximately 2-fold increase in ​q ​
p
​(Figure 2A). However, it is worth noting that the              
transfection of a plasmid with HC and LC under swapped promoters contributed to 2-fold              
higher ​q​
p ​of Rituximab when comparing the mock samples between the two experiments             
(data not shown). Next, we set out to investigate if the effector genes would give rise to                 
increase in ​q​
p
in stable Rituximab-producing cell lines of different origin. We examined the              
effect of effector genes in three different monoclonal cell lines from two different cell hosts.               
However, no increase in ​q ​
p
was observed when transiently expressing effector genes at             
different dosages in CHO-S and CHO-K1 clonally-derived cell lines, stably expressing           
Rituximab at different ​q​
p
(6 pcd (clone E9_2), 10 pcd (clone C6_2) and 15 pcd (clone GSR))                 
(​Figure 2B​), despite achieving similar transfection efficiency than in CHO-S wt (data not             
shown).  
All in all, the increase in ​q ​
p
for all four effector genes seems to be present only when                  
Rituximab is transiently expressed, and not in clonally-derived Rituximab-producing stable          
cell lines, even for the already established effector gene, ​Xbp1s​. Further, the three novel              
effector genes increase ​q​
p
upon transient co-expression only when the Rituximab expression            
cassette comprises the CMV-HC and EF1α-LC composition.  
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Figure 2: Specific productivity upon co-expression of novel effector genes and           
Rituximab under different experimental and cellular conditions  
(A) Transient co-expression of novel effector genes and Rituximab was performed with different             
Rituximab expression cassette compositions in CHO-S cells using 6-well plates. Three days            
post-transfection, ​q ​
p
was assessed for each condition and normalized to the mock value. Value range               
from the transfection replicates is shown for the mock sample (​n = 2). ​(B) Transient overexpression of                 
effector genes was performed in stable Rituximab-producing cell lines of different origin using 6-well              
plates. Three days post-transfection, ​q ​
p
was assessed for each condition and normalized to the mock               
value. Value range from the transfection replicates is shown for the mock sample (​n = 2). CL - cell line;                    
EG - effector gene; FC - fold change. *The monoclonal cell lines were established using Rituximab B                 
plasmid. **The monoclonal cell line was established using a Rituximab plasmid with GS selection              
marker.  
3.3 Increase of ​q​
p
via LC mRNA upregulation is observed for ​Epas1 and ​Mafb in               
a promoter-independent way  
Since the candidate effector genes were selected on the basis of having potential effects on               
processes in the secretory pathway, we hypothesised that an increase in ​q ​
p
was not              
originating from increased mRNA levels of Rituximab, but rather from processes further            
downstream. To investigate this, we examined the HC and LC mRNA levels. Surprisingly,             
when transiently co-expressing Rituximab in a CMV-HC-EF1α-LC composition (Rituximab A          
and B) and effector genes, 2- to 3.5-fold increase of LC transcript was observed for two novel                 
effector genes, namely ​Epas1 ​and ​Mafb​, while the established transcriptional regulator           
Xbp1s increased both, the HC and LC transcripts (​Figure 3A ​and 3B​). This first suggested               
that ​Epas1 and ​Mafb ​increase the ​q ​
p
of Rituximab via transcriptional regulation of the EF1α               
promoter. However, when HC and LC were under the swapped promoters, we observed LC              
upregulation coupled with HC downregulation for Epas1 and to a lesser extent for ​Mafb              
(​Figure 3C​), indicating these two effector genes might be upregulating LC in a promoter              
independent manner. In contrast, in the Rituximab-producing cell line C6_2 overexpression           
of ​Mafb​, ​Nfe2 or ​Xbps1 did not increase HC or LC transcript levels, however, a marginal LC                 
increase/HC decrease was observed with ​Epas1​ overexpression (​Figure 3D​).  
In conclusion, ​novel effector genes, Epas1 and ​Mafb, seem to be direct or indirect              
transcriptional regulators that increase the amount of present LC transcript in a            
promoter-independent manner. However, their LC-specific upregulation is causing increased         
q​
p
only when Rituximab being transiently expressed is in the CMV-HC and EF1α-LC             
composition (Figure 2A). On the other hand, ​Nfe2 seems to be having a different              
q​
p​-increasing mechanism that does not seem to rely on transcriptional regulation of LC or              
HC.  
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Figure 3: Rituximab heavy chain (HC) and light chain (LC) mRNA transcript levels upon              
co-expression of novel effector genes and Rituximab  
Rituximab HC and LC mRNA transcript levels were measured three days after the transfection of               
novel effector genes. Transcript levels were normalized to the values of the mock sample. The error                
bars represent the standard deviations of the technical replicates (​n = 3). ​(A) ​HC and LC mRNA                 
transcript levels upon transient co-expression of novel effector genes and Rituximab A. ​(B) ​HC and               
LC mRNA transcript levels upon transient co-expression of novel effector genes and Rituximab B. (C)               
HC and LC mRNA transcript levels upon transient co-expression of novel effector genes and              
Rituximab B - swap. (D) ​HC and LC mRNA transcript levels upon transient overexpression of novel                
effector genes in stable Rituximab-producing cell line C6_2. FC - fold change. 
3.4 Detection of post-transcriptional bottlenecks upon transient expression of         
Rituximab 
Next, we wanted to investigate whether any transcriptional or post-transcriptional          
bottlenecks were present when Rituximab was either expressed transiently or constitutively.           
In our transient expression-based platform, we performed titration using varying Rituximab           
A dosages ranging from 0% to 100%, while maintaining a fixed total plasmid load. While a                
linear relationship between the Rituximab plasmid dosage and ​q ​
p ​seemed to be present in the               
range of 0% to 20%, a non-linear relationship was observed for 33% and 66% plasmid               
dosage and ​q​
p
even decreased at 100% dosage (​Figure 4A​). Increasing HC and LC transcript               
levels were observed upon increasing Rituximab plasmid dosages, however, in a non-linear            
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manner (​Figure 4B​). This indicated a possible post-transcriptional bottleneck in production           
of Rituximab A with an onset after 33% plasmid dosage, where a plateau of ​q ​
p
is observed                 
with the increasing LC/HC transcript levels (​Figure 4C​). This suggests that a            
post-transcriptional bottleneck was present when we examined the effect of effector genes on             
q​
p
(​i.e. ​at 80% Rituximab dosage). Next, to unveil whether or not any bottlenecks were               
present in the Rituximab-producing C6_2 clonal cell line, we transiently overexpressed           
Rituximab B in this cell line using a 80% gene dosage (transfection efficiency: 61%              
GFP-positive cells). No increase in ​q ​
p
was observed (​Figure 4D​), as well as no increase in LC                 
transcript, while a marginal increase in HC transcript level was demonstrated (​Figure 4E​).             
This indicated a possible presence of a transcriptional bottleneck upon Rituximab           
overexpression, suggesting that the rate-limiting step in ​q ​
p
in the C6_2 clonal cell line is at                
the transcriptional level.  
In conclusion, a transcriptional bottleneck was detected in the Rituximab-producing clonal           
cell line C6_2 and post-transcriptional bottleneck was detected upon transient expression of            
Rituximab in CHO-S cells. It seems the conditions surrounding the post-transcriptional           
bottleneck of transiently expressed Rituximab with CMV-HC and EF1α-LC composition are a            
prerequisite for observing the effector gene-induced increase of ​q​
p​.  
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Figure 4: Investigation of intracellular bottlenecks in the production of transiently or            
constitutively expressed Rituximab 
(A) (B) (C) ​Titration of Rituximab was performed in duplicates (two independent transfections)             
using 0%, 8%, 20%, 33%, 66% and 100% plasmid dose of Rituximab A in a 3.75 µg of total plasmid                    
DNA load. ​(A) ​q ​p ​and (B) Rituximab ​HC and LC mRNA transcript levels were measured three days                  
post-transfection. Transcript levels were normalized to the values of the 100% sample. Value range              
from the transfection replicates is shown (​n = 2). (C) Determination of a secretion bottleneck of                
transiently expressed Rituximab A. (D) (E) ​Rituximab B was overexpressed (80% dose) in stable              
Rituximab-producing cell line C6_2. (D) ​q ​
p
and (E) Rituximab HC and LC mRNA transcript levels               
were measured three days post-transfection and normalized to the mock value. ​q ​
p
value range from               
the transfection replicates is shown for the mock sample (​n = 2). The error bars of the mRNA levels                   
represent the standard deviations of the technical replicates (​n = 3). ​UT - untransfected; PTB -                
post-transcriptional bottleneck; FC - fold change. 
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3.5 UPR upregulation observed when Rituximab and the two novel effector           
genes are transiently co-expressed  
After detecting a post-transcriptional bottleneck when Rituximab is expressed transiently          
and a transcriptional bottleneck when expressed constitutively in stable cell lines, we            
hypothesized that the expression of Rituximab would give rise to ER stress, and thereby              
induce the UPR. Therefore, we performed analysis of transcript levels of two UPR-responsive             
genes, namely BiP and HERP. Transient expression of Rituximab A did not considerably             
upregulate the UPR levels, with similarly elevated levels of BiP and HERP in the absence and                
presence of post-transcriptional bottleneck (​Figure 5A​). When co-expressing effector genes          
and Rituximab B with a post-transcriptional bottleneck-inducing plasmid dosage (80%), we           
observed an upregulation of HERP when ​Epas1 ​, ​Mafb and ​Xbp1s were overexpressed            
(​Figure 5B​). Therefore, the UPR seems to be induced upon overexpression of effector genes              
that in post-transcriptional bottleneck conditions increase the ​q ​
p
via LC transcript           
upregulation. When transiently overexpressing Rituximab in the Rituximab-producing C6_2         
cell line, the possible presence of transcriptional bottleneck had no UPR-inducing effects            
(​Figure 5C​). All in all, we demonstrated that UPR levels are upregulated when ​Epas1 and               
Mafb​ increase ​q​
p​ of Rituximab via LC-inducing transcriptional regulation. 
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Figure 5: Induction of UPR levels  
(A) ​BiP and HERP mRNA transcript levels were examined upon transient expression of 0%, 20% (​i.e.                
absence of post-transcriptional bottleneck) and 100% (​i.e. presence of post-transcriptional bottleneck)           
Rituximab plasmid dose. Transcript levels were normalized to the values of the 0% sample. Value               
range from the transfection replicates is shown (​n = 2). ​(B) ​BiP and HERP mRNA transcript levels                 
were examined upon transient co-expression of novel effector genes and Rituximab B, expressed at              
the post-transcriptional bottleneck (80% dose). Transcript levels were normalized to the mock            
sample. The error bars represent the standard deviations of the technical replicates (​n = 3). (C) ​BiP                 
and HERP mRNA transcript levels were examined upon transient overexpression of Rituximab B             
(80% dose) in stable Rituximab-producing cell line C6_2. Transcript levels were normalized to the              
mock sample. The error bars represent the standard deviations of the technical replicates (n = 3). ​PTB                 
- post-transcriptional bottleneck; FC - fold change. 
3.6 Increase in ​q ​
p
is observed for different IgG1 molecules, but not for an              
Fc-fusion protein 
We further examined whether the ​q ​
p​-increasing effect of effector genes was applicable to             
other therapeutic glycoproteins, such as different IgG1 molecules (Adalimumab and          
Trastuzumab) and an Fc-fusion protein (Etanercept). We observed an increase in ​q ​
p
when             
transiently co-expressing the individual effector genes and either Adalimumab or          
Trastuzumab (​Figure 6A​), both in the CMV-HC and EF1α-LC expression cassette           
composition. The effect was most prominently observed for ​Mafb and to a lesser extent for               
Epas1 and ​Nfe2​. On the other hand, no clear ​q ​
p
increase was seen for the novel effector genes                  
when co-transfected with either CMV or EF1α promoter-based Etanercept-encoding         
plasmids, however, a modest effect was observed for the positive control, ​Xbp1s (​Figure             
6B​). In conclusion, the ​q​
p​-increasing effect of the three novel effector genes seems to be               
applicable to different IgG molecules of the same subclass (IgG1).  
 
 
 
Figure 6: Transient co-expression of novel effector genes and other r-proteins 
Transient co-expression of novel effector genes and either ​(A) two different IgG1 molecules             
(Adalimumab and Trastuzumab) with the CMV-HC and EF1α-LC expression cassette composition or            
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(B) an Fc-fusion protein (Etanercept) with CMV or EF1α promoter was performed in CHO-S cells               
using 6-well plates. Three days post-transfection, ​q ​
p
was assessed for each condition and normalized              
to the mock value. Value range from the transfection replicates is shown for the mock sample (​n = 2).                   
FC - fold change.  
4. Discussion 
Based on the reconstructed mouse secretory pathway, combined with transcriptome data           
from CHO non-producing and IgG-producing cells ​(29)​, we extracted a panel of candidate             
effector genes that could be overexpressed and might have the potential to enhance the              
secretory capacity of CHO cells for IgG production. By ectopically co-expressing this panel of              
candidate effector genes and Rituximab in our transient expression-based screening          
platform ​(30)​, we identified three novel effector genes (namely ​Epas1, Mafb and Nfe2​) with              
positive effects on our phenotype of interest, ​q​
p​. With the objective of elucidating the              
mechanism by which these novel effector genes give rise to the ​q ​
p​-increasing effect, we              
analyzed a host of cellular and experimental factors. 
The three novel effector genes reproducibly increased ​q​
p ​of the cells transiently expressing             
different IgG1 molecules (Rituximab, Adalimumab, Trastuzumab) delivered in a vector with           
a CMV-HC-EF1α-LC expression cassette composition. When a Rituximab-encoding plasmid         
with swapped promoters (EF1α-HC-CMV-LC composition) was transiently transfected into         
CHO-S cells, no ​q​
p​-increasing effects of effector genes were observed. Therefore, it seems             
that only the CMV-HC-EF1α-LC expression cassette composition created the conditions in           
which the novel effector genes were able to increase ​q ​
p​. It has been previously demonstrated               
that the HC:LC ratio at both the mRNA and polypeptide levels affects the folding and               
secretion rates of IgG molecules ​(11, 39)​. Since a 2-fold increase in ​q ​
p
was observed for the                 
swapped promoter construct compared to non-swapped promoter construct, the swapped          
EF1α-HC-CMV-LC composition might generate HC:LC ratios at the mRNA/polypeptide level          
that are more optimal for IgG folding and secretion. LC might be in excess under the                
seemingly more potent CMV promoter, resulting in lower HC to LC ratio that was previously               
reported to improve IgG folding and assembly ​(40)​. Next, when analyzing the HC and LC               
mRNA transcript levels, we observed that ​Epas1 ​and ​Mafb but not ​Nfe2​, ​increased q ​
p ​via LC                
transcript-specific upregulation in a promoter-independent manner. Since the LC-increasing         
effect was observed regardless of Rituximab promoter composition, this indicates that ​Epas1            
and ​Mafb ​function as direct or indirect transcriptional regulators of LC under the given              
cellular conditions. Meanwhile, ​Xbp1s serving as the ‘positive control’ effector gene increased            
both LC and HC transcript levels and increased ​q ​
p
independent of the Rituximab promoter              
composition. This is consistent with its function as a general transcription factor            
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downstream of the UPR transducer IRE1α ​(41)​. Moreover, the ​q ​
p​-increasing effect of ​Xbp1s             
has been consistent with several previous reports showing an increase in ​q ​
p
and/or in              
product titer in different settings and for different r-proteins, such as secreted alkaline             
phosphatase (SEAP) and vascular endothelial growth factor (VEGF) ​(22)​, erythropoietin          
(EPO) ​(23)​, an Fc-fusion protein ​(18)​, α1-antitrypsin and C1 esterase inhibitor ​(30) and IgGs              
(24, 27, 42)​.  
To test whether the effect of effector genes was not limited only to transient expression in the                 
heterogeneous polyclonal CHO-S pool, we transiently overexpressed effector genes in three           
stable Rituximab-producing cell lines. These cell lines were of different cell host origin and              
clonality to address the possibility of both, host-specific and clone-specific effector gene            
effects. Upon effector gene overexpression, no ​q​
p ​increase was observed in any of the stable               
Rituximab-producing cell lines with a range of different ​q ​
p
(​i.e. 6–15 pcd). Further, no              
considerable increase in HC and LC mRNA transcript levels was observed upon effector             
genes overexpression in the Rituximab-producing C6_2 cell line. There are several possible            
causes to these observations. First, stable cell lines undergo several stages of selection that              
are designed to isolate either clones with an innate capability to cope with high levels of                
r-protein-induced ER stress or clones that have inherently lower ER stress levels ​(31)​.             
Studying the effect of effector genes in stable cell lines is likely biased towards phenotypes               
inherently adapted to r-protein production. It would therefore be beneficial to integrate the             
effector genes into the genome of a clonal cell line before the r-protein-encoding gene, as               
proposed in our review ​(31)​. Second, isolated clones might have significantly different            
endogenous levels of effector genes in comparison to the heterogenous polyclonal host cell             
line. Therefore, overexpressing effector genes in clonally-derived cell lines might not give rise             
to an observable effect on ​q​
p
with the dosages used in this study; hence transfection of                
different effector gene-encoding plasmid dosages into these cell lines are warranted.           
RNA-seq data from our previous studies show that the endogenous levels of novel effector              
genes are very low or undetectable, both in CHO-S wt cells, as well as in stable cell lines                  
producing different r-proteins ​(43, 44)​. And third, previous studies have shown that while             
the effects of certain effector genes can be observed in different expression platforms (YY1 in               
(45)​), other effector genes might not have the wanted effect in cells transiently and              
constitutively expressing the r-protein unless rate-limiting conditions in the biosynthetic          
pathway of r-proteins are present (XBP1 in ​(23)​; PDI in ​(46)​). The Rituximab-producing cell              
lines used in this study possibly have different rate-limiting steps in Rituximab synthesis             
and/or secretion. Different rate-limiting steps in IgG production might be the reason why             
only 1 out of 15 ‘positive control’ effector genes (namely ​Xbp1s ​) gave rise to ​q ​
p
in our                 
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transient expression-based screening platform, even though they have been previously          
validated in stable cell lines. Therefore, it would be beneficial if the screening conditions for               
discovering novel effector genes would as closely as possible capture the environment under             
which the effector genes are desired to be used, ​i.e. in a stable cell line with an identified                  
rate-limiting step in the secretory pathway.  
Since our observations suggest that the three novel effector genes only give rise to an               
increase in ​q ​
p
when the r-protein is transiently expressed, we hypothesized that there might              
be a post-transcriptional bottleneck present when Rituximab was transiently but not           
constitutively expressed. We were able to identify bottlenecks in the biosynthetic pathway of             
Rituximab in both expression systems. When transiently expressed, a post-transcriptional          
bottleneck was detected at 33% or higher Rituximab-encoding plasmid doses, suggesting that            
a post-transcriptional bottleneck was present when investigating the effect of effector genes.            
In contrast, a transcriptional bottleneck seemed to be present in the Rituximab-producing            
cell line C6_2. This possible bottleneck could explain why transient overexpression of the             
novel effector genes did not give rise to an increase in LC mRNA levels and therefore no                 
detectable effect on ​q ​
p​. As we previously suggested, the intracellular imbalance of HC and LC               
polypeptides might be causing suboptimal folding and secretion rates of IgG when Rituximab             
is transiently expressed. In a recent study, the HC and LC polypeptides were shown to have                
different rates of intracellular decline, which was dependent on the type of IgG produced              
(47)​. The authors further demonstrated that when lower LC decline was observed, higher             
percentage of total IgG localized within the cis-Golgi, suggesting that the LC excess might              
result in more efficient transportation of IgG to the Golgi apparatus. It remains to be               
investigated what is the cause of the intracellular post-transcriptional bottleneck detected in            
the present study and further, whether or not there is an imbalance between the LC and HC                 
polypeptides. As also previously shown by others ​(18, 23)​, our study highlights the             
importance of determining potential intracellular bottlenecks in the biosynthetic pathway of           
r-proteins in order to understand under which conditions effector genes have a positive             
effect on ​q​
p​.  
We further investigated if the levels of UPR were upregulated when Rituximab was             
transiently expressed at levels that gave rise to a post-transcriptional bottleneck. We were             
able to show that the transient expression of Rituximab, with or without the presence of a                
post-transcriptional bottleneck, did not considerably increase the levels of UPR-responsive          
genes. However, the overexpression of ​Epas1 ​, ​Mafb and ​Xbp1s when Rituximab was            
expressed at levels giving rise to a post-transcriptional bottleneck upregulated the mRNA            
level of the UPR-responsive gene HERP. It remains to be investigated whether the UPR              
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upregulation is a direct effect of effector gene overexpression or an indirect consequence of              
their mechanism, ​i.e. ​q ​
p​-increasing function when Rituximab is at levels giving rise to a              
post-transcriptional bottleneck. On the other hand, the upregulation of UPR levels was            
expected for ​Xbp1s as a transcription factor in one of the three UPR pathways ​(21)​. Further,                
transcript levels of UPR-responsive genes were not upregulated upon transient Rituximab           
overexpression in the Rituximab-producing cell line C6_2. However, we have not assessed            
the UPR levels in the C6_2 cell line: a) inherently present in comparison to CHO-S wt cells,                 
or b) present upon overexpression of effector genes alone.   
As opposed to general effector genes, such as ​Xbp1s​, our novel effector genes displayed a               
limited and conditional ​q​
p​-increasing effect, not widely applicable for different expression           
designs and r-proteins. In fact, only 3 out of 20 candidate effector genes showed positive               
effects on ​q​
p
under the conditions used in this study. This suggests that effector gene               
engineering prior to integration of r-protein into the genome could be a preferred strategy to               
enable beneficial effects of novel effector genes ​(31)​. Further, our results suggest that a              
plausible unfavorable HC:LC ratio with the CMV-HC-EF1α-LC expression cassette         
composition can be improved by vector cassette optimization, giving rise to the increase in              
q​
p​.  
Despite exploring a variety of cellular and experimental conditions in this study, the             
underlying q ​
p​- and mRNA(LC)-increasing mechanisms of these novel effector genes have yet            
to be uncovered. All three novel effector genes are transcription factors, reported to             
modulate expression levels of genes that are not directly connected to r-protein synthesis or              
secretion processes. ​Epas1 (endothelial PAS domain protein 1) encodes hypoxia-inducible          
transcription factor alpha (HIF2α) that is one of the key regulators of the cellular response to                
hypoxia ​(48)​. After activation by hypoxia, ​Epas1 binds to the hypoxia responsive element             
(HRE) located in the enhancer and promoter regions of hypoxia-inducible genes ​(49)​,            
involved in metabolism, cell survival, erythropoiesis, and vascular remodeling ​(50)​. ​Mafb           
(v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B) encodes a         
transcriptional activator or repressor that binds to the Maf recognition element (MARE) by             
dimerization ​(51) to regulate lineage-specific gene expression during hematopoiesis ​(52)​.          
Nfe2 (nuclear factor, erythroid derived 2) is a subunit of the NF-E2 complex that binds the                
AP-1-like core palindrome present in a number of erythroid and megakaryocytic gene            
promoters, thereby regulating their maturation and differentiation ​(53)​. It would be of            
interest in future studies to investigate which gene elements or motifs the effector             
gene-encoded proteins bind to using ​e.g. a chromatin immunoprecipitation (ChIP) assay.           
Identified genes or gene elements could be further investigated via functional protein            
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association networks to uncover their possible links to transcriptional regulation of LC/HC            
transcripts and/or r-protein secretion processes.  
Considering the current results, we propose the following multi-layered regulatory          
mechanism of ​Epas1 and ​Mafb​: transient expression of Rituximab in a CMV-HC and             
EF1α-LC expression cassette composition creates conditions under which there is a lack of             
LC polypeptides. This imbalance between HC and LC polypeptides causes a decreased rate of              
IgG folding and assembly, which gives rise to a post-transcriptional bottleneck. Upon            
post-transcriptional bottleneck, ​Epas1 and ​Mafb directly or indirectly act as transcriptional           
regulators to increase the levels of LC (and to a smaller extent decrease the levels of HC) and                  
thereby optimize the HC:LC ratio at the mRNA and polypeptide levels. The optimized ratio              
results in an increased rate of IgG folding and assembly, which in turn gives rise to an                 
increase in ​q​
p​. In turn ER stress and UPR are induced, perhaps due to increased protein                
folding demand in ER (increased LC mRNA levels), which in turn gives rise to accumulation               
of incorrectly folded IgG polypeptides. Further investigation is required to demonstrate           
whether ​q​
p​-increasing phenotype is specific to IgG-based post-transcriptional bottlenecks         
caused by the imbalanced HC and LC levels. In contrast, the mechanism for ​Nfe2 is unclear,                
since its only observed effect in this study was the increase of ​q ​
p​, which is insufficient to draw                  
any meaningful conclusions.  
Future studies are warranted to understand how are the novel effector genes able to alleviate               
CHO-S wt cells from a post-transcriptional bottleneck originating from transient expression           
of IgG1 molecules in a CMV-HC and EF1α-LC expression cassette composition. Even though             
the ​q​
p​-increasing effect of effector genes seems to be product-specific, it remains to be              
explored whether the effect could be observed for other secretory cargoes with similar             
production bottlenecks present.  
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 Concluding remarks and future perspectives 
With an ever increasing market share and global demand, the biotherapeutics production in             
mammalian cell lines is steadily growing. The advancements made in upstream           
bioprocessing have led to improvement in speed and efficiency of generating robust and             
high-producing cell lines for large-scale production of biotherapeutics. IgGs currently still           
account for the majority of the approved biotherapeutics, but in the years to come, the               
next-generation biotherapeutics, such as alternative scaffolds and difficult-to-produce        
proteins, will be increasingly more prevalent ​(41, 83, 84)​. Further, production of biosimilars,             
biotherapeutics similar to the already approved drug, will expand as many patents are             
expiring ​(85)​. With the advent of precision medicine, recombinant production of tailored            
biotherapeutics, fitting the individual patient, might ultimately come to fruition ​(86)​.  
In the scope of this thesis, clone screening and genome editing tools were developed with the                
aim to achieve improved and predictable recombinant protein production in CHO cells and             
accommodate the inevitable expansion of biotherapeutics portfolio.  
In ​Chapter 1​, we established a clone screening method enabling measurements of            
confluence and product titer in a relatively high-throughput manner. We further           
benchmarked a ​q ​
p​-based clone ranking, using an early stage ​q ​p proxy (TTC ratio), against an               
established titer-based clone ranking. In a systematic and unbiased comparison, we           
demonstrated that both clone selection strategies deliver unique clonal cell lines with            
relatively high product titer in suspension, however, with a low predictive power. Only one              
other study so far has performed in-depth evaluation of the clone selection criteria ​(40)​,              
despite the fact that clone screening is one of the most crucial stages of early CLD. Hopefully,                 
studies like ours will encourage the field to systematically examine the clone screening             
methods used today, to improve the understanding of different selection criteria and their             
prediction power. In addition, to demonstrate the usefulness of the established screening            
workflow, we have generated a stable, high IgG-producing cell line (C6_2 producer) that was              
used in several studies throughout the thesis and elsewhere, as well as for the identification               
of a novel, safe harbor integration site in CHO-S genome.  
In ​Chapter 2​, we developed a CRISPR/Cas9-based toolbox for generation of site-specific            
recombinant cell lines that can be utilized for systematic screening of different expression             
cassette components. The mammalian cell engineering community can now decipher how           
multiple components contribute to the final expression of recombinant genes in           
characterized integration sites. The toolbox therefore facilitates optimized mammalian cell          
engineering and a detailed characterization of proposed safe harbors across different           
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 mammalian expression platforms. Future work could focus on boosting the productivity of            
biotherapeutics, by creating synthetic circuits that are dynamically responsive to culture           
conditions; or for effector gene engineering by precisely defining and controlling the optimal             
expression level of multiple effector genes in stable producing cell lines. All in all, this               
toolbox could pave the way toward CHO multigene engineering approaches, currently           
exceeding our ability to coordinately balance and test the expression of multiple single             
effector genes. 
There are three fundamental approaches to increase the productivity of a recombinant            
protein: host cell engineering, vector design engineering, and the optimization of the cell             
culture processes ​(83)​. ​Chapter 3 has covered current state of the art of host cell               
engineering by ectopically expressing the effector genes improving the secretory capacity of            
CHO cells. Several cellular and experimental factors were described, affecting the outcomes            
of such engineering approaches. Whereas, in ​Chapter 4​, a study was performed where we              
screened a panel of candidate effector genes to identify novel, ​q ​
p​-increasing effectors.            
Alongside the candidate panel, we have screened a ‘positive control’ panel with effector genes              
from published studies and demonstrated that only a few had reproducible effects on ​q ​
p
​in               
conditions used in our study. We alleviated the secretion of transiently expressed IgG1             
molecules by overexpressing three novel effector genes, and then attempted to determine            
which rate-limiting step in IgG1 production was relieved upon effector gene overexpression.            
In the scope of the thesis, we have not yet conclusively determined what is the underlying                
mechanism of the novel effector genes, and whether or not the effects are cell line- and/or                
protein-specific. However, we have shown that effector gene studies require a fundamental            
understanding of the recombinant protein of interest, as well as a well-designed set of              
experiments to discover and effectively alleviate its secretion bottlenecks. Furthermore, given           
the existence of product-interacting effector genes, cell process-specific or non-specific          
(pleiotropic) effector genes, an overexpression of a single effector gene may not be sufficient              
for improving the recombinant protein production. Instead, coordinated expression of          
multiple effector genes is likely to be a preferred option for future cell engineering strategies.               
Traditionally, several non-specific effectors have been used to universally enhance different           
cell functions (​e.g. transactivators). However, these effectors may simultaneously and          
unpredictably affect many cellular processes that are irrelevant or even adverse to            
product-specific recombinant production. Therefore, effector genes that alleviate specific,         
rate-limiting cellular processes (​e.g. secretory vesicle formation, UPR induction) are the           
logical engineering targets in a product- and process-specific context.  
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 In conclusion, coordinated application of the tools developed in this thesis supports rational             
engineering of next-generation CHO cell factories and has the potential to substantially            
improve the production of a wide range of biotherapeutics. 
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Figure S2. Establishing an etanercept-producing polyclonal pool using methionine 
sulfoximine (MSX) selection 
Three days post-nucleofection, cells were subjected to 25 µM MSX selection for 14 days in order to establish a 
polyclonal pool of etanercept-producing CHO-S cells. (A-B) Viability and viable cell density of the etanercept 
(Enbrel) polyclonal pool and CHO-S wild-type (wt) cells during 14 days of selection by MSX and no glutamine 
(Gln-). Every 2-3 days, the selection media was replaced (i.e. passaging) until cells recovered. 	
  
 
Figure S3. Correlation analysis of FACS-based staining intensity of single cells and qp 
in 96-half-deepwell microplates 
Correlation analysis of AlexaFluor 488 fluorescence intensity values and average qp from day 0 to 2 for all the 
clones with seeding density > 1 x 105 cells/mL in 96-half-deepwell (HDW) microplates (n = 125). Nonlinear 
regression with a straight-line model and relative weighing was applied (R2 without and without elimination 
of the outliers is shown). 
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Figure S4. Platform for high-throughput screening of titer and confluence for static 
cultures of suspension-adapted cells  
Following surface labelling and single-cell sorting to 384-well plates using FACS, clones are incubated 
statically for 10-15 days.  Surviving single-cell colonies are identified using image cytometry and moved to 96-
well flat-bottom plates using a liquid handler. After 3-4 days of static incubation, sub-confluent single-cell 
derived clones are screened for titer and confluence, using bio-layer interferometry and image cytometry, 
respectively. Clones are then ranked according to either titer-to-confluence (TTC) ratio or titer. 
 
 
Figure S5. Confluence measurement of suspension-adapted clones grown statically in 
96-well microplates. 
Confluence measurements of sub-confluent clones grown statically in 96-well microplates were performed on 
the Celígo imaging cell cytometer using the label-free, bright field confluence application. Detected cells are 
shown in green color and the area of cells covering the well is defined as confluence. Highlighted wells show a 
range of confluence values: A1 – negative control (no cells seeded into the well), E5 – 30% confluence, A6 – 
- Chapter 1 (Supplementary) - 
114
  
50% confluence and C6 – 70% confluence. The shown 96-well microplate is representative of all analysed 
plates and clones. 
 
 
 
 
Figure S6. Correlation analysis between confluence values and cell counts of clones 
in 96-well microplates 
Correlation analysis of confluence values and cell counts of clones from 96-well microplate in Figure S4 (n = 
96) was performed using linear regression. Cell numbers were estimated by the Celígo imaging cell cytometer 
using the direct cell counting bright field application.   
	
	
 
Figure S7. Confluence and TTC ratio of all analysed clones  
Confluence values of clones grown statically and the corresponding titer-to-confluence (TTC) ratios are shown. 
Clones above the TTC cut-off (i.e. 7) were selected for further examination in 96-half-deepwell (96-HDW) 
microplates (n = 56). Clones, marked in red, did not survive the transfer into 96-HDW microplates (n = 16). 
Only clones with positive TTC values are shown (n = 672). 	
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Figure S8. Correlation analysis between seeding density and specific growth rate or 
maximum titer of clones in suspension in 96-half-deepwell microplates 
Clones were selected and evaluated as described in Figure 3. (A) Correlation analysis between initial seeding 
density and specific growth rate (µ) in the exponential phase for top TTC- and titer-selected clones (n = 76) in 
96-half-deepwell (96-HDW) microplates, using linear regression. (B) Correlation analysis between initial 
seeding density and maximum titer for top TTC- and titer-selected clones in 96-HDW microplates using linear 
regression. 
(1) IDs of selected clones indicate the TTC-based ranks and can be seen in Table S4. 
 
 
	
Figure S9. Performance of top TTC- and titer-selected clones with seeding density 
above 4 x 105 cells/mL in suspension in 96-half-deepwell microplates 
Top ranking titer-to-confluence- (TTC) and titer-selected clones based on static cultures were evaluated in 
suspension in 96-half-deepwell (HDW) microplates, as described in Fig. 3. Only clones with a seeding density 
above 4 x 105 cells/mL are shown here. (A) Comparison of specific growth rate of 96-HDW batch cultures 
between top TTC clones (n = 29) and top titer clones (n = 52) is shown. Statistical significance was calculated 
using Welch’s t test (bars represent mean ± SD). (B) Comparison of specific productivity (qp) of 96-HDW batch 
cultures between top TTC clones and top titer clones. Statistical significance was calculated using Mann-
Whitney test (bars represent median ± interquartile range (IQR)). 	
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Figure S10. Correlation analysis of confluence and specific cell growth rate: Static 
versus suspension culture  
Selected clones were transferred from static culture to suspension in 96-half-deepwell (HDW) microplates, 
where specific cell growth rate (µ) was assessed in two-day batch cultures. Correlation of confluence values 
under static incubation and µ in suspension is shown for all the clones with seeding density > 1 x 105 cells/mL 
in 96-HDW microplates (n = 158) using nonlinear regression with a straight line model. R2 without and with 
relative weighing and elimination of outliers is reported. 
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Figure S11. Viable cell density and viability of top 12 TTC- and titer-selected clones in 
shake flask batch cultures 
Top 12 TTC- and titer-selected clones were evaluated in shake flask batch cultures as described in Figure 4. (A) 
Viability and viable cell density of top 12 titer-to-confluence (TTC) clones throughout the batch culture with 
corresponding clone IDs are shown. (B) Viability and viable cell density of top 12 titer clones throughout the 
batch culture with corresponding clone IDs. Encircled clones (clone 1, 5, 9 and 12) are overlapping clones 
present in both groups (n = 4). 
(1) IDs ranging from 1-20 were assigned to clones in shake flask batch cultures and the corresponding titer- 
and TTC-based ranks can be seen in Table S4. 	
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Figure S12. Performance of top 12 TTC- and titer-selected clones in suspension in 96-
half-deepwell microplates 
Top 12 ranking titer-to-confluence- (TTC) and titer-selected clones based on static cultures were evaluated in 
suspension in 96-half-deepwell (HDW) microplates, where specific cell growth rate (µ) and specific 
productivity (qp) were assessed in two-day batch cultures. (A) Comparison of specific growth rate of 96-HDW 
batch cultures between top TTC clones (n = 12) and top titer clones (n = 12) with corresponding clone IDs are 
shown. Statistical significance was calculated using Welch’s t test (bars represent mean ± SD). (B) Comparison 
of qp of 96-HDW batch cultures between top TTC clones and top titer clones. Statistical significance was 
calculated using unpaired t test (bars represent mean ± SD). 
(1) Only clones with a seeding density above 1 x 105 cells/mL were analyzed. (2) IDs ranging from 1-20 were 
assigned to clones in shake flask batch cultures and the corresponding titer- and TTC-based ranks can be 
seen in Table S4.
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Material and methods 
Generation of C6_2 cell line 
Plasmid used for generation of C6_2 cell line consisted of the Rituximab expression cassette (CMV-
HC-BGHpA-EF1α-LC-BGHpA) and the vector backbone with the selection marker (SV40-NeoR-
SV40pA) and is depicted in Figure S3. CHO-S cells (Thermo Fisher Scientific) were transfected with 
Rituximab plasmid using FuGENE® HD transfection reagent (Promega), followed by G418 selection 
(500 µg/mL; Sigma Aldrich). After stable polyclonal pools were established, single-cell cloning, 
clone screening for high-producers, titer and specific productivity measurement were performed as 
described in our previous study (1). Copy number of integrated Rituximab were measured as 
previously described (2) by using EF1α promoter and BGHpA terminator as target genes and 
Vinculin as a control gene for normalization. Next, a 2-month long-term cultivation in 125 mL 
Erlenmeyer flasks (Corning Inc.) was performed. The C6_2 cell line was passaged every 2-3 days and 
the supernatants 0, 4 and 8 weeks after the start point of cultivation were stored at -80°C. Rituximab 
titer was subsequently determined in the supernatant samples as previously described (3). Specific 
Rituximab productivity was calculated based on Rituximab titer and integral viable cell density 
measurements as previously described (4) with the objective of assessing stability of production. 
 
Supplementary Figure S1: Percentile ranks from expression levels of neighboring genes of T2 
and T9 site 
Published RNA-seq datasets from CHO-S cell line (5) were analyzed and regions identified with consistently 
high expression profiles across 40 samples, thereby selecting new candidate integration sites (site T2 and T9). 
The percentile ranks from expression levels of T2 and T9 neighboring genes across all samples of CHO-S cell 
line are provided. The error bars represent the standard deviation across all the samples (n = 40). 
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Supplementary Table S1: Integration site coordinates according to old (CHO-K1) and new PICR 
assembly, their chromosomal locations and chromatin states 
 
Old assembly 
(orientation of 
integration) 
Internal 
site name 
New PICR 
assembly  (6) 
Chromosome 
location in 
Chinese 
hamster 
genome (6) 
Genomic 
location 
Expression 
level of 
corresponding 
gene in CHO-S 
cell line (7) 
Upstream 
gene 
Downstream 
gene 
Chromatin state 
within integration 
site according to CHO-
Epigenome database 
(8) 
NW_003614466.
1: 715154 (+) 
Site A Picr_5:335888
93 
2 Intron 2 of 
Polk  
Intermediate 
expression 
Col4A3bp Pdhb Weak enhancer 
(state number 6) - 
enriched mark: 
H3K4me1 
NW_003613881.
1: 1456617 (+) 
 
Site T2  Picr_36:8978
007 
 
3 Intergenic / Acot13 Uncharacter
ized protein 
C6orf62 
homolog 
Strong 
transcription (state 
number 4) – 
enriched mark: 
H3K36me3  
NW_003614758.
1: 453083 (+) 
 
Site T9 Picr_29:19091
106 
 
3 Intergenic / Stim1 Rrm1 Weak enhancer 
(state number 6), 
only at one time 
point (lag phase of 
the culture) – 
enriched mark: 
H3K4me1 
 
 
Supplementary Table S2: sgRNA target sequences and 750 bp long 5’ and 3’ homology arm 
sequences for all three sites  
 
Site  sgRNA 
target 
sequence 
5’ homology arm 3’ homology arm 
A AACATAGTAA
CCCCAAAGA
GAGG 
GAAGCTTACCCCCAGGATTTCCTGATACTACTTTAGAAAA
AAACTAGCTTTAATATATTGGCATCAATATATTATTTTTCCT
CTCTGCCTCCTTTTCTTTCTTTTTTTAATTTTTTATTAATTTAT
TTTTTACAGTCCAATCCCAGTTCCCCCTCCCTCCTGTCCTCC
TGTTCCTCCTACTCCCCCTGCATCTGCTCCTTGGAGAGGGT
AAGGCCTCCCCTTTTCCTTTCTTGAGGGGAAAATTTTTAAG
GCAGCTAAGATCCTTCTCCTGAAGGCACTCACTGTTAGTG
ATCTAATACAATAAGGGCTGTGGTGAAAACAAGTACAAG
AAGATTAATTCTCTGGCACAGAAGAGAAAGAGCCAGATG
ACTTTCAAGGGATGTTTGAGTTGACTCTTGAAAGCTTGTG
ACAGAGCTCAGAGAGGTGTTCAAAACAGAGCCAGCCAGG
GTCAGAGTCCCTCAGGTCATTCAGAGTTGGAGACTCGGCA
AGAGTAGGCCTGCAGACATTCAGCCTCTGCTACAGACAGA
TGTGACTTAGGGCCTTTTCTAAGAGAGGAATTGCAGTGTT
ATTACCCAGCTAGTGGACAGCTAATGTGTTCCTCCTGAAG
AAGACTATGAAACAAGTATTCTGTAGAGTGAGGGCAAGA
TGGAAGACCAGCATGGGGGTGGGAGGGGGTACATTATA
CCTTTGTGGTTCTCCACATAAGGTAGGTTGCTTTCATTTAA
GAGATCACTTGCTTTGGGCTGTTTT 
ATGCCTCCATTGATTCTTTCAGTGGCACCAGACATTGTTCC
ATGTTCCGTGTGTTGTGCTTGCTTTATTGCTGTTTTCTCTTA
TGATTTACCTTAATGGTATAAGCAACTTCCTTACAGGTTGC
TACAATTAAAACAATCACATAGCTACCCTTTGCATGGTAAG
CTGGGAAAGCACACATACAACATTAGTAGAGGCAGTCCAT
AAAAAGCAAGCTAAGGATACTTTTGCTATATAATCTCCCTT
TTTTTTGTTTGTTTGTTTGTTTTTCAAGTTAGGGTTTCTCTG
TGGCTTTGGAGGCTGTCTTGGAACTAGCTCTTGTAGACCA
GGCTGGTCTTGAACTCACAGAGATCTCCCTGCCTGTGCCTC
CCGAGTGCTGGGACTAAAGGCATGCGCCACCACTGCCCA
GTTTATATAATCCCTTTTTTTTTTTCACTCATCTAGTTTATTT
CTATGTTTATTTCTCTTTTATCTTTTAATCCAATAATTTGTCT
TCAAAGAGGCCAATATTTTTAAAGATTATAATTCTGCATTG
TTATATTTGACATATATATTAAAATTTTATGAAAAATAAGC
TTCATCTTCAGTTTTCAATTGGTGTTTGTATAGAATAACCAT
CTCAGACGTTAGCTGTGGTCCTGGCTAGACTTATGTCAAC
CTGCCAGAAGCCAGAGTCAGGGAAGAGGAACTCCCAATT
GAGAAAATGACTCAATAAGATCAAGCTGTAGTCAAGTCTA
TAAGGTATTTTCT 
T2 GAGATCTGT
GGGCCGAGT
AA 
GTTTCTACACCATCCTAAAGAAGTTGAGTGTTTGGAATAG
AAAAAAATATTAAAAGTGGGGATCTTACATTGTAAAATTA
ACCAGAGTGTCAAGAGTTCTAAAAGCAGAACTCAATTGTG
CAATGAACATAAGGAAAGACTACTGTATAGCTTTTTTATTT
TTACTTTTTTGTTTTTTGTTTTTTGTTTTTTTTTTTTTTTCTTTT
AAATGAAGAAAGGCTTTGCTTAAGGGTTGCATACTTTTAT
TGGAGTAAATCGGAATGATCCTGCTCCATTGGAGTAAAAC
TAGTGCTTACTGGTTTCCATTTGTATTTAGCTTCTGGTTGG
AATTTGGAAAAAAAAAATGAAACCTAAATAAAATAGGTG
AAAGCTTCCTGGCTATTCAGATGAATATATAAAATCTGCA
AGTCCACAGATTCTGAATGAAAGAAAAATATTTATTTGGC
AGAACATCCACAATTTAAAGATATGAGGAACAGGATACTG
CTATCAGATCACTACCACCCAAGAGAGCTAGAGGTTGCTC
TCAGTCCACACATAGCACCTGAGGCCCTGCCCTGAAGGGA
CTGGTACCTATTGGCTGAATTGAATTTCCATAACAAATCCA
CCAGCTTGCTTCCTGAGCACCACCACTGGTTTTGAAGGTTC
CCTAAGGCCAGGCATTGTTCTACAGCTGTCTTTAACAGCTT
GGAGTGGAAGTAGACATCCAGGTTGAGAAATTTGCCCAA
GCTCATATAAGTAGAGGATTTAAATCACCAGATGCCAGTG
GCTTTTTAAAATCCGTTTTACTGTTACACTGTTACTGTTGAA
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Supplementary Figure S2: Depictions of plasmids, used in this study  
  
A – Rituximab plasmid for generation of C6_2 cell line  
 
 
 
 
B – sgRNA plasmid 
 
 
 
C – Landing pad donor plasmid 
 
 
 
 
 
 
 
ATGTTAACTTTTTTATCCCATGTCTTTCATCACTTAAGGTTT
ATTCAGAAAAAAAGAACTGGCAGTTGTAACTTGAACAAG
AACCTAAGACAGAGTTGGTCAGCTTCAATAGCTCCCTGCC
CTTTGCTTTGTTTCATAGAAAAGGAAAAAATAACCATTCTT
AATGTAAAAGGGCATTTTTACATGTTCTCTGATTTTGTTCT
CTGACTAGTTCGAAGGTAGAATCAATTTGATACAACATTTT
CAAAGTTTCCTTTTTTTGTTGTTTTTCCAGACAGGGTTTCTC
TGTAGCTTTGGAGACTGTCCTGGTACTAGCTCTGTAGATC
AGACTGGCCTCTAATTCA 
CATATTAGGTAATTCAGTAGCCATTTTAACTCGGGATGATC
AGAAAAGTTGGCACGAACAATATGGGATGTTCTGGTGTA
ACACATTAAGATTTTAACATTTTGCACATACTTTTCTCTTTG
CACATATTTGCCCAACCATTGCATTTGTTGCACACATTTACT
TTTTGCCCTTTGGTACTTATGGCCATGTTACAAGTAAGTAT
AGGATTTGGTGATGGAGGGGTGTTCCTGGTTACAATATCT
TACAGTATTATTACCAAGCTTCCAACATGACAGTATACCAT
TCATGTTCTAGTTAACTGTCTCAGAAAATTCAGTTTGTCTA
TGGTTAGCTTGACTTTGTA 
T9 GCCCACTACA
GGTTCGGGC
G 
GATAAACTATTCTTCATTTGCCAGGGGTGAACGAAACTCC
AGTGCACATTTCTCAGCTCTATAGCTGAGAGATACCTCATA
AAACATAGGATACTTAGGTAAATTTGAGTTTCAGGTGAAG
ATTTTTTAAGTATAATCATGTCTTGCACAATGTTTGGGATT
CATTTTTATTGATTAAATCTGACAGTCCTTTTTTTTTCTTTCC
TTTAAAAAACTTTTTTTTTTTTTTAAAGACAGGGTCTTATGT
ATCCTAAGGTGACCTTGAACTTGCCTTGTAGATGAGTCTG
GCTTTGAGCCCCTAATACCTACCTCCACCTCTCAAATCCTA
GGATTACAGGTGTATACCACTCTACCCATTTGACAATTCTA
CTTTTGAGCCATCTTAAAGGTAAAAAGTACACTTATTTATC
ATATGCCTGTGTGTGGAAGTCAGAACAACTTGTGGTAGTT
GGTTCTTTCCTTCATGGGGGCCCTGGGGGTTAGACTCCAA
TTGTCAGGCTTGCTGGTAAATGCCTTATTACCACCTTGATG
TGGAGGTACAAATAATGATTCACAGGACTAGGTTCAAATA
TTAAATATAATTTATTCCGGGGAGAAGTCACTTACAGAAG
AAGCAGACAGCTGCTGCAGGTTCCAGCTCTAAGGATCCGC
ACAGGCTACTCCCTGTGGCCCAACCAGACGGAAGTGAGA
GCCACCTGCTGGGACCCCAGACCTAAACTCACTCCCAGTC
AGGTCCTCACCTGTAACCAC 
TGGATATCTCACTACACTTTGATGGCCCAATCTTTTTTTAAA
AGCATATATTTATTGAATAAAATATGAGTTCATATTGGCAT
CCTCATGCATGTCTGGCAAGTACTTGGCTATTATTCACTTC
CTCCTCTAAATCCCATCCATTCTTGGGTCCATAAACCTATCA
TCTTAGTTTCTCCTCATTTCAAAAGAAATTAGGAAACAGAA
GTTTGTAACAGGAAATGGATTTATTTATAGTTTTGCCACTG
GGGAGAAAAAATAACTCCATCCTGTTCTCTAACATGCTGG
TAGTCTTTTACAGTTTATTGAAAACTATGAGACGGGATGG
AGAGGTGGTTCAGAGGTTAAGAGCAATGGCTGTTCTTCCA
GAGGTCCTGAGTTCAATTCCCAGCAACCACATAGTAGCTC
ACAGCTATCTGTAATGAGATCTGGTGTGCAAGCATACATG
CCGGCAGAACACTGTATACAAAATAAATAAATCTTAAAAA
AAAAAAGAAAACTATGAGACAAAGACAAGAAGGTATGTA
GCTTTGCTGTGAGACAGTTCAACATGGCTTTTCTGGGGTT
GTGAGGAGGTCACTAGTTTCATATGACCTGCAGTATCTCA
GTTCTCAGCAGTTCTTGTTTAGCATGGAGGGGGTCTCTCTT
TACAATTTTGCCATGGTTCCAGCCCTTTCTCAAGCATGGAA
TCACTGCTATATTAGTGTCCTCTTTGTTATGGGGTAAAAAC
CCAGAGACCATTCAAGCAAC 
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D – RMCE eGFP donor plasmids, used for proof-of-principle experiment 
 
 
 
E – A panel of RMCE eGFP donor plasmids 
 
 
 
F – A panel of RMCE EPO donor plasmids 
 
 
 
Supplementary Table S3: All the primers used in this study 
 
A – Cloning primers used for constructing the landing pad donor plasmids  
 
Primer Sequence 
A 5HA LA_fwd AGTCGGTGUGAAGCTTACCCCCAGGATTTCC 
A 5HA LB_rev ACGCTGCTUAAAACAGCCCAAAGCAAGTGAT 
A 3HA LD_fwd AGGTCTGAGUATGCCTCCATTGATTCTTTC 
A 3HA O1_rev AGCGACGUAGAAAATACCTTATAGACTTGACTA 
T2 5HA LA fwd AGTCGGTGUGTTTCTACACCATCCTAAAGA 
T2 5HA LB rev ACGCTGCTUTGAATTAGAGGCCAGTCTGAT 
T2 3HA LD fwd AGGTCTGAGUAGTCCACAGATTCTGAATGAA 
T2 3HA O1 rev AGCGACGUTACAAAGTCAAGCTAACCATAG 
T9 5HA LA fwd AGTCGGTGUGATAAACTATTCTTCATTTGC 
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T9 5HA LB rev ACGCTGCTUGTGGTTACAGGTGAGGACC 
T9 3HA LD fwd AGGTCTGAGUTGGATATCTCACTACACTTTG 
T9 3HA O1 rev AGCGACGUGTTGCTTGAATGGTCTCTGG 
pJ204 backbone O5 fwd ACTTGCGUAGTGAGTCGAATAAGGGCGACACAAA 
pJ204 backbone LA rev ACACCGACUGAGTCGAATAAGGGCGACACCCCA 
Lox2272-mCherry O4 rev AGACTGTGUATAACTTCGTATAAAGTATCCTATACGAAGTTAT 
CTACTTGTACAGCTCGT 
LoxP-EF1a LB fwd AAGCAGCGUATAACTTCGTATAGCATACATTATACGAA 
GTTATGTGAGGCTCCGGTGCC 
BGHpA fwd O4 ACACAGTCUCTGTGCCTTCTAGTTGCCA 
NeoR LD rev ACTCAGACCUCAGACATGATAAGATACATTG 
CMV O1 fwd ACGTCGCUGTTGACATTGATTATTGACT 
BGHpA O5 rev ACGCAAGUCCATAGAGCCCACCGCATCC 
 
B – Cloning primers used for constructing RMCE eGFP donor plasmids  
 
Primer Sequence 
CP fwd AGTTATAGUCAATGGGAAAAACCCATTGGAGCC 
CP strg Kozak rev ATGGTGGCGUAGGCGCCGGTCACAGCTT 
BB CP strg Kozak fwd ACGCCACCAUGCATGTGAGCAAGGGCGA 
BB CP rev ACTATAACUTCGTATAATGTATGCTATACGAAG 
CP weak Kozak rev AAAAAGUAGGCGCCGGTCACAGCTT 
BB CP weak Kozak fwd ACTTTTUTATGCATGTGAGCAAGGG 
SV40 fwd AGTTATCUGTGGAATGTGTGTCAGTTAG 
SV40 strg Kozak rev AAAATGGAUATACAAGCTCCCGGGAGCTT 
BB SV40 strg kozak fwd ATCCATTTUCGGCCACCATGCATGTGAGC 
BB SV40 rev AGATAACUTCGTATAATGTATGCTATACGAAG 
SV40 weak Kozak rev AACGAAAAUGGATATACAAGCTCCCGG 
BB SV40 weak Kozak fwd ATTTTCGTUTTTTATGCATGTGAGCAA 
EF1α fwd AGTTATGUGAGGCTCCGGTGCCCGTC 
EF1α strg Kozak rev AGTGCTGUGGACTTTACCTTCTTTTTTTGAAA 
BB EF1α strg Kozak fwd ACAGCACUGCCACCATGCATGTGAGC 
BB EF1α rev ACATAACUTCGTATAATGTATGCTATACGAAG 
CMV fwd AGTTATGTUGACATTGATTATTGACTAGT 
CMV strg Kozak rev ATTTCGAUAAGCCAGTAAGCAGTGGG 
BB CMV strg Kozak fwd ATCGAAAUGCCACCATGCATGTGAGC 
BB CMV rev AACATAACUTCGTATAATGTATGCTATACGAAG 
eGFP RMCE donor w strg Kozak fwd           ACGCCACCAUGCATGTGAGCAAGGGCGA 
eGFP RMCE donor w strg Kozak rev           AATAACUTCGTATAATGTATGCTATACGAAG 
 
C – Cloning primers used for constructing RMCE EPO donor plasmids  
 
Primer Sequence 
LoxP CP LA fwd AGTCGGTGUATAACTTCGTATAGCATACATTATACGAAGTTAT 
AGTCAATGGGAAAAACCCATTGG 
CP LC rev ATGACGTCUGTAGGCGCCGGTCACAGC 
LoxP CMV LA fwd AGTCGGTGUATAACTTCGTATAGCATACATTATACGAAGTTAT 
GTTGACATTGATTATTGACTAGT 
CMV LC rev ATGACGTCUATTTCGATAAGCCAGTAAGC 
EF1α LC rev ATGACGTCUTCACGACACCTGAAATGGA 
LoxP EF1α LA fwd AGTCGGTGUATAACTTCGTATAGCATACATTATACGAA 
GTTATGTGAGGCTCCGGTGC 
pJ204 backbone O5 fwd ACTTGCGUAGTGAGTCGAATAAGGGCGACACAAA 
pJ204 backbone LA rev ACACCGACUGAGTCGAATAAGGGCGACACCCCA 
Kozak coEPO LC fwd AGACGTCAUCGCCACCATGGGAGTGCACG 
Lox2272 coEPO O5 rev ACGCAAGUATAACTTCGTATAAAGTATCCTATACGAAGTTATTCATCTATCGCCGGTCC 
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D – Cloning primers used for 5’/3’ junction PCRs  
 
Primer Sequence 
A 5' junction fwd  GCCGCATGACCTTGTTCAAA 
5' junction general rev  ATCCTGGCCCGCATTTACAA 
3' junction general fwd  CTGGACGAAGAGCATCAGGG 
A 3' junction rev  TCTGGCACAAGATGTAATGCTG 
T2 5' junction fwd CTCTTTCCCCGAGTTGCTGT 
T2 3’ junction rev CTGCCATCAGTCACTAGCAGT 
T9 5'junction fwd GCATGCACAGAGAGGGACAT 
T9 3'junction rev CCCTCTGCAACTGCTAACCA 
 
 
Supplementary Table S4: Sequences of all genes of interest (GOIs), promoters, terminators and 
Kozaks used in this study  
 
Promoters Sequence 
EF1α GTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGA
ACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGG
GAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGT
GTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTCCAGTACGTGATTCT
TGATCCCGAGCTGGAGCCAGGGGCGGGCCTTGCGCTTTAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCG
CTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGA
TGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAGGATCTGCACACTGGTATTTCGGTTTTTGGGG
CCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCG
GACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGG
CTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTCCAGGGGGCTCAAAATGGAGGACGC
GGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAGGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCC
ACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTGGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTT
TTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATT
TGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA 
CP 
(mCMV-hEF1α-5’HTLV)  
AGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACATAAGGTCAA
TAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTTTCCAATGGGTTTTGCCCAGTAC
ATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCATTACTGACATGTATACTGAGTCATTAGGGACTTTCCAATGGGTTTT
GCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCCATTGGAGCCAAGTACACTGAGTCAATAGGGACTTTCCA
TTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTTTTCCCATTATTGGCACATACATAAGGTCAATAGG
GGTGACTAGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCC
TAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGT
ATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCA
TCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGC
CTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACC
TAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
ATCCAAGCTGTGACCGGCGCCTAC 
SV40 early promoter CTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTA
GTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCA
TAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTA
TTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCA
AAAAGCTCCCGGGAGCTTGTATATCCATTTTCG 
CMV GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTAC
ATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGT
AACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCA
TATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGC
GGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCC
AAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCT
GGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAAT 
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Terminators Sequence 
BGHpA CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTC
CTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGG
GGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG 
SV40pA CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTC
CTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGG
GGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG 
GOIs and Kozaks Sequence 
mCherry ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAAC
GGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGG
GTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATC
CCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTG
ACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAA
TGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAG
AGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGG
CGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGC
CGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAG 
eGFP ATGCATGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA
GTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCC
CGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA
GGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGC
ACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGAT
CCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCT
GCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC
GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG 
NeoR ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAAC
GGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGG
GTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATC
CCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTG
ACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAA
TGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAG
AGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGG
CGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGC
CGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAG 
ZsGreen ATGGCCCAGTCCAAGCACGGCCTGACCAAGGAGATGACCATGAAGTACCGCATGGAGGGCTGCGTGGACGGCCACAAGTTCGTG
ATCACCGGCGAGGGCATCGGCTACCCCTTCAAGGGCAAGCAGGCCATCAACCTGTGCGTGGTGGAGGGCGGCCCCTTGCCCTTC
GCCGAGGACATCTTGTCCGCCGCCTTCATGTACGGCAACCGCGTGTTCACCGAGTACCCCCAGGACATCGTCGACTACTTCAAGAA
CTCCTGCCCCGCCGGCTACACCTGGGACCGCTCCTTCCTGTTCGAGGACGGCGCCGTGTGCATCTGCAACGCCGACATCACCGTGA
GCGTGGAGGAGAACTGCATGTACCACGAGTCCAAGTTCTACGGCGTGAACTTCCCCGCCGACGGCCCCGTGATGAAGAAGATGA
CCGACAACTGGGAGCCCTCCTGCGAGAAGATCATCCCCGTGCCCAAGCAGGGCATCTTGAAGGGCGACGTGAGCATGTACCTGCT
GCTGAAGGACGGTGGCCGCTTGCGCTGCCAGTTCGACACCGTGTACAAGGCCAAGTCCGTGCCCCGCAAGATGCCCGACTGGCA
CTTCATCCAGCACAAGCTGACCCGCGAGGACCGCAGCGACGCCAAGAACCAGAAGTGGCACCTGACCGAGCACGCCATCGCCTC
CGGCTCCGCCTTGCCCAAGCTTCCGCGGAGCCATGGCTTCCCGCCGGCGGTGGCGGCGCAGGATGATGGCACGCTGCCCATGTCT
TGTGCCCAGGAGAGCGGGATGGACCGTCACCCTGCAGCCTGTGCTTCTGCTAGGATCAATGTGTAG 
EPO ATGGGAGTGCACGAGTGTCCTGCTTGGCTGTGGCTGCTGCTGTCCCTGCTGTCTCTGCCTCTGGGACTGCCTGTGCTGGGCGCTCC
TCCTAGACTGATCTGCGACTCCCGGGTGCTGGAAAGATACCTGCTGGAAGCCAAAGAGGCCGAGAACATCACCACCGGCTGCGC
CGAGCACTGCTCCCTGAACGAGAATATCACCGTGCCCGACACCAAAGTGAACTTCTACGCCTGGAAGCGGATGGAAGTGGGCCA
GCAGGCTGTGGAAGTGTGGCAGGGACTGGCTCTGCTGAGCGAGGCTGTGCTGAGAGGACAGGCCCTGCTCGTGAACTCCTCCCA
GCCTTGGGAACCCCTGCAGCTGCACGTGGACAAGGCTGTGTCCGGCCTGAGATCCCTGACCACCCTGCTGAGAGCACTGGGAGCC
CAGAAAGAGGCCATCTCTCCACCTGACGCCGCCTCTGCTGCTCCTCTGAGAACCATCACCGCCGACACCTTCAGAAAGCTGTTCCG
GGTGTACTCCAACTTCCTGCGGGGCAAGCTGAAGCTGTACACCGGCGAGGCTTGCCGGACCGGCGATAGATGA 
Strong Kozak GCCACC 
Weak Kozak TTTTTT 
 
 
Supplementary Table S5: TaqMan assays (primers and probes) for qPCR 
 
Gene Forward Primer Reverse Primer TaqMan Probe Dye Primer Efficiency 
mCherry GACTACTTGAAGCTGTCCTTCC CGCAGCTTCACCTTGTAGAT TTCAAGTGGGAGCGCGTGATGAA FAM-MGB 96.4% 
NeoR GCTATCAGGACATAGCGTTGG GATACCGTAAAGCACGAGGAAG ACCCGTGATATTGCTGAAGAGCTTGG FAM-MGB 101% 
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eGFP GCACAAGCTGGAGTACAACTA TGTTGTGGCGGATCTTGAA AGCAGAAGAACGGCATCAAGGTGA FAM-MGB 98.75% 
COSMC ACCCGAACCAGGTAGTAGAA ACATGTCCAAAGGCCCTAAG AGTGACAGCCATATTGGAACAGCATCC VIC-MGB 101% 
coEPO CTGGAAAGATACCTGCTGGAAG AGGCGTAGAAGTTCACTTTGG CCAAAGAGGCCGAGAACATCACCA FAM-MGB 94.19% 
Fkbp1a CTCTCGGGACAGAAACAAGC GACCTACACTCATCTGGGCTAC ATGCTAGGCAAGCAGGAGGTGATC VIC-MGB 100% 
Gnb1 CCATATGTTTCTTTCCCAATGGC AAGTCGTCGTACCCAGCAAG ACTGGTTCAGACGATGCTACGTGC ABY-QSY 99% 
 
Supplementary Figure S3: Residual productivity and copy numbers of Rituximab in randomly 
integrated high-producing CHO-S monoclonal cell line throughout the 2-month stability assay 
Specific productivity and copy number of Rituximab were measured at week 0, 4 (only specific productivity) and 
8 from the start of the 2-month stability assay and normalized to week 0 values (RQ = 1). 
 
 
 
 
Supplementary Figure S4: Targeted MiSeq deep-sequencing of two PCR product encompassing 
integrated construct and flanking genomic regions of site A  
At week 0 and 8 from the start of the 2-month stability assay, genomic DNA of C6_2 cell line was extracted 
and the region surrounding site A, predicted from Cergentis’s TLA sequencing (9), was PCR amplified. 
Obtained 9-kb PCR products were MiSeq deep-sequenced and aligned to the integrated Rituximab plasmid.   
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Supplementary Figure S5: 5’ and 3’ junction PCRs for confirmation of specific integration of 
mCherry landing pad in all three integration sites for all 15 selected platform cell lines (PCLs) 
 
A – 5’ junction (left) and 3’ junction (right) PCRs for validation of integration in site A for five 
selected PCLs        
 
 
 
 
 
 
B – 5’ junction (left) and 3’ junction (right) PCRs for validation of integration in site T2 for five 
selected PCLs        
 
 
 
 
 
 
C – 5’ junction (left) and 3’ junction (right) PCRs for validation of integration in site T9 for five 
selected PCLs        
 
 
 
 
 
 
 
Supplementary Figure S6: mCherry and NeoR copy number in 15 selected PCLs 
mCherry and NeoR copy numbers were measured in genomic DNA of 15 selected PCLs, where integration of 
mCherry landing pad in site A, T2 and T9 was confirmed by 5’ and 3’ junction PCR (Figure S4). COSMC was 
used as a control gene for normalization and PCLs’ copy numbers were compared to two control samples, 
verified in our previous studies (10, 11) to contain one copy of mCherry landing pad integrated in COSMC and 
T2 site, respectively. The error bars represent the standard deviation of the technical replicates (n = 3). 
C5 C9 C10 D8 D9
A8 C11 D1 E2 G3A8 C11 D1 E2 G3
C5 C9 C10 D8 D9
E6 E11 F12 G4 G5 E6 E11 F12 G4 G5
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Supplementary Figure S7: mCherry fluorescence homogeneity in 15 selected PCLs at the time of 
validation  
mCherry fluorescence was measured in unstained suspension PCL cells using Xcyto 10 image cytometer and 
was considered homogenous when ≥ 98% cells were mCherry positive.  
 
 
 
Supplementary Figure S8: Growth curves of 15 selected PCLs during batch cultivation 
15 PCLs were cultivated under batch conditions for 6-9 days (i.e. until the viability dropped below 60% of cells). 
Viable cell density (VCD) and viability were measured daily. Encircled clones, A-D1, T2-C9 and T9-G4, are the 
representative PCL clones for site A, T2 and T9, respectively, used for the majority of recombination 
experiments.   
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Supplementary Figure S9: Target-to-reference ratios for bulk-sorted samples recombined with 
codon optimized EPO (coEPO) using digital PCR (dPCR) 
A-D1, T2-C9 and T9-G4 PCLs were recombined with RMCE EPO donor plasmids and bulk sorted by FACS 
(mCherry negative cells). Copy number of EPO was measured in recovered bulk-sorted populations using 
dPCR, being reported as coEPO/COSMC reads (%), with COSMC being used as one-copy control gene. 
coEPO/COSMC ratio of bulk-sorted populations was compared to the ratio of a control sample (monoclonal 
cell line, verified in our previous study to contain one copy of EPO in site T9 (12). The error bars represent 95% 
confidence intervals, averaged between the technical replicates (n = 2). 
 
 
 
Supplementary Figure S10: Target-to-reference ratios for titration experiment with A-CP eGFP 
bulk-sorted sample using dPCR 
Titration experiment was performed using dPCR, with genomic DNA of A-CP eGFP bulk-sorted sample being 
incrementally spiked in genomic DNA of CHO-S wt (i.e. in 0%, 10%, 20%, 50%, 80% and 100% of the total 
DNA). eGFP/COSMC reads (%) are reported for each titration mix, with COSMC being used as one-copy 
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control gene. The error bars represent 95% confidence intervals, averaged between the technical replicates (n 
= 2). 
 
 
 
Supplementary Figure S11: Target-to-reference ratios for bulk-sorted samples recombined with 
eGFP using dPCR 
A-D1, T2-C9 and T9-G4 PCLs were recombined with RMCE eGFP donor plasmids and bulk sorted by FACS 
(mCherry negative/eGFP positive cells). Copy number of eGFP was measured in recovered bulk-sorted 
populations using dPCR, being reported as eGFP/COSMC reads (%), with COSMC being used as one-copy 
control gene. Three bulk-sorted populations (namely A-CP, A-SV40 and T2-CP) were generated twice, 
independently (for more details refer to Material and Methods in the main text), here marked as Rep2 samples. 
The error bars represent 95% confidence intervals, averaged between the technical replicates (n = 2). 
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Supplementary Figure S1: Depictions of plasmids, used in this study  
  
A – Rituximab A  
 
 
B – Rituximab B and B swap 
 
 
C – Adalimumab and Trastuzumab 
 
 
D – Etanercept 
 
 
E – Effector genes and the empty vector 
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